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 i  
ABSTRACT 
Mitochondria produce most of the ATP needed for the cell as an energy 
source. It is well known that cellular respiration results in oxidative damage to the 
cell due to the production of reactive oxygen species (ROS). Mitochondrial 
dysfunction is believed to contribute to a number of degenerative diseases; 
because of this the mitochondrial respiratory chain is considered as potential drug 
target. 
A few series of idebenone analogues with quinone, pyridinol and 
pyrimidinol redox cores have been synthesized and evaluated as antioxidants able 
to protect cellular integrity and, more specifically, mitochondrial function. The 
compounds exhibited a range of activities. The activities observed were used for 
the design of analogues with enhanced properties as antioxidants. Compounds 
were identified which provide better protection against oxidative stress than 
idebenone, and it is thought that they do so catalytically.  
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CHAPTER 1 
1. INTRODUCTION 
Mitochondria are organelles that are found in the eukaryotic cells; they are 
responsible for various processes within the cell, such as production of energy and 
cell signaling.1-3 Mitochondria produce most of the ATP needed by the cell as an 
energy source. ATP is synthesized by the electron transport chain, which consists 
of a series of transmembranal proteins located in the inner mitochondrial 
membrane (Figure 1).4 
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Figure 1: Electron transport chain. 
 
Electrons are first transferred from NADH and succinate (via FADH2) to 
complex I and complex II, respectively. The electrons are then transferred from 
complexes I and II to coenzyme Q10 (CoQ10) (Figure 2) and transported to 
complex III. Complex III then transfers the electrons to cytochome c, which 
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transports them to complex IV. Finally complex IV transfers the electrons to 
oxygen to form water. When electrons pass through complexes I, III and IV there 
is a translocation of protons from the matrix to the intermembrane space. This 
proton gradient is then used by ATP synthase to synthesize ATP from ADP and 
inorganic phosphorus.5,6 
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Figure 2: Reduction-oxidation cycle of CoQ10. 
 
In normal mitochondria, when two electrons are transported trough 
complex I, four protons are translocated into the mitochondrial intermembrane 
space. When these two electrons are transported through complex III and complex 
IV, six more protons are transported to the intermembrane space, two when they 
pass through complex III and four when transported through complex IV. In total, 
ten protons are transported to the intermembrane space for each two electrons 
from NADH. It is interesting that when two electrons are transported through 
complex II no protons are translocated; thus only six protons are transported to 
the intermembrane space. NADH and succinate are metabolites produced in 
glycolysis and the citric acid cycle when carbohydrates, lipids and amino acids 
are metabolized to generate energy. ATP synthase utilizes about three protons to 
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generate a molecule of ATP, thus oxidation of one NADH and one succinate 
produces ~ 3 ATP’s and 2 ATP’s respectively.  
The large production of ATP by the electron transport chain requires an 
elevated consumption of oxygen; in fact, 80% of the oxygen consumption related 
to ATP production occurs in mitochondria.7,8 Molecular oxygen is a vital 
substance but at the same time could be converted to very lethal toxins, namely 
reactive oxygen species (ROS).  Mitochondria are considered the principal source 
of reactive oxygen species in the cell. These reactive oxygen species are produced 
from 1-2 % of the oxygen consumed during cellular respiration in normal 
mitochondria.9,10 As shown in Figure 3, ROS are formed when an electron is 
transferred to molecular oxygen, usually at complex I and III sites,11,12 to form 
superoxide. Superoxide could be further converted to hydrogen peroxide by 
means of superoxide dismutase (SOD).  
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Figure 3: Mitochondrial formation and disposal of superoxide. Adapted from 
Ref. 11. 
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Superoxide and hydrogen peroxide are not harmful by themselves; 
actually they are essential to the function of a number of enzymes.13 However 
hydrogen peroxide can be converted to hydroxyl radicals in the presence of metal 
ions such as copper and iron by the Fenton reaction (Figure 4).14,15 
 
HOOH   +  Fe2+ Fe3+   +    ·OH   +   -OH  
Figure 4: Formation of hydroxyl radicals by the Fenton reaction. 
 
Hydroxyl radicals are highly reactive chemical species and can react with 
any macromolecule in the mitochondria including DNA, RNA, lipid membranes 
and proteins.16 Normally, cells are detoxified by a combination of antioxidant 
enzymes including superoxide dismutase, glutathione peroxidase and catalase 
(Figure 3);17,18 they are also protected by non-enzymatic antioxidants like 
ubiquinol-10 (reduced form of CoQ10), ascorbic acid, glutathione (GSH) and α-
tocopherol (Figure 5).17,19  
Since mitochondria are the organelles in charge of producing most of the 
energy required by cell, and are involved in several other processes, is not 
surprising that mitochondrial dysfunction is strongly linked to the pathogenesis of 
a number of human diseases (e.g. diabetes, cardiovascular diseases and 
neurodegenerative diseases).20-27  
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Figure 5: Structure of some non-enzymatic antioxidants. 
 
Defects in any of the complexes in the electron transport chain can cause a 
mitochondrial disorder. Such defects could be the product of mutations in 
mitochondrial DNA or genes located in the nucleus that encode proteins used in 
mitochondria.28-30 Also, mitochondrial function could be affected by factors 
exogenous to the mitochondria such as side effects of drugs, infections, or other 
environmental factors.31,32 It is thought that mitochondrial dysfunction is closely 
related to an impairment of the electron flow through the mitochondrial 
complexes. This leads to an increased production of ROS, exhausting the capacity 
of the cell for detoxification.33-39   
One very well known reaction of hydroxyl radicals is the peroxidation of 
lipid membranes (Figure 6).40,41 The hydroxyl radical abstracts a hydrogen from 
the lipids forming a carbon centered radical. This radical can react with molecular 
oxygen to form a peroxyl radical. The peroxyl radical is also reactive enough to 
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abstract another hydrogen from another lipid molecule, forming a new carbon 
centered radical. This process occurs in a chain reaction manner producing many 
lesions in membranes from a single hydroxyl radical.    
 
·OH   +   RH R·   +   H2O
R·   +   O2 ROO·
ROO·   +   RH ROOH   +   R·
Initiation
Propagation
 
Figure 6: Free radical chain reaction leading to lipid peroxidation. 
 
 As mentioned above, the antioxidant mechanism in the cell involves a 
series of non-enzymatic scavengers of ROS. The most abundant antioxidants in 
humans are water soluble like glutathione and ascorbic acid, and hydrophobic like 
ubiquinol-10 and α-tocopherol.  
Coenzyme Q10 is the most abundant ubiquinone present in the inner 
membrane of the mitochondria and is the factor normally used to transport 
electrons from complex I and II to complex III. As a reduced form (ubiquinol-10), 
CoQ10 is one of the most potent antioxidants in cell membranes and is fully 
capable of quenching lipid peroxidation.42-44 When ubiquinol-10 is oxidized, it is 
reduced back again by effects of the electron transport chain as shown previously 
in Figure 2. α-Tocopherol is part of the vitamin E family (Figure 7) and is also a 
potent lipophilic antioxidant with excellent properties in quenching lipid 
peroxidation.45 
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Figure 7: Structures of vitamin E components. 
 
Quenching peroxidation of lipid membranes could be accomplished by 
inhibition of the initiation step or propagation step. Phenolic antioxidants (like 
ubiquinol-10 and α-tocopherol) are able to inhibit lipid peroxidation by 
transferring their phenolic hydrogen to the carbon centered or to the peroxyl 
radical (Figure 8).  
 
R·   +   ArOH RH   +   ArO·
ROO·   +   ArOH ROOH   +   ArO·  
Figure 8: Inhibition of lipid peroxidation by phenolic antioxidants. 
 
It has been shown that α-TOH reacts much faster with peroxyl radicals 
than carbon centered radicals during lipid peroxidation,46-49 hence one can assume 
that phenolic antioxidants should act in the same manner. Also, oxygen reacts 
with carbon center radicals in a diffusion controlled process. 
When α-TOH transfers the phenolic hydrogen to a peroxyl radical, a 
radical is form within the antioxidant molecule (Figure 9). The α-TOH radical is 
stabilized by resonance, which contributes to its facile formation. This 
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delocalization of the unpaired electron in the aromatic core makes α-TOH radical 
less reactive for abstraction of another hydrogen from a membrane lipid, therefore 
quenching the propagation step of lipid peroxidation. 
 
OR
OH
ROO ROOH
OR
O
OR
O
Ascorbic acidAscorbic acid
NADH NAD+
 
Figure 9: Quenching of lipid peroxidation by α-TOH and recycling of α-TOH by 
ascorbic acid and NADH.  
 
 The formed α-TOH radicals can be reduced back to α-TOH by other 
redox molecules, such as ascorbic acid and NADH (Figure 9).50  
 The appropriate performance of the mitochondria, especially the electron 
transport chain, is extremely important for human health.  Thus, the synthesis of 
CoQ10 and α-TOH analogues with enhanced properties as antioxidants and as 
electron carriers through the electron transport chain is an important goal, 
especially for treating individuals with impaired mitochondrial function.      
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CHAPTER 2 
2. SYNTHESIS AND CHARACTERIZATION OF IDEBENONE 
ANALOGUES AS MEDIATORS OF OXYGEN CONSUMPTION IN 
MITOCHONDRIA 
2.1 INTRODUCTION 
Mitochondria dysfunction is believed to make an important contribution to 
a number of degenerative diseases.51 Because of this, mitochondria, and more 
specifically the electron transport chain, are considered potential drug targets.52 In 
order to study and treat the impaired electron flow in affected mitochondria, it is 
necessary to create drugs able to reach the inner mitochondrial membrane where 
the electron transport chain is located.    
Coenzyme Q10 (Figure 10a) is one of the electron carriers in the electron 
transport chain, but the effect of using it as therapeutic agent could be expected to 
be weak due to its extreme hydrophobicity (octanol/water partition > 1020), and 
therefore its poor bioavailability.53  
 
O
O
O
O
H
10
a) b) c)
O
O
O
O
OH
10
idebenone
O
O
O
O
PPh3
n
mitoQ'scoenzyme Q10
n = 3, 5, 10
 
Figure 10: Structure of a) coenzyme Q10, b) mitoQ’s and c) idebenone. 
 
 10  
In order to overcome this problem mitochondrial targeted ubiquinone 
antioxidants with varying carbon side chains bearing lipophilic cations at the end, 
such as the triphenylphosphonium group, have been developed (Figure 10b).54,55 
These molecules, called mitoQ’s, accumulate several hundred fold within the 
mitochondria because of the large mitochondrial membrane potential (~150 to 
~170 mV, negative inside). However, accumulation of these cationic species 
might cause depolarization of the mitochondrial membrane and subsequent failure 
of the respiration.56-58 Also, it has been shown that once in the reduce form, the 
mitoQ’s are not able to transfer electrons to complex III.59    
Idebenone is another analogue of CoQ10 that consists of the same redox 
core as coenzyme Q10 but has a shorter aliphatic side chain. (Figure 10c) The side 
chain used in idebenone is only 10 carbons long and bears a hydroxyl group at the 
end. It is thus less lipophilic than coenzyme Q10 but lipophilic enough to interact 
with lipid bilayers. Idebenone is currently in clinical trials phase III for the 
treatment of Friedreich’s ataxia;60 however, studies have revealed that, idebenone 
inhibits complex I in the respiratory chain.61,62  
As part of our efforts to define the structural elements of coenzyme Q10 
essential to support mitochondrial respiration, a family of ubiquinones was 
developed based on idebenone scaffold as a coenzyme Q10 surrogate (Figure 11). 
Thus, the ubiquinones synthesized consisted of analogues containing the same 
lipophilic side chain and having methyl and methoxyl groups at varying positions 
on the redox core.    
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Figure 11: Structures of idebenone analogues 2.1-2.3. 
 
The effect of varying groups (methyl and methoxyl) attached to the 
quinone cores of the analogues synthesized here was then evaluated by their 
ability to support oxygen consumption in the mitochondrial respiratory chain and 
by their ability to confer protection from oxidative stress to cultured CEM cells 
treated with diethyl maleate.     
 
2.2 RESULTS 
 
2.2.1 Synthesis of idebenone analogues 
In order to synthesize idebenone and analogues bearing different redox 
cores, a short pathway was developed (Figure 12). The strategy followed 
consisted of a radical addition of the aliphatic chain to the non-substituted carbon 
of the corresponding quinone core. The radical on the alkyl chain was generated 
from the silver salt of the corresponding carboxylic acid.63  
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O
O
R1
R2 R3
O
O
R1
R2
+
HO
O
R3
R1 = R2= OMe  
R1 = R2= Me     
R1 = OMe   R2 = Me
R1 = Me      R2 = OMe
R3 = aliphatic side chain  
Figure 12: Retrosynthetic analysis of quinone analogues. 
 
The syntheses of idebenone and analogues 5-(10-hydroxydecyl)-2,3,6-
trimethyl-p-benzoquinone (2.1), 2-(10-hydroxydecyl)-5-methoxy-3,6-dimethyl-p-
benzoquinone (2.2) and 2-(10-hydroxydecyl)-6-methoxy-3,5-dimethyl-p-
benzoquinone (2.3) commenced with the preparation of their corresponding 
quinone precursors 2,3,5-trimethyl-p-benzoquinone (2.4), 2-methoxy-3,6-
dimethyl-p-benzoquinone (2.7) and 2-methoxy-3,5-dimethyl-p-benzoquinone 
(2.11) (Scheme 1).  
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Scheme 1: Route employed for the synthesis of quinone cores 2.4, 2.7 and 2.11. 
 
Thus, oxidation of 2,3,5-trimethylphenol using a mixture of iodine, 
sulfuric acid, and aqueous hydrogen peroxide64 at 23 °C afforded compound 2.4 
in 94% yield. Treatment of 2,5-dimethyl-p-benzoquinone with acetic anhydride 
and boron trifluoride-etherate65 at 40 °C afforded 1,2,4-triacetoxy-3,6-
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dimethylbenzene (2.5) in 92% yield; compound 2.5 was then treated with sodium 
hydroxide and dimethyl sulfate in methanol65 at 23 °C to provide 1,2,4-
trimethoxy-3,6-dimethylbenzene (2.6) in 82% yield. Finally, compound 2.6 was 
oxidized using phenyliodine diacetate (PIDA)66 to obtain compound 2.7 in 65% 
yield. Jones oxidation of 2,6-dimethylphenol provided 2,6-dimethyl-p-
benzoquinone (2.8) in 94% yield.67 Quinone 2.8 was then subjected to the same 
synthetic procedures as for the preparation of compound 2.7. Treatment of 
compound 2.8 with acetic anhydride and boron trifluoride etherate at 40 °C 
afforded 1,2,4-triacetoxy-3,5-dimethylbenzene (2.9) in 82% yield; compound 2.9 
was then treated with sodium hydroxide and dimethyl sulfate in methanol at 23 °C 
to provide 1,2,4-trimethoxy-3,5-dimethylbenzene (2.10) in 24% yield. Finally, 
compound 2.10 was oxidized using phenyliodine diacetate (PIDA) to obtain 
compound 2.11 in 66% yield. 
The aliphatic side chain was then introduced (Scheme 2). First, 
commercially available 11-bromoundecanoic acid was treated with the sodium 
salt of benzyl alcohol in DMF at 75 °C to afford 11-benzyloxyundecanoic acid 
(2.12) in 60% yield. Treatment of CoQ0 and of compound 2.4 with compound 
2.12, silver nitrate, and potassium persulfate, in acetonitrile–water63 in the dark at 
75 °C afforded 5-(10-benzyloxydecyl)-2,3-dimethoxy-6-methyl-p-benzoquinone 
(2.13) and 5-(10-benzyloxydecyl)-2,3,6-trimethyl-p-benzoquinone (2.14) in 17% 
and 37% yields, respectively. Cleavage of the benzyl ether protecting group of 
compounds 2.13 and 2.14 by catalytic hydrogenation using palladium-on-carbon 
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in methanol led to idebenone and to compound 2.1 in 82% and 53% yields, 
respectively. 
Br
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H2, Pd/C; then air
AgNO3, K2S2O8, CoQ0
1:1 CH3CN/H2O
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2.1
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BnO
O
OH11
2.12
2.13
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Scheme 2: Route employed for the synthesis of idebenone and analogue 2.1. 
 
For the synthesis of compounds 2.2 and 2.3, 11-hydroxyundecanoic acid 
(2.15) was used directly without any further protection of the hydroxyl group 
(Scheme 3). First, commercially available 11-bromoundecanoic acid was treated 
with aqueous potassium hydroxide at reflux to afford compound 2.15 in 96% 
yield. Treatment of compound 2.7 and compound 2.11 with compound 2.15, 
silver nitrate, and potassium persulfate, in acetonitrile–water in the dark at 75 °C 
afforded compounds 2.2 and 2.3 in 10% and 15% yields, respectively. 
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Scheme 3: Route employed for the synthesis of idebenone analogues 2.2 and 2.3. 
 
2.2.2 Electrochemical evaluation of the redox cores 
Cyclic voltammetric analyses of the redox cores 2.4, 2.7 and 2.11 are 
presented in comparison with CoQ0. Figure 13 shows that the redox cores of 2.7 
and 2.11 have similar redox potentials and that they are harder to reduce than 
CoQ0. However, CoQ0 shows a second process at more negative potentials than 
compounds 2.7 and 2.11, which might correspond to the second electron 
reduction process.  Compound 2.4 showed a more negative reduction potential 
than any of the other cores evaluated.  
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Figure 13: Cyclic voltammetry of CoQ0 (green), 2.4 (red), 2.7 (blue) and 2.11 
(brown) in 0.1 M tetrabutylammonium perchlorate in acetonitrile using Ag/AgCl 
electrode as a reference. Experiment performed by Manikandadas M. Madathil. 
 
2.2.3 Biochemical and biological evaluation of idebenone analogues 
In order to evaluate the structural effects of the prepared analogues of 
idebenone 2.1-2.3, the compounds were tested for oxygen consumption and in cell 
viability assays. 
 
2.2.3.1 Oxygen consumption assay 
C2C12 cells pretreated with 25 nM rotenone were further treated with 
10µM of compounds 2.1-2.3 and idebenone, either in the presence or absence of 5 
O
O
O
O
O
O
O
O
O
O
O
O
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µM of FCCP (carbonylcyanide p-trifluoromethoxyphenylhydrazone). Oxygen 
consumption was monitored for 2 h and quantified. As shown in Figure 14, 
rotenone + idebenone stimulated mitochondrial oxygen consumption about 50% 
above the basal level. This was consistent for each of the idebenone analogues as 
well, and all four compounds stimulated maximal O2 consumption about 3-fold.  
 
 
Figure 14: Effects of idebenone and compounds 2.1-2.3 in supporting 
mitochondrial oxygen consumption in C2C12 cells. Modified from Ref. 68. This 
experiment was performed by Robert A. Schoenfeld.   
 
2.2.3.2 Cytoprotective effects of idebenone analogues 
The promising effects noted with idebenone and its analogues 2.1-2.3 in 
supporting mitochondrial oxygen consumption encouraged us to assay these 
compounds for their ability to protect mammalian cells from the effects of 
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oxidative stress. Accordingly, cultured CEM leukemia cells were treated with 5 
mM diethyl maleate to deplete cellular glutathione, thus exposing the cells to the 
effects of oxidative stress. Pretreatment of the cells with idebenone and 2.1-2.3 
prior to diethyl maleate treatment actually did confer protection to the cells, as 
summarized in Table 1. As shown in Table 1 compound 2.1, containing two 
methyl groups in place of the methoxyl groups in idebenone, was actually the 
most effective, conferring virtually complete protection against depletion of 
glutathione when employed at a concentration of 2.5 µM and affording the best 
protection when used at 0.1 µM concentration. Compounds 2.1 and 2.2 showed 
similar protection at 0.5 µM concentration. Compound 2.3 was the least effective 
at all concentrations tested.  
   
Table 1: Cytoprotective effects of idebenone and 2.1-2.3 on cultured CEM cells 
treated with diethyl maleate. Experiment performed by Nidhi Raghav 
 Viable cells (% of control) 
Compound 0.1 µM 0.5 µM 2.5 µM 
idebenone 24.6 ± 1.2 35.8 ± 3.3 86.2 ± 4.1 
2.1 34.8 ± 3.4 77.3 ± 2.8 96.3 ±3.7 
2.2 22.9 ± 0.8 74.7 ± 7.7 82.3 ± 3.7 
2.3 8.27 ± 0.7 21.2 ± 1.0 77.1 ± 1.4 
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2.3 DISCUSSION  
The key step for the synthesis of idebenone and analogues 2.1-2.3 was the 
radical addition of the aliphatic chain. For the synthesis of idebenone and 
analogue 2.1 the hydroxyl group of the aliphatic chain was protected giving 
modest yields; however, having the hydroxyl group deprotected did not affect the 
yields for the radical addition. The substitution of methoxyl groups on the 
quinone ring for methyl groups causes a shift of the reduction potential to more 
negative regions, which means that they are harder to reduce.  
While the errors associated with mitochondrial oxygen consumption 
measurements do not permit a more detailed analysis of those structural elements 
within the quinone moiety, they do suggest that some variation in substituents on 
the quinone moiety can be tolerated, and thus support the concept that 
exogenously supplied coenzyme Q analogues may be envisioned as 
mechanistically and therapeutically relevant probes. Idebenone and each of its 
analogues 2.1-2.3 promoted basal mitochondrial O2 consumption by about 50%, 
and maximal mitochondrial O2 consumption by about 300%, i.e. much more than 
in the presence of rotenone itself.  The method by which idebenone and its 
analogues increased mitochondrial O2 consumption could be either through 
uncoupling mitochondria, or through supporting maximal electron transport 
activity.  Since rotenone + FCCP only produced a 50% increase in O2 over 
rotenone alone, whereas idebenone and analogues + FCCP produced a 300% 
increase, the latter hypothesis (facilitation of maximal electron transport activity) 
is better supported.  However, further studies of absolute mitochondrial 
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productivity (like ATP synthesis and interaction with the components of the 
electron transport chain) are necessary to confirm this idea. 
 
2.4 EXPERIMENTAL 
Reactions were carried out under an atmosphere of argon unless specified 
otherwise.  The glassware was dried in an oven at 110 °C prior to use.  All other 
solvents were of analytical grade and were used without further purification. Flash 
column chromatography was carried out using silica gel (Silicycle R10030B, 60 
Å particle size, 230-400 mesh), applying a low pressure stream of nitrogen or air.  
Analytical thin layer chromatographic separations were carried on glass plates 
coated with silica gel (60 Å particle size, 250 µm thickness, F-254, Silicycle).  
The TLC chromatograms were developed using iodine vapor, or by immersing the 
plates either in 2.5% phosphomolybdic acid in ethanol, or in 2.0% anisaldehyde in 
ethanol/sulfuric acid/acetic acid, followed by heating (heat gun).  1H NMR 
chemical shifts were reported relative to residual CHCl3 at 7.26 ppm; 13C NMR 
chemical shifts were reported relative to the central line of CDCl3 at 77.0 ppm. 
High resolution mass spectra were obtained in the Arizona State University CLAS 
High Resolution Mass Spectrometry Laboratory. 
 
O
O
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Trimethyl-p-benzoquinone (2.4).64 To a stirred solution containing 1.00 g (6.57 
mmol) of trimethyl-p-hydroquinone in 20 mL of methanol at 23 °C was added 
83.3 mg (0.33 mmol) of iodine followed by 329 µL (2.90 mmol) of 30% aq 
hydrogen peroxide and 329 µL (0.93 mmol) of sulfuric acid. The reaction mixture 
was stirred at 23 °C for 3 h and was then diluted with 150 mL of ether.  The 
organic layer was washed with three 75-mL portions of water, then with one 75-
mL portion of satd aq sodium thiosulfate and finally with 75 mL of brine.  The 
organic layer was dried (MgSO4) and concentrated under diminished pressure to 
afford compound 2.4 as yellow crystals: yield 930 mg (94%); mp 29-30 ºC; silica 
gel TLC Rf  0.65 (3:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 2.03 (m, 9H) 
and 6.56 (s, 1H); 13C NMR (CDCl3) δ 12.0, 12.3, 15.9, 133.0, 140.7, 140.9, 145.3, 
187.5 and 187.9. 
OAc
OAc
OAc
 
1,2,4-Acetoxy-3,6-dimethylbenzene (2.5).65 To a stirred solution at 23 °C 
containing 1.00 g (7.34 mmol) of 2,5-dimethyl-p-benzoquinone in 8.0 mL of 
acetic anhydride was added 400 µL (3.13 mmol) of boron trifluoride etherate.  
The reaction mixture was stirred at 40 °C for 48 h and was then poured into 100 
mL of water. The formed precipitate was collected by filtration, and was dried 
under diminished pressure to afford compound 2.5 as a colorless solid: yield 1.89 
g (92%); mp 97-98 °C; silica gel TLC Rf 0.5 (1:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 1.95 (s, 3H), 2.14 (s, 3H), 2.29 (s, 9H) and 6.84 (s, 1H); 13C 
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NMR (CDCl3) δ 10.1, 16.0, 20.2, 20.7, 20.8, 121.4, 122.5, 129.5, 139.2, 141.8, 
146.7, 167.8, 167.9 and 168.8; mass spectrum (EI), m/z 280.0927 (M)+ (C14H16O6 
requires 280.0947). 
OMe
OMe
OMe
 
1,2,4-Trimethoxy-3,6-dimethylbenzene (2.6).65 To a stirred solution at 23 °C 
containing 1.84 g (6.74 mmol) of compound 2.5 in 6.0 mL of methanol was added 
5.0 mL (6.7 g; 52 mmol) of dimethyl sulfate followed by the slow addition of a 
solution containing 2.17 g (54.3 mmol) of sodium hydroxide in 2.5 mL of water. 
The reaction mixture was stirred at 23 °C for 16 h.  The reaction mixture was 
poured into 60 mL of water and was then extracted with 80 mL of 1:1 diethyl 
ether–hexanes and then with 60 mL of hexanes.  The combined organic layer was 
washed with 80 mL of water and then with 80 mL of brine.  The solution was 
dried (MgSO4) and was then concentrated under diminished pressure.  The 
residue was applied to a silica gel column (10 × 6 cm); elution with 3:1 hexanes–
ethyl acetate afforded compound 2.6 as a colorless oil; yield 1.08 g (82%); silica 
gel TLC Rf  0.62 (4:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 2.12 (s, 3H), 
2.27 (s, 3H), 3.78 (s, 3H), 3.79 (s, 3H), 3.83 (s, 3H) and 6.43 (s, 1H); 13C NMR 
(CDCl3) δ 8.7, 16.0, 55.7, 60.3, 60.3, 107.5, 118.0, 128.5, 145.3, 151.8 and 153.8; 
mass spectrum (EI), m/z 196.1094 (M)+ (C11H16O3 requires 196.1100). 
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2-Methoxy-3,6-dimethyl-p-benzoquinone (2.7). To a stirred solution containing 
900 mg (4.85 mmol) of compound 2.6 in 30 mL of 9:1 water–methanol at 23 °C 
was added 2.21 g (6.86 mmol) of phenyliodine diacetate (PIDA). The reaction 
mixture was stirred at 40 °C for 16 h, and then poured into 100 mL of water.  The 
product was extracted with 150 mL of ether.  The organic layer was washed with 
100 mL of water, then with 100 mL of satd aq sodium bicarbonate solution and 
100 mL of brine, and was then dried (MgSO4) and concentrated under diminished 
pressure. The residue was applied to a silica gel column (10 × 6 cm); elution with 
3:1 hexanes–ethyl acetate afforded compound 2.7 as a yellow solid: yield: 543 mg 
(65%); mp 58-59 °C; silica gel TLC Rf  0.46 (4:1 hexanes–ether); 1H NMR 
(CDCl3) δ 1.93 (s, 3H), 2.03 (s, 3H), 3.98 (s, 3H) and 6.51 (s, 1H); 13C NMR 
(CDCl3) δ 8.8, 15.7, 60.8, 128.8, 133.1, 143.7, 155.5, 183.6 and 188.5; mass 
spectrum (EI), m/z 166.0632 (M)+ (C9H10O3 requires 166.0630). 
O
O
 
2,6-Dimethyl-p-benzoquinone (2.8).67 To a stirred solution at 23 °C containing 
2.00 g (16.4 mmol) of 2,6-dimethylphenol in 20 mL of diethyl ether was added 
dropwise a solution containing 11.0 g (36.9 mmol) of sodium dichromate-
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dihydrate and 7 mL of sulfuric acid in 20 mL of water (Jones’ reagent).  The 
reaction mixture was stirred at 23 °C for 16 h, and was then poured into 150 mL 
of water.  The product was extracted using three 150-mL portions of ether.  The 
combined organic layer was washed with 150 mL of water, then with 150 mL of 
brine, and was then dried (MgSO4) and concentrated under diminished pressure to 
afford compound 2.8 as a yellow solid; yield 2.10 g (94%); mp 65-66 °C; silica 
gel TLC Rf  0.60 (5:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 2.05 (s, 6H) 
and 6.55 (s, 2H); 13C NMR (CDCl3) δ 16.0, 17.0, 133.3, 145.8, 187.6 and 188.2. 
OAc
OAc
OAc
 
1,2,4-Acetoxy-3,5-dimethylbenzene (2.9).65 To a stirred solution containing 1.10 
g (8.08 mmol) of compound 2.8 in 8.0 mL of acetic anhydride at 23 °C was added 
360 µL (3.23 mmol) of boron trifluoride etherate. The reaction mixture was 
stirred at 40 °C for 48 h. The reaction mixture was poured into 100 mL of water 
and the product was extracted with two 75-mL portions of ethyl acetate.  The 
combined organic layer was washed with 60 mL of water, then with 60 mL of 
satd aq sodium bicarbonate and 60 mL of brine, and was dried (MgSO4) and 
concentrated under diminished pressure.  The residue was applied to a silica gel 
column (12 × 3 cm); elution with 3:1 hexanes–ethyl acetate afforded compound 
2.9 as a colorless solid: yield 1.86 g (82%); mp 94-95 °C; silica gel TLC Rf  0.25 
(3:1 hexanes/ethyl acetate); 1H NMR (CDCl3) δ 1.97 (s, 3H), 2.13 (s, 3H), 2.25 (s, 
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3H), 2.33 (s, 3H), 2.99 (s, 3H) and 6.92 (s, 1H); 13C NMR (CDCl3) δ 10.5, 16.3, 
20.2, 20.4, 20.6, 121.9, 125.1, 128.7, 139.2, 139.9, 145.8, 167.8, 168.3 and 168.3; 
mass spectrum (APCI), m/z 281.1031 (M+H)+ (C14H17O6 requires 281.1025). 
OMe
OMe
OMe
 
1,2,4-Trimethoxy-3,5-dimethylbenzene (2.10).65 To a stirred solution containing 
1.77 g (6.31 mmol) of compound 2.9 in 5.0 mL of methanol at 23 °C was added 
5.0 mL (6.7 g; 52 mmol) of dimethyl sulfate followed by the slow addition of a 
solution containing 5.25 g (56.3 mmol) of sodium hydroxide in 6 mL of water. 
The reaction mixture was stirred at 23 °C for 16 h, and was then poured into 60 
mL of water.  The product was extracted with 80 mL of 1:1 ethyl acetate–hexanes 
and then with 60 mL of hexanes. The combined organic layer was washed with 80 
mL of water, then with 80 mL of brine, and was dried (MgSO4) and concentrated 
under diminished pressure.  The residue was applied to a silica gel column (12 × 3 
cm); elution with 3:1 hexanes–ethyl ether afforded compound 2.10 as a colorless 
oil: yield 292 mg (24%); silica gel TLC Rf 0.5 (9:1 hexanes–ether); 1H NMR 
(CDCl3) δ 2.21 (s, 3H), 2.52 (s, 3H), 3.66 (s, 3H), 3.77 (s, 3H), 3.81 (s, 3H) and 
6.56 (s, 1H); 13C NMR (CDCl3) δ 9.4, 16.0, 55.9, 59.9, 60.3, 111.5, 125.2, 125.7, 
145.8, 148.9 and 150.6; mass spectrum (EI), m/z 196.1094 (M)+  (C11H16O3 
requires 196.1100). 
 27  
O
O
OMe
 
2-Methoxy-3,5-dimethyl-p-benzoquinone (2.11). To a stirred solution 
containing 500 mg (2.55 mmol) of compound 2.10 in 15 mL of 9:1 water–
methanol at 23 °C was added 1.22 g (3.78 mmol) of PIDA.  The reaction mixture 
was stirred at 40 °C for 16 h, and was then poured into 50 mL of water.  The 
product was extracted with 150 mL of ether.  The organic layer was washed with 
100 mL of water, then with 100 mL of satd aq sodium bicarbonate, and with 100 
mL of brine, and was dried (MgSO4) and concentrated under diminished pressure.  
The residue was applied to a silica gel column (12 × 3 cm); elution with 3:1 
hexanes–diethyl ether afforded compound 2.11 as a yellow solid: yield 282 mg 
(66%); mp 55-56 °C; silica gel TLC Rf  0.47 (4:1 hexanes–diethyl ether); 1H 
NMR (CDCl3) δ 1.95 (s, 3H), 2.03 (s, 3H), 4.01 (s, 3H) and 6.43 (s, 1H); 13C 
NMR (CDCl3) δ 8.8, 15.7, 60.8, 128.8, 131.4, 145.7, 155.5, 183.6 and 188.5; 
mass spectrum (EI), m/z 166.0625 (M)+ (C9H10O3 requires 166.0630). 
O OH
O
 
11-Benzoxyundecanoic acid (2.12). To a stirred solution containing 330 mg 
(8.25 mmol) of sodium hydride in 15 mL of anhydrous DMF at 23 °C was added 
dropwise 490 µL (510 mg; 4.71 mmol) of anhydrous benzyl alcohol followed by 
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1.00 g (3.77 mmol) of 11-bromoundecanoic acid.  The reaction mixture was 
stirred at 75 °C for 3 h, and was then poured into 100 mL of ether.  The formed 
precipitate was collected by filtration.  The solid was then dissolved in 70 mL of 
water and the pH was adjusted to ~1.  The product was extracted with 75 mL of 
dichloromethane.  The organic layer was washed with two 60-mL portions of 
water, then with 60 mL of brine, and was then dried (MgSO4) and concentrated 
under diminished pressure to afford compound 2.12 as a colorless wax: yield 660 
mg (60%); silica gel TLC Rf  0.15 (4:1 hexanes–ethyl acetate); 1H NMR (CDCl3) 
δ 1.28 (m, 12H), 1.62 (m, 4H), 2.34 (t, 2H, J = 7.6 Hz), 3.46 (t, 2H, J = 6.8 Hz), 
4.50 (s, 2H), 6.98 (m, 1H) and 7.03 (m, 4H); 13C NMR (CDCl3) δ 24.7, 26.1, 
29.0, 29.2, 29.3, 29.4, 29.5, 29.7, 34.0, 70.5, 72.8, 127.4, 127.6, 127.6, 128.3, 
128.3, 138.7 and 179.7; mass spectrum (APCI), m/z 293.2106 (M+H)+ (C18H29O3 
requires 293.2117). 
O
O
O
O O
 
5-(10-Benzyloxydecyl)-2,3-dimethoxy-6-methyl-p-benzoquinone (2.13). To a 
stirred solution containing 900 mg (3.07 mmol) of compound 2.12 and 500 mg 
(2.74 mmol) of coenzyme Q0 in 50 mL of acetonitrile at 23 °C was added 464 mg 
(2.74 mmol) of silver nitrate. The reaction mixture was heated to 75 °C, then 900 
mg (3.32 mmol) of potassium persulfate in 50 mL of water was added very 
slowly.  The reaction mixture was stirred at 75 °C for 4 h and was then cooled to 
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23 °C, and poured into 25 mL of water.  The product was extracted with 50 mL of 
ethyl acetate.  The organic layer was washed with 25 mL of satd aq sodium 
bicarbonate, then with 25 mL of brine, and was then dried (MgSO4) and 
concentrated under diminished pressure.  The residue was applied to a silica gel 
column (12 × 4 cm); elution with 3:1 hexanes–ethyl acetate afforded compound 
2.13 as an orange oil: yield 200 mg (17%); silica gel TLC Rf  0.75 (4:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 1.34 (m, 14H), 1.60 (quint, 2H, J = 5.2 Hz), 
2.04 (s, 3H), 2.44 (t, 2H, J = 8.4 Hz), 3.46 (t, 2H, J = 6.4 Hz), 3.98 (s, 6H), 4.50 
(s, 2H), 7.27 (m, 1H), 7.34 (m, 4H); 13C NMR (CDCl3) δ 11.9, 26.2, 26.4, 28.7, 
29.3, 29.4, 29.5, 29.8, 61.1, 70.5, 72.8, 127.44, 127.6, 128.3, 138.6, 138.7, 143.1, 
144.29, 144.30, 184.1 and 184.7; mass spectrum (APCI), m/z 429.2637 (M+H)+ 
(C26H37O5 requires 429.2641). 
O
O
O
O OH
 
Idebenone.69 To a stirred solution containing 200 mg (467 µmol) of compound 
2.13 in 5 mL of anh methanol at 23 °C was added 15 mg of 10 % palladium-on-
carbon in one portion.  The reaction mixture was stirred at 23 °C under an 
atmosphere of hydrogen for 24 h.  Air was then bubbled through the reaction 
mixture at 23 °C for 24 h.  The suspension was filtered through Celite® and the 
filtrate was concentrated under diminished pressure to afford idebenone as an 
orange solid: yield 130 mg (82%); mp 46-47 °C; 1H NMR (CDCl3) δ 1.34 (m, 
 30  
14H), 1.60 (quint, 2H, J = 7.6 Hz), 2.04 (s, 3H), 2.44 (t, 2H, J = 8.0 Hz), 3.63 (t, 
2H, J = 6.8 Hz) and 3.99 (s, 6H); 13C NMR (CDCl3) δ 11.9, 25.7, 26.4, 28.7, 29.3, 
29.4, 29.5, 29.8, 32.7, 61.1, 63.0, 138.6, 143.1, 144.3, 184.1 and 184.7. 
O
O
O
 
5-(10-Benzyloxydecyl)-2,3,6-trimethyl-p-benzoquinone (2.14). To a stirred 
solution containing 600 mg (3.11 mmol) of 2.12 and 450 mg (3.00 mmol) of 
compound 2.4 in 50 mL of acetonitrile at 23 °C was added 509 mg (3.00 mmol) 
of silver nitrate.  The reaction mixture was heated to 75 °C and then 981 mg 
(3.63 mmol) of potassium persulfate in 50 mL of water was added very slowly.  
The reaction mixture was stirred at 75 °C for 3 h in the dark, and was then 
allowed to cool to 23 °C and poured into 25 mL of water.  The product was 
extracted with 50 mL of ethyl acetate.  The organic layer was washed with 25 mL 
of water, then with 25 mL of satd aq sodium bicarbonate, and 25 mL of brine, 
then dried (MgSO4). Concentration was then carried out under diminished 
pressure.  The residue was purified by chromatography on silica gel column (13 × 
4 cm); elution with 3:1 hexanes–ethyl acetate afforded compound 2.14 as an 
orange oil: yield 330 mg (37%); silica gel TLC Rf  0.75 (3:1 hexanes–ethyl 
acetate); 1H NMR  (CDCl3) δ 1.26 (m, 14H), 1.59 (quint, 2H, J = 7.2 Hz), 2.00 
(m, 9H), 2.43 (t, 2H, J = 8.0 Hz), 3.44 (t, 2H, J = 6.4 Hz), 4.50 (s, 2H), 7.25 (m, 
1H) and 7.31 (m, 4H); 13C NMR (CDCl3) δ 12.1, 12.3, 26.2, 26.6, 28.8, 29.3, 
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29.4, 29.5, 29.8, 29.9, 70.5, 72.8, 127.4, 127.6, 128.3, 138.7, 140.0, 140.3, 144.5, 
187.1 and 187.8; mass spectrum (EI), m/z 296.2676 (M)+ (C26H36O3 requires 
396.2665). 
O
O
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5-(10-Hydroxydecyl)-2,3,6-trimethyl-p-benzoquinone (2.1). To a stirred 
solution containing 330 mg (0.832 mmol) of compound 2.14 in 6 mL of 
anhydrous methanol at 23 °C was added 20 mg of 10% palladium-on-carbon.  
The reaction mixture was stirred at 23 °C under a hydrogen atmosphere for 24 h, 
then air was bubbled through the reaction mixture at 23 °C for 24 h.  The 
suspension was filtered through Celite and the filtrate was concentrated under 
diminished pressure.  The residue was applied to a silica gel column (13 × 4 cm); 
elution with 3:1 hexanes–ethyl acetate afforded compound 2.1 as a yellow solid: 
yield 130 mg (51%); mp 61-62 °C; silica gel TLC Rf 0.4 (3:1 hexanes–ethyl 
acetate); 1H NMR (CDCl3) δ 1.26 (m, 14H), 1.53 (quint, 2H, J = 6.4 Hz), 2.00 (m, 
9H), 2.43 (t, 2H, J = 8.0 Hz) and 3.61 (t, 2H, J = 6.8 Hz); 13C NMR (CDCl3) δ 
12.1, 12.3, 25.7, 26.6, 28.8, 29.31, 29.34, 29.4, 29.5, 29.8, 32.7, 63.0, 140.0, 
140.3, 140.4, 144.5, 187.2 and 187.9; mass spectrum (APCI), m/z 307.2270 
(M+H)+ (C19H31O3 requires 307.2273). 
HO OH
O
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11-Hydroxyundecanoic Acid (2.15). To 70 mL of 2 M aq potassium hydroxide 
solution was added 1.60 g (6.08 mmol) of 11-bromoundecanoic acid.  The 
reaction mixture was stirred at 100 °C for 16 h, and was then cooled to 23 °C.  
The pH was adjusted to ~1 by addition of conc HCl.  The formed precipitate was 
collected by filtration and was then dried under diminished pressure to afford 
compound 2.15 as a colorless solid: yield 1.18 g (96%); mp 65-66 °C; 1H NMR 
(CDCl3) δ 1.28 (m, 12H), 1.62 (m, 4H), 2.34 (t, 2H, J = 7.6 Hz) and 3.63 (t, 2H, J 
= 6.8 Hz); 13C NMR (CDCl3) δ 24.6, 25.6, 29.0, 29.1, 29.3, 29.4, 32.7, 34.0, 63.0 
and 179.3; mass spectrum (APCI), m/z 203.1651 (M+H)+ (C11H23O3 requires 
203.1647). 
O
O
O
OH
 
2-(10-Hydroxydecyl)-5-methoxy-3,6-dimethyl-p-benzoquinone (2.2). To a 
stirred solution containing 110 mg (0.54 mmol) of compound 2.15 and 85.0 mg 
(0.51 mmol) of compound 2.7 in 2.5 mL of acetonitrile at 23 °C was added 87.0 
mg (0.51 mmol) of silver nitrate.  The reaction mixture was heated to 75 °C, then 
167 mg (0.61 mmol) of potassium persulfate in 2.5 mL of water was added very 
slowly.  The reaction mixture was stirred at 75 °C for 4 h, and was then allowed 
to cool to 23 °C, and poured into 50 mL of water. The product was extracted with 
75 mL of dichloromethane.  The organic layer was washed with 75 mL of water, 
then with 75 mL of satd aq sodium bicarbonate and 75 mL of brine, and was then 
dried (MgSO4) and concentrated under diminished pressure.  The residue was 
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applied to a silica gel column (10 × 3 cm); elution with 19:1 dichloromethane–
ethyl ether afforded compound 2.2 as an orange solid: yield 25 mg (15%); mp 58-
59 °C; silica gel TLC Rf  0.32 (3:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 
1.28 (m, 14H), 1.59 (quint, 2H, J = 7.0 Hz), 1.93 (s, 3H), 2.01 (s, 3H), 2.44 (t, 2H, 
J = 7.0 Hz), 3.62 (t, 2H, J = 6.5 Hz) and 3.95 (s, 3H); 13C NMR (CDCl3) δ 8.8, 
12.2, 26.16, 26.22, 28.7, 29.4, 29.5, 29.8, 60.9, 63.0, 72.8, 128.6, 140.3, 143.1, 
155.4, 183.4 and 188.7; mass spectrum (APCI), m/z 322.2217 (M+H)+ (C19H31O4 
requires 322.2222). 
O
O
O OH
 
2-(10-Hydroxydecyl)-6-methoxy-3,5-dimethyl-p-benzoquinone (2.3). To a 
stirred solution containing 364 mg (1.79 mmol) of compound 2.15 and 282 mg 
(1.69 mmol) of compound 2.11 in 10 mL of acetonitrile at 23 °C was added 288 
mg (1.69 mmol) of silver nitrate.  The reaction mixture was heated to 75 °C, then 
552 mg (2.04 mmol) of potassium persulfate in 10 mL of water was added 
dropwise.  The reaction mixture was stirred at 75 °C for 4 h, then allowed to cool 
to 23 °C, and then poured into 50 mL of water. The mixture was extracted with 75 
mL of dichloromethane.  The organic layer was washed with 75 mL of water, then 
with 75 mL satd aq sodium bicarbonate, and 75 mL of brine, and was then dried 
(MgSO4) and concentrated under diminished pressure.  The residue was applied to 
a silica gel column (12 × 3 cm); elution with 19:1 dichloromethane–ether afforded 
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compound 2.3 as an orange wax: yield 56 mg (10%); silica gel TLC Rf 0.33 (3:1 
hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.28 (m, 14H), 1.59 (quint, 2H, J = 
7.2 Hz), 1.93 (s, 3H), 2.01 (s, 3H), 2.43 (t, 2H, J = 8.0 Hz), 3.62 (t, 2H, J = 6.8 
Hz) and 3.95 (s, 3H); 13C NMR (CDCl3) δ 8.8, 12.2, 26.2, 28.7, 29.4, 29.5, 29.8, 
60.9, 63.0, 72.8, 128.6, 140.3, 143.1, 155.4, 183.4 and 188.7; mass spectrum 
(APCI), m/z 323.2229 (M+H)+ (C19H31O4 requires 323.2222). 
 
Measurement of oxygen consumption 
C2C12 cells were grown in DMEM supplemented with 10% fetal bovine 
serum and 2nM glutamine. Mitochondrial O2 consumption was performed 
essentially as described in literature70 with minor modifications. Briefly, C2C12 
cells were trypsinized and resuspended in phenol red-free growth medium, treated 
with 25 nM of rotenone and plated at 200,000 cells/well in a 96-well BD Oxygen 
Biosensor plate. Compounds 2.1-2.3 and idebenone (10 µM) were added and 
fluorescence was monitored for 2 h in a PerSeptive Biosystems Cytofluor Series 
4000 plate reader (ex 485 nm; em 620 nm). Oxygen consumption was quantified 
by calculating M/T, that is, the slope of 50% maximum divided by the time to 
reach 50% maximum. This experiment was performed by Robert A. Schoenfeld, 
UC Davis. 
 
Measurement of cytoprotective effects of idebenone analogues  
CEM cells were grown in RPMI medium 1640 (Gibco, Grand Island, NY) 
supplemented with 10% fetal bovine serum (Hylcone South Logan Utah) and 1% 
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penicillin-streptomycin solution (Cellgro, Manassas, VA). In a 12-well cell 
culture plate 500,000 cells per well were seeded and treated with compounds 2.1-
2.3 and idebenone for 18 h. Cells were then treated with DEM (diethyl meleate) at 
37 °C for 4 h in a humidified atmosphere of 5% CO2 in air. The viability of the 
cells was measured by staining with 0.4% trypan blue. Viable cells exclude the 
dye and non-viable cells take-up the dye. Cell viability is calculated as percentage 
of positive control (cells not treated with DEM or the idebenone analogues). Data 
are expressed as mean ± SDE (n=3).  This experiment was performed by Nidhi 
Raghav, ASU. 
 
Cyclic voltammetry  
Cyclic voltammetry (CV) studies were carried out using a Model 1030 
multi-potentiostat from CH Instruments.  The platinum working electrode (2 mm 
diameter, model CHI102), platinum wire counter electrode (model CHI115), and 
Ag/AgCl reference electrode (model CHI111) were obtained from CH 
Instruments.  Cyclic voltammetry measurements were performed in a precut 20 
mL vial at room temperature in 2 mL of a 0.1 M tetrabutylammonium perchlorate 
solution in acetonitrile containing the quinone analyte at a 1 mM (CoQ0, 
compounds 2.7 and 2.11) and 2 mM (compound 2.4) concentrations.  The 
analytes were dissolved in acetonitrile.  The vial was covered with a Teflon cap 
(CHI223) and sealed using parafilm.  All samples were purged with nitrogen for 5 
min to remove any oxygen.  The substrate was then added with a syringe and 
stirred for 1 minute.  Stirring was stopped and the nitrogen stream was focused 
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above the sample so that only the headspace was streamed with nitrogen.  The cell 
was allowed to sit for one minute to allow for the diffusion layer to set up and 
come to equilibrium.  The parameters used for the starting and vertex potential 
were –1.5 V and 1.5 V respectively, and the scan rate was 100 mV/s.  The cyclic 
voltammagrams of the quinone cores were recorded using an initial reductive 
sweep. Between each CV experiment, the electrodes were rinsed with 
dichloromethane.  The platinum working electrode was then rinsed with water and 
polished with 0.05 micron aluminum powder and distilled water on a polishing 
pad (CHI120).  Immediately before each CV was performed, all electrodes were 
rinsed with acetonitrile. This experiment was performed by Manikandadas 
Mathilakathu Madathil. 
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CHAPTER 3 
3. SYNTHESIS AND CHARACTERIZATION OF PYRIDINOL AND 
PYRIMIDINOL AS MULTIFUNCTIONAL RADICAL QUENCHERS 
 
3.1 INTRODUCTION 
It is well know that cellular respiration is the process that produces more 
oxidative damage to the cell due to the production of ROS.71 Increased production 
of ROS is linked to mitochondrial dysfunction, more specifically to an inefficient 
electron transport through the respiratory chain.  Several human 
neurodegenerative diseases including Alzheimer’s disease, MELAS syndrome, 
and Friedreich’s ataxia are strongly linked to mitochondrial dysfunction. 37,72  
One of the most common autosomal recessive ataxia in the Caucasian 
population is Friedreich’s ataxia (FRDA);73 approximately, 1 in 50,000 people in 
the United States are affected. Currently there are no effective therapeutic 
strategies to treat this disease. Friedreich’s ataxia is caused by a reduced 
production of the protein frataxin, approximately in the range of 5% to 30% of 
normal levels.34 It is believed that frataxin is involved in trafficking of iron within 
the mitochondria and the assembly of iron sulfur (Fe-S) clusters. Low levels of 
frataxin leads to iron accumulation, inappropriate function of Fe-S cluster 
containing enzymes, and a high incidence of Fenton’s type reactions producing 
high levels of ROS.74,75  
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Idebenone (Catena®), a synthetic analogue of coenzyme Q10, is currently 
the only compound that has reached phase III clinical trials for the treatment of 
FRDA.60  
It has been shown that a major source of superoxide production during 
respiration occurs at complex III. The redox cycle in this complex involve the 
formation of ubisemiquinone radical, which could be oxidized back by oxygen 
generating superoxide (Figure 15).11,12 Then, it can be assume that quinone 
analogues of CoQ10 could generate superoxide in the same fashion as CoQ10. 
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Figure 15:  Oxidation of ubisemiquinone radical by molecular oxygen. 
 
α-TOH is one of the best lipophilic antioxidants; although, it has been 
shown that the α-TOH radical formed during inhibition of lipid peroxidation in 
low density lipoproteins (LDL) particles is capable of promoting oxidation of 
lipids under mild conditions by initiating the peroxidation chain reaction.76,77   
The activity of phenolic antioxidants in quenching lipid membrane 
peroxidation relies on their ability to transfer the phenolic hydrogen to a carbon or  
peroxyl radical and on the stability of the phenoxyl radical formed. Thus, novel 
synthetic and more potent antioxidants than α-TOH are currently under 
development.   
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The stability of phenoxyl radicals formed could be measured by O-H bond 
dissociation energy (O-H BDE), the lower the BDE, the more stable the radical 
formed. It has been shown that increasing the ring electronic density of phenolic 
antioxidants lowers the hydroxyl BDE, thus their activity as antioxidants is 
enhanced.78,79 Nonetheless, some antioxidants with strong electron donating 
groups are unstable to air. 46,80 Air stability is correlated to the ionization potential 
(IP) of molecules, lower the IP, easier is to abstract an electron from the molecule. 
If an antioxidant has a very low IP, it could transfer an electron to molecular 
oxygen, losing its properties as an antioxidant and becoming a source superoxide. 
Recognizing that the O-H BDE depends mostly on π-interactions with 
ortho and para substituents and IP depends on σ-induced electron density, a 
series of aminopyridinols has been synthesized and evaluated as antioxidants 
(Figure 16).81,82 Their particular structure confers upon them greater inhibition 
rate constants than α-tocopherol in quenching lipid peroxidation and enhanced air 
stability. These properties are due to the presence of electron donating groups 
attached to the aromatic core that lowers the O-H BDE and the presence of 
nitrogen atoms as part of the aromatic ring that increase the IP (more stable 
towards oxidation).83 
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Figure 16: Pyridinols with enhanced activities as antioxidants. 
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As part of the effort to synthesize compounds with enhanced antioxidant 
activity a family of pyridinols (Figure 17) and pyrimidinols (Figure 18) with 
different substituents attached to the core was developed. Also, to study their 
ability to reach mitochondria and their interaction with the electron transport 
chain, different lipophilic side chains were attached. 
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Figure 17: Series of pyridinol analogues synthesized and evaluated. 
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Figure 18: Series of pyrimidinol analogues synthesized and evaluated. 
 
The effect of varying groups and lipophilic side chains attached to 
pyridinol and pyrimidinol cores of the analogues synthesized here was then 
evaluated by their ability to confer protection from oxidative stress to cultured 
FRDA lymphocytes cells treated with diethyl maleate. The effect of the analogues 
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synthesized towards interaction with the electron transport chain complexes was 
studied using submitochondrial particles (SMP) prepared from bovine heart.    
 
3.2 RESULTS 
In order to synthesize a first generation of pyridinol and pyrimidinol 
analogues having a methyl group at the position ortho to the phenolic hydroxyl 
group, a concise strategy was followed (Figure 19). The strategy consisted of 
synthesizing a fully protected pyridine and pyrimidine core followed by 
attachment of the aliphatic chain. These intermediates were then deprotected and 
modified in order to synthesize the proposed analogues.  
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N
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X = CH, N
R1 = aliphatic side chain  
Figure 19: Retrosynthetic analysis for the synthesis of pyridinol and pyrimidinol 
analogues with a methyl substituent at the position ortho to the phenolic hydroxyl 
group. 
 
 For the synthesis of those pyridinol and pyrimidinol analogues containing 
a methoxyl group at position ortho of the phenolic hydroxyl group, a different 
approach was followed (Figure 20). The strategy consisted of attaching the 
 43  
lipophilic side chain to the pyridine or pyrimidine core prior to its corresponding 
modification to the final pyridinol or pyrimidinol analogue. 
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Figure 20: Retrosynthetic analysis for the synthesis of pyridinol and pyrimidinol 
analogues with a methoxyl substituent at the position ortho to the phenolic 
hydroxyl group. 
 
 In order to create a larger library of pyrimidinol analogues, a different 
strategy was proposed (Figure 21). This strategy consisted of synthesizing a fully 
protected core containing a short side chain with a functional group that could 
work as anchoring point for different lipophilic side chains. A terminal alkene 
was chosen as the functionality for the attachment of other side chains by cross 
metathesis.  
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Figure 21: Retrosynthetic analysis for the synthesis of pyrimidinol analogues by 
cross metathesis.  
 
3.2.1 Synthesis and evaluation of pyridinol and pyrimidinol analogues. 
3.2.1.1 Synthesis of pyridinol analogues  
6-(N,N-dimethylamino)-2-(10-hydroxydecyl)-4-methylpyridin-3-ol (3.1) 
was synthesized in eight steps (Scheme 4). First, 2-amino-5-bromo-4,6-
dimethylpyridine (3.26) was prepared in 84% yield by treating commercially 
available 2-amino-4,6-dimethylpyridine with N-bromosuccinimide.84,85 
Compound 3.26 was then treated with 2,5-hexanedione in presence of p-
toluensulfonic acid to obtain 3-bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2,4-
dimethylpyridine (3.27) in 62% yield.84,86 3-(Benzyloxy)-6-(2,5-dimethyl-1H-
pyrrol-1-yl)-2,4-dimethylpyridine (3.28) was prepared in 82% yield by treating 
compound 3.27 with potassium hydroxide in presence of Pd2dba3 and 2-di-tert-
butylphosphino-2,4,6-triisopropylbiphenyl (L1),87 followed by protection of the 
hydroxyl group by means of benzyl ether. The fully protected core 3.28, was then 
treated with phenyllithium in the presence of 1-bromo-9-
(methoxymethoxy)nonane (3.25) to obtain 3-(benzyloxy)-6-(2,5-dimethyl-1H-
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pyrrol-1-yl)-2-(10-(methoxymethoxy)decyl)-4-methylpyridine (3.29) in 60% 
yield. 88,89  
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Scheme 4: Route employed for the synthesis of pyridinol analogue 3.1. 
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Compound 3.25 was previously prepared by treating 9-bromo-1-nonanol 
with methoxymethyl chloride in presence of sodium hydride in 70% yield.90 
Compound 3.29 was deprotected by treating it with hydroxylamine hydrochloride 
in the presence of potassium hydroxide to obtain 2-amino-5-(benzyloxy)-6-(10-
(methoxymethoxy)decyl)-4-methylpyridine (3.30)  in 56% yield.84,86 Then, 
compound 3.30 was treated with methyl iodide in presence of sodium hydride to 
obtain 3-(benzyloxy)-6-(N,N-dimethylamino)-2-(10-(methoxymethoxy)decyl)-4-
methylpyridine (3.31) in 21% yield.84 6-(N,N-Dimethylamino)-2-(10-
hydroxydecyl)-4-methylpyridin-3-ol (3.1) was obtained in 77% yield by treating 
compound 3.31 first with HCl and then with palladium hydroxide under a 
hydrogen atmosphere. 
6-Amino-2-(10-hydroxydecyl)-4-methylpyridin-3-ol (3.2) (Scheme 5) was 
synthesized from compound 3.30 by deprotection of the aliphatic hydroxyl group 
using acidic conditions followed by hydrogenolysis in 29% yield over two steps. 
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Scheme 5: Route employed for the synthesis of pyridinol analogue 3.2. 
 
6-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-(10-hydroxydecyl)-4-methylpyridin-3-
ol (3.3) and 6-(2,5-dimethylpyrrolidin-1-yl)-2-(10-hydroxydecyl)-4-
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methylpyridin-3-ol (3.4)  (Scheme 6) were synthesized using the same conditions 
in 17% and 5% yields, respectively, by treating compound 3.29 under acidic 
conditions followed by hydrogenolysis. 
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Scheme 6: Route employed for the synthesis of pyridinol analogues 3.3 and 3.3. 
 
In order to synthesize 2-(10-hydroxydecyl)-6-methoxy-4-methylpyridin-3-
ol (3.5) (Scheme 7), compound 3.30 was treated with sodium nitrite under 
aqueous conditions followed by selective O-methylation using methyl iodide in 
presence of silver carbonate to obtain 3-(benzyloxy)-6-methoxy-2-(10-
(methoxymethoxy)decyl)-4-methylpyridine (3.32) in 26% yield over two steps.85 
Then compound 3.32 was treated under acidic conditions followed by 
hydrogenolysis to obtain compound 3.5 in 67% yield. 
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Scheme 7: Route employed for the synthesis of pyridinol analogue 3.5. 
 
6-(N,N-Dimethylamino)-2-(10-hydroxydecyl)-4-methoxypyridin-3-ol 
(3.6) (Scheme 8) was synthesized in eight steps. First, dimethyl 2-(1-
aminoethylidene)malonate (3.33) was obtained in 60% yield by treating dimethyl 
malonate with acetonitrile in presence of tin tetrachloride.91 Then compound 3.33 
was treated with N,N’-dimethylacetamide dimethyl acetal in presence of a strong 
base, sodium tert-butoxide, to obtain methyl 6-(N,N-dimethylamino)-4-hydroxy-
2-methylnicotinate (3.34) in 51% yield.92 Then the hydroxyl group of compound 
3.34 was methylated in presence of sodium carbonate and methyl iodide to obtain 
methyl 6-(N,N-dimethylamino)-4-methoxy-2-methylnicotinate (3.35) in 47% 
yield. Compound 3.35 was then hydrolyzed followed by decarboxylation via 
thermolysis to obtain 2-(N,N-dimethylamino)-4-methoxy-6-methylpyridine (3.36) 
in 34% yield.93 2-(N,N-Dimethylamino)-4-methoxy-6-(10-
(methoxymethoxy)decyl)pyridine (3.37) was obtained in 70% yield by treating 
compound 3.36 with n-BuLi in the presence of compound 3.25.88,89 Then 
compound 3.37 was brominated at position 5 using N-bromosuccinimide to obtain 
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5-bromo-2-(N,N-dimethylamino)- 4-methoxy-6-(10-
(methoxymethoxy)decyl)pyridine (3.38) in 44% yield.  
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Scheme 8: Route employed for the synthesis of pyridinol analogue 3.6. 
 
The bromine at position 5 was then replaced by a hydroxyl group by 
treating compound 3.38 with n-BuLi, then with trimethyl borate, and finally with 
hydrogen peroxide in subsequent steps in order to obtain 6-(N,N-dimethylamino)-
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4-methoxy-2-(10-(methoxymethoxy)decyl)pyridin-3-ol (3.39) in 21% yield.94  
Finally, the hydroxyl group on the aliphatic chain was deprotected by treating 
compound 3.39 with dilute HCl to obtain compound 3.6 in 40% yield.   
6-(N,N-Dimethylamino)- 2-(10-hydroxydecyl)-4,5-dimethylpyridin-3-ol 
(3.7) was synthesized in seven steps (Scheme 9). First, 6-amino-2,4,5-
trimethylpyridin-3-ol (3.40) was synthesized according to a literature procedure.95  
Then the exocyclic amine of compound 3.40 was protected by treating it with 2,5-
hexanedione in presence of p-toluenesulfonic acid to obtain 6-(2,5-dimethyl-1H-
pyrrol-1-yl)-2,4,5-trimethylpyridin-3-ol (3.41) in 75% yield. 3-(Benzyloxy)-6-
(2,5-dimethyl-1H-pyrrol-1-yl)-2,4,5-trimethylpyridine (3.42) was prepared in 
78% yield by treating compound 3.41 with sodium hydride and then with benzyl 
bromide. The fully protected core, compound 3.42, was then treated with n-BuLi 
in the presence of TMEDA (N,N,N’,N’-tetramethylethylenediamine) followed by 
compound 3.25 to obtain 3-(benzyloxy)-6-(2,5-dimethyl-1H-pyrrol-1-yl)- 2-(10-
(methoxymethoxy)decyl)-4,5-dimethylpyridine (3.43) in 41% yield. The 
previously protected amine moiety of compound 3.43 was deprotected by treating 
it with hydroxylamine hydrochloride in presence of potassium hydroxide to obtain 
2-amino-5-(benzyloxy)-6-(10-(methoxymethoxy)decyl)-4,5-dimethylpyridine 
(3.44)  in 13% yield. Compound 3.44 was then treated with a formaldehyde 
solution and sodium cyanoborohydride in presence of acetic acid to obtain 3-
(benzyloxy)-6-(N,N-dimethylamino)-2-(10-(methoxymethoxy)decyl)-4,5-
dimethylpyridine (3.45) in 77% yield. 6-(N,N-Dimethylamino)-2-(10-
hydroxydecyl)-4,5-dimethylpyridin-3-ol (3.7) was obtained in 79% yield by 
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treating compound 3.45 first with HCl in methanol and then with palladium 
hydroxide-on-carbon under a hydrogen atmosphere. 
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Scheme 9: Route employed for the synthesis of pyridinol analogue 3.7. 
 
In order to synthesize compounds 3.8 and 3.9 (Scheme 10), compound 
3.42 was first alkylated at the methyl group of the pyridine ring by treating it with 
n-BuLi followed by 1-bromopentadecane to obtain 3-(benzyloxy)-6-(2,5-
dimethyl-1H-pyrrol-1-yl)- 2-hexa3decyl-4,5-dimethylpyridine (3.46) in 48% 
yield. The exocyclic amine of compound 3.46 was then deprotected by treating it 
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with hydroxylamine hydrochloride and potassium hydroxide in order to obtain 5-
(benzyloxy)-6-hexadecyl-3,4-dimethylpyridin-2-amine (3.47) in 61% yield.  
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Scheme 10: Route employed for the synthesis of pyridinol analogues 3.8 and 3.9. 
 
Then the exocyclic amine of compound 3.47 was methylated using 
formalin in presence if sodium cyanoborohydride and acetic acid in order to 
obtain 3-(benzyloxy)-6-(N,N-dimethylamino)-2-hexadecyl-4,5-dimethylpyridine 
(3.48) in 70% yield. Finally, compound 3.8 was obtained in 98% yield by treating 
compound 3.48 with hydrogen in presence of a palladium catalyst. 3-(Acetoxy)-6-
(N,N-dimethylamino)-2-hexadecyl-4,5-dimethylpyridine (3.9) was obtained in 
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82% yield by treating compound 3.8 with acetic anhydride in presence of 
potassium carbonate. 
In order to study the redox properties of the pyridinol analogues, three 
representative pyridinol cores were synthesized (Scheme 11). The redox core of 
compound 3.1 was synthesized in two steps starting from 2-amino-5-bromo-4,6-
dimethylpyridine (3.26). First, compound 3.26 was treated with methyl iodide 
followed by sodium hydride to obtain 3-bromo-6-(N,N-dimethylamino)-2,4-
dimethylpyridine (3.49) in 55% yield. Then compound 3.49 was treated with 
potassium hydroxide in presence of Pd2dba3 and 2-di-tert-butylphosphino-2,4,6-
triisopropylbiphenyl (L1) to obtain 6-(N,N-dimethylamino)-2,4,-dimethylpyridin-
3-ol  (3.50) in 35% yield. The redox core of analogue 3.6 was synthesized in two 
steps starting from 2-(N,N-dimethylamino)-4-methoxy-6-methylpyridine (3.36). 
3-Bromo-6-(N,N-dimethylamino)-4-methoxy-2-methylpyridine (3.51) was 
obtained in 95% yield by treating compound 3.36 with N-bromosuccinimide. 
Then compound 3.51 was treated with n-BuLi followed by trimethyl borate and 
hydrogen peroxide to obtain 6-(N,N-dimethylamino)-4-methoxy-2-methylpyridin-
3-ol (3.52) in 11% yield. The redox core of compound 3.7 was synthesized from 
6-amino-2,4,5-trimethylpyridin-3-ol (3.40) by treatment with formalin in presence 
of sodium cyanoborohydride and acetic acid to obtain 6-(N,N-dimethylamino)-
2,4,5-trimethylpyridin-3-ol (3.53) in 50% yield. 
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Scheme 11: Routes employed for the synthesis of pyridinol redox cores. 
 
3.2.1.2 Synthesis of pyrimidinol analogues  
The synthesis of 2-(N,N-dimethylamino)-4-(10-hydroxydecyl)-6-
methylpyrimidin-5-ol (3.10) was completed in nine steps (Scheme 12). First 
guanidine sulfate was treated with 2,4-pentanedione in presence of sodium 
carbonate to obtain 2-amino-4,6-dimethylpyrimidine (3.54) in 95% yield.84,96 2-
Amino-5-bromo-2,6-dimethylpyridine (3.55) was obtained in 83% yield after the 
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treatment of compound 3.54 with N-bromosuccinimide.84,85 The exocyclic amine 
of compound 3.55 was protected by treating it with 2,5-hexanedione in presence 
of p-toluenesulfonic acid to obtain 5-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-
dimethylpyrimidine (3.56) in 81% yield.84,86 Then, compound 3.56 was treated 
with potassium hydroxide in the presence of Pd2dba3 and 2-di-tert-
butylphosphino-2,4,6-triisopropylbiphenyl (L1)87 followed by benzyl protection of 
the hydroxyl group to obtain 5-(benzyloxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-
dimethylpyrimidine (3.57) in 76% yield. 5-(Benzyloxy)-2-(2,5-dimethyl-1H-
pyrrol-1-yl)-4-(10-(methoxymethoxy)decyl)-6-methylpyrimidine (3.58) was 
obtained in 56% yield by treatment of compound 3.57 with n-BuLi in presence of 
3.25.88,89 The previously protected amine of compound 3.58 was deprotected by 
treating it with hydroxylamine hydrochloride in presence of potassium hydroxide 
to obtain 2-amino-5-(benzyloxy)-4-(10-(methoxymethoxy)decyl)-6-
methylpyrimidine (3.59) in 76% yield.84,86 The exocyclic amine of compound 
3.59 was dimethylated and the MOM protecting group was cleaved by treatment 
with a solution of 1:1 35% aq formaldehyde–formic acid to obtain 5-(benzyloxy)-
2-(N,N-dimethylamino)-4-(10-hydroxydecyl)-6-methylpyrimidine (3.60) in 44% 
yield.84,85 Finally, the benzyl ether group of compound 3.60 was cleaved by the 
treatment with hydrogen in presence of palladium hydroxide in methanol to 
obtain 2-(N,N-dimethylamino)-4-(10-hydroxydecyl)-6-methylpyrimidin-5-ol 
(3.10) in quantitative yield, which after column purification gave a 26% recovery. 
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Scheme 12: Route employed for the synthesis of pyrimidinol analogue 3.10. 
 
6-Amino-2-(10-hydroxydecyl)-4-methylpyrimidin-3-ol (3.11) (Scheme 
13) was synthesized from 2-amino-5-(benzyloxy)-6-(10-
(methoxymethoxy)decyl)-4-methylpyrimidine (3.59) by deprotection of the 
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aliphatic hydroxyl group under acidic conditions followed by hydrogenolysis. The 
yield was 69% over two steps. 
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Scheme 13: Route employed for the synthesis of pyrimidinol analogue 3.11. 
 
In order to synthesize 2-(10-hydroxydecyl)-6-methoxy-4-methylpyridin-3-
ol (3.12) (Scheme 14), compound 3.59 was treated with tert-butyl nitrite in 
presence of benzyltrimethyl ammonium chloride to obtain 3-(benzyloxy)-6-
chloro-2-(10-(methoxymethoxy)decyl)-4-methylpyrimidine (3.61) in 16% yield. 
Then compound 3.61 was treated with sodium methoxide to obtain 3-
(benzyloxy)-6-methoxy-2-(10-(methoxymethoxy)decyl)-4-methylpyrimidine 
(3.62) in 74% yield.  
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Scheme 14: Route employed for the synthesis of pyrimidinol analogue 3.12.  
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Compound 3.62 was then treated under acidic conditions followed by 
hydrogenolysis to obtain compound 3.12 in 97% yield over two steps. 
6-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-(10-hydroxydecyl)-4-
methylpyrimidin-3-ol (3.13) and 6-(2,5-dimethylpyrrolidin-1-yl)-2-(10-
hydroxydecyl)-4-methylpyridin-3-ol (3.14) (Scheme 15) were synthesized using 
the same conditions in 8% and 14% yields, respectively, by treating compound 
3.58 under acidic conditions followed by hydrogenolysis. 
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Scheme 15: Route employed for the synthesis of pyrimidinol analogues 3.13 and 
3.14. 
 
The synthesis of 2-(N,N-dimethylamino)-4-(10-hydroxydecyl)-6-
methoxylpyrimidin-5-ol (3.15) was accomplished in five steps (Scheme 16). First, 
2-amino-4-methoxy-6-methylpyrimidine was treated with methyl iodide in 
presence of sodium hydride to obtain 2-(N,N-dimethylamino)-4-methoxy-6-
methylpyrimidine (3.63) in 80% yield. Then the side chain was attached by 
treating compound 3.63 with n-BuLi in presence of compound 3.25 to obtain 2-
(N,N-dimethylamino)-4-methoxy-6-(10-(methoxymethoxy)decyl)pyrimidine 
(3.64) in 71% yield. Then compound 3.64 was brominated at position 5 using N-
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bromosuccinimide to obtain 5-bromo-2-(N,N-dimethylamino)-4-methoxy-6-(10-
(methoxymethoxy)decyl)pyrimidine (3.65) in 53% yield. The bromine at position 
5 was then replaced by a hydroxyl group by treating compound 3.65 with n-BuLi, 
then with trimethyl borate, and finally with hydrogen peroxide in subsequent steps 
in order to obtain 6-(N,N-dimethylamino)-4-methoxy-2-(10-
(methoxymethoxy)decyl)pyrimidin-3-ol (3.66) in 51% yield.97  Finally, the 
hydroxyl group on the aliphatic chain was deprotected by treating compound 3.66 
with dilute HCl to obtain compound 3.15 in 40% yield. 
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Scheme 16: Route employed for the synthesis of pyrimidinol analogue 3.15. 
 
Compounds 2-(N,N-dimethylamino)-4-methyl-6-pentylpyrimidin-5-ol 
(3.16), 2-(N,N-dimethylamino)-4-decyl-6-methylpyrimidin-5-ol (3.17) and 2-
(N,N-dimethylamino)-4-hexadecyl-6-methylpyrimidin-5-ol (3.18) were 
synthesized in analogy with the synthesis of compound 3.10 (Scheme 17).  First, 
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the fully protected pyrimidinol 3.57 was monoalkylated on one of the methyl 
groups by generating the carbanion with n-BuLi in presence of butyl bromide, 
nonyl bromide and pentadecyl bromide to afford 5-(benzyloxy)-2-(2,5-dimethyl-
1H-pyrrol-1-yl)-4-methyl-6-pentylpyrimidine (3.67), 5-(benzyloxy)-4-decyl-2-
(2,5-dimethyl-1H-pyrrol-1-yl)-6-methylpyrimidine (3.68) and 5-(benzyloxy)-2-
(2,5-dimethyl-1H-pyrrol-1-yl)-4-hexadecyl-6-methylpyrimidine (3.69) in 69%, 
53% and 24% yields, respectively. The exocyclic amines were then deprotected 
by treatment of compounds 3.67, 3.68 and 3.69 with hydroxylamine 
hydrochloride to afford 2-amino-5-(benzyloxy)-4-methyl-6-pentylpyrimidine 
(3.70), 2-amino-5-(benzyloxy)-4-decyl-6-methylpyrimidine (3.71) and 2-amino-
5-(benzyloxy)-4-hexadecyl-6-methylpyrimidine (3.72) in 80%, 75% and 100% 
yields, respectively. The exocyclic amines of compounds 3.70, 3.71 and 3.72 
were then dimethylated using formalin and sodium cyanoborohydride to afford 5-
(benzyloxy)-2-N,N-dimethylamino-4-methyl-6-pentylpyrimidine (3.73), 5-
(benzyloxy)-4-decyl-2-N,N-dimethylamino-6-methylpyrimidine (3.74) and 5-
(benzyloxy)-2-N,N-dimethylamino-4-hexadecyl-6-methylpyrimidine (3.75) in 
41%, 46% and 41% yields, respectively. Finally, compounds 3.16, 3.17 and 3.18 
were obtained quantitatively by respective hydrogenolysis of compounds 3.73, 
3.74 and 3.75 over Pd(OH)2/C in methanol.  
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Scheme 17:  Route employed for the synthesis of pyrimidinol analogues 3.16, 
3.17 and 3.18. 
 
The syntheses of 4-decyl-2-(N,N-dimethylamino)-6-methoxypyrimidin-5-
ol (3.19) and 2-(N,N-dimethylamino)-4-hexadecyl-6-methoxypyrimidin-5-ol 
(3.20) were accomplished in analogy with the synthesis of 3.15 (Scheme 18). 
First, 2-(N,N-dimethylamino)-4-methoxy-6-methylpyrimidine (3.63) was 
monoalkylated on one of the methyl groups by generating the carbanion with n-
BuLi in presence of nonyl bromide and pentadecyl bromide to afford 4-decyl-2-
N,N-dimethylamino-6-methoxypyrimidine (3.76) and 2-N,N-dimethylamino-4-
hexadecyl-6-methoxypyrimidine (3.77) in 66% and 62% yields, respectively. The 
pyrimidines 3.76 and 3.77 were then brominated at position 5 to obtain 5-bromo-
4-decyl-2-N,N-dimethylamino-6-methoxypyrimidine (3.78) and 5-bromo-2-N,N-
dimethylamino-4-hexadecyl-6-methoxypyrimidine (3.79) in 82% and 95% yields, 
respectively. Finally, compounds 3.19 and 3.20 were obtained in 27% and 55% 
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yields, respectively by treating compounds 3.78 and 3.79 with n-BuLi in presence 
of TMEDA, then with trimethyl borate and finally with hydrogen peroxide in 
subsequent steps. Compound 3.20 was then O-acetylated in order to obtain 5-
acetoxy-2-N,N-dimethylamino-4-hexadecyl-6-methoxypyrimidine (3.21) in 80% 
yield. 
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Scheme 18: Route employed for the synthesis of pyrimidinol analogues 3.19, 
3.20 and 3.21. 
 
In order to create a large library of compounds containing the same core, 
5-(benzyloxy)-4-(γ-butenyl)-2-N,N-dimethylamino-6-methoxypyrimidine (3.83) 
was synthesized as a common intermediate (Scheme 19). First, compound 3.63 
was treated with n-BuLi in presence of TMEDA to form the corresponding 
carbanion on the methyl group and then treated with allyl bromide to obtain 4-(γ-
butenyl)-2-N,N-dimethylamino-6-methoxypyrimidine (3.80) in 50% yield. Then, 
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the pyrimidine core of compound 3.80 was brominated at position 5 using N-
bromosuccinimide to obtain 5-bromo-4-(γ-butenyl)-2-N,N-dimethylamino-6-
methoxypyrimidine (3.81). Compound 3.81 was then converted to 4-(γ-butenyl)-
2-(N,N-dimethylamino)-6-methoxypyrimidin-5-ol (3.82) in 70% yield by first 
treating it with n-BuLi in presence of TMEDA, then with trimethyl borate and 
finally with hydrogen peroxide in subsequent steps. Finally, the hydroxyl group of 
compound 3.82 was benzylated using benzyl bromide in presence of potassium 
carbonate to obtain compound 3.83 in 98% yield.   
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Scheme 19: Route employed for the synthesis of intermediate 3.83. 
 
For the synthesis of 2-(N,N-dimethylamino)-4-methoxy-6-
tetradecylpyrimidin-5-ol (3.22), 2-(N,N-dimethylamino)-4-methoxy-6-(10-
methyladamantyloxydecyl)pyrimidin-5-ol (3.23) and 2-(N,N-dimethylamino)-4-
methoxy-6-octadecylpyrimidin-5-ol (3.24) a different approach was used (Scheme 
20). Compound 3.83 was attached to 1-dodecene, 1-methyladamantyloxy-γ-
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octene (3.84) and 1-hexadecene by cross metathesis reaction using 2nd generation 
Grubb’s catalyst followed by hydrogenation in presence of palladium-on-carbon 
to obtain 3.22, 3.23 and 3.24 in 40%, 11% and 36% yields, respectively. 
Compound 3.84 was previously synthesized by treating 8-bomo-1-octene with 1-
(hydroxymethyl)adamantane and sodium hydride in 58% yield.     
 
Br +
HO NaH
anh. DMF
O
3.84
N N
N
O
OBn
1. Grubb's catalyst 2nd Gen.,
1-dodecene, anh CH2Cl2
2. H2, Pd(OH)2/C
methanol
2. H2, Pd(OH)2/C
methanol
2. H2, Pd(OH)2/C
methanol
1. Grubb's catalyst 2nd Gen.,
3.84, anh CH2Cl2
1. Grubb's catalyst 2nd Gen.,
1-hexadecene, anh CH2Cl2
40%
11%
36%
3.83
N N
N
O
OH
O
N N
N
O
OH
N N
N
O
OH
3.22
3.23
3.24
58%
 
Scheme 20: Route employed for the synthesis of pyrimidinol analogues 3.22, 
2.23 and 3.24.  
 
The redox cores of compounds 3.10 and 3.15 were synthesized in three 
and four steps, respectively (Scheme 21). First, the exocyclic amine of compound 
3.57 was deprotected by treatment with hydroxylamine hydrochloride to obtain 2-
amino-5-(benzyloxy)-4,6-dimethylpyrimidine (3.85) in 98% yield. Then, 
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compound 3.85 was dimethylated using a mixture of formalin and formic acid to 
obtain 5-(benzyloxy)-2-N,N-dimethylamino-4,6-dimethylpyrimidine (3.86) in 
23% yield. Finally, the hydroxyl group of compound 3.86 was deprotected 
quantitatively using palladium-on-carbon under a hydrogen atmosphere to obtain 
2-(N,N-dimethylamino)-4,6-dimethylpyrimidin-5-ol (3.87). 2-(N,N-
Dimethylamino)-4-methoxy-6-methylpyrimidin-5-ol (3.89) was prepared in two 
steps starting from intermediate 3.63. First, compound 3.63 was brominated at 
position 5 using N-bromosuccinimide to obtain 5-bromo-2-(N,N-dimethylamino)-
4-methoxy-6-methylpyrimidine (3.88) in 73% yield. The bromine of compound 
3.88 was then replaced by a hydroxyl group by first treating it with n-BuLi in 
presence of TMEDA, then with trimethyl borate, and finally with hydrogen 
peroxide in subsequent steps to obtain 2-(N,N-dimethylamino)-4-methoxy-6-
methylpyrimidin-5-ol (3.89) in 8% yield. 
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Scheme 21: Route employed for the synthesis of redox cores 3.87 and 3.89. 
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3.2.1.3 Evaluation of pyridinol and pyrimidinol analogues 
 
3.2.1.3.1 Electrochemical evaluation of pyridinol and pyrimidinol redox cores 
The ability of compound 3.1 to transfer its phenolic hydrogen atom and 
form a stabilized radical has been studied by the use of electron spin resonance 
(ESR). Figure 22A shows the signal obtained from the radical activation of 
compound 3.1 in the presence of illuminated di-tert-butyl peroxide. The hyperfine 
splitting constants are as follows: aH (3H, o-methyl) = 3.5 G, aH (2H, o-carbon 
chain) = 3.3 G, aH (1H, o-carbon chain) = 3.4 G, aH (1H, m-ring) = 1.9 G, aH (6H, 
p-NMe2) = 4.2 G, aN (1N, ring) = 1.1 G, aN (1N, p-NMe2) = 5.9 G, and g = 
2.00493  
A) B) 
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Figure 22: A) ESR signal and simulation of compound 3.1 (5 mM) in dry 
de-aerated benzene at 25 °C. B) Resonance stabilized 3-pyridinoxyl radical 
resulting from abstraction of the O-H hydrogen atom.98 Experiment performed by 
Dr. Ruth Goldschmidt and Manikandadas M. Madathil. 
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The simulation corresponds to the experimental signal with a relative error 
of R = 0.983. Figure 22B shows the resonance contributors of the stabilized 3-
pyridinoxyl radical putatively formed. 
Cyclic voltammetry 
Cyclic voltammetric analyses of the redox cores of compounds 3.1, 3.6 
and 3.7 (compounds 3.50, 3.52 and 3.53, respectively) are presented in Figure 23. 
 
Figure 23: Cyclic voltammetry of compounds 3.50 (green), 3.52 (red) and 3.53 
(blue) in 0.1 M tetrabutylammonium perchlorate in acetonitrile using Ag/AgCl 
electrode as a reference. Experiment performed by Manikandadas M. Madathil. 
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Figure 23 shows that the redox cores 3.50, 3.52 and 3.53 are more easily 
reduced than CoQ0 (cf. Figure 13). Compound 3.50 showed a more negative 
reduction potential than any of the other pyridinol cores evaluated.  
Figure 24 shows that the redox core of compound 3.1 (compound 3.50) is 
unstable to repetitive redox cycles while the redox core of compound 3.7 
(compound 3.53) was completely unstable. 
 
 
Figure 24: Normalized peak current (ip(n)- ip(1)) plotted against time in continuous 
cyclic voltammetric analysis of compound 3.50 (black) versus compound 3.53 
(red).98 Experiment performed by Manikandadas M. Madathil. 
 
Cyclic voltammetric analyses of the redox cores of compounds 3.10 and 
3.15  (compounds 3.88 and 3.89, respectively) are presented in Figure 25. The 
figure shows that the redox cores 3.88 and 3.89 are more easily reduced than 
N
N
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CoQ0 (cf. Figure 13). The redox core 3.88 is more easily reduce than the redox 
core 3.89. 
 
Figure 25: Cyclic voltammetry of compounds 3.88 (blue) and 3.89 (red) in 0.1 M 
tetrabutylammonium perchlorate in acetonitrile using Ag/AgCl electrode as a 
reference. Experiment performed by Manikandadas M. Madathil. 
 
3.2.1.3.2 Biochemical evaluation of pyridinol and pyrimidinol analogues  
Inhibition of lipid peroxidation 
The ability of the pyridinol analogues to quench lipid peroxidation has 
been studied in FRDA lymphocytes depleted of glutathione by treatment with 
diethyl maleate (DEM). The cells were pre-incubated with the test compounds for 
16 h prior to DEM treatment. Lipid peroxidation was measured by a quantitative 
N N
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N N
N
O
OH
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FACS analysis using the fluorescent probe, C11-BODIPY581/591, reported to be 
highly accurate in measuring lipid peroxidation.99 The results, presented in Table 
2, show the most potent activity for compounds 3.4 and 3.7 among the pyridinol 
analogues with idebenone side chain. Compound 3.1, lacking a methyl group at 
position 6, was slightly less potent than idebenone, and better than compound 3.2. 
However, the redox core of compound 3.1 (compound 3.50) lacked significant 
activity. Finally, compound 3.3 had the lowest activity for suppressing lipid 
peroxidation among the analogues having a 10-hydroxydecyl side chain.  
Compounds 3.5 and 3.6 had activities similar to compound 3.3 (data not shown).  
 
Table 2: Suppression of lipid peroxidation by pyridinol antioxidants in cultured 
FRDA lymphocytes treated with DEM. Experiment performed by Dr. Omar M. 
Khdour. 
 Lipid peroxidation quenching activity (%) 
Compound 2.5 µM 5.0 µM 
idebenone  68 ± 6.4 77 ± 2.4 
3.1 71 ± 6.0 82 ± 3.7 
3.2 62 ± 6.4 74 ± 4.7 
3.3 20 ± 10 39 ± 7.6 
3.4 90 ± 2.9 97 ± 2.3 
3.7 87 ± 5.1 97 ± 3.1 
3.50 3.5 ± 2.3 3.9 ± 3.0 
 71  
Pyrimidinol analogues 3.17 and 3.19 exhibited better activity as compared 
to compounds 3.10 and 3.15, respectively. In general, pyrimidinol analogues with 
long aliphatic side chains exhibited good quenching activity, except for 
compound 3.24 that had a comparable activity as 3.15. Compound 3.16 had a 
poor activity even at higher concentrations. 
 
Table 3: Suppression of lipid peroxidation by pyrimidinol antioxidants in 
cultured FRDA lymphocytes treated with DEM. Experiment performed by Dr. 
Omar M. Khdour. 
 Lipid peroxidation quenching activity (%) 
Compound 0.1 µM 0.25 µM 0.5 µM 
3.10 1.3 ± 1.6 1.3 ± 0.5 31 ± 3.2 
3.15 12 ± 1.6 35 ± 4.4 67 ± 3.2 
3.16 - 33 ± 18 26 ± 3.8 
3.17 - 90 ± 4.8  94 ± 4.8 
3.18 - 93 ± 5.0 95 ± 4.8 
3.19 42 ± 6.0 94 ± 3.0 97 ± 1.6 
3.20 94 ± 0.6 98 ± 1.0 101 ± 1.6 
3.22 92 ± 3.8 96 ± 1.6 101 ± 2.6 
3.23 88 ± 2.7 97 ± 0.5 97 ± 2.1 
3.24 15 ± 4.4 44 ± 3.9 77 ± 2.6 
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Reactive oxygen species 
The ability of the pyridinol and pyrimidinol analogues to suppress ROS 
induced by depletion of glutathione was evaluated in CEM cells and FRDA 
lymphocytes. ROS was measured in a quantitative FACS experiment, using 
dichlorofluorescin diacetate (DCFH-DA) as a substrate for determining 
intracellular oxidant production. DCFH-DA is hydrolyzed by esterases to afford 
2,7-dichlorodihydrofluorescin (DCFH), the latter of which is trapped within the 
cell. This non-fluorescent molecule is then oxidized to fluorescent 
dichlorofluorescin (DCF) by the action of cellular oxidants. Protection of CEM 
cells, presented in Table 4, shows that analogues 3.8 and 3.4 were more potent 
than compound 3.1, which was more potent than idebenone. Similar (Table 5), 
most of the pyrimidinol analogues were more potent than idebenone. Compounds 
3.15, 3.20, 3.22 and 3.23 were more potent than their parent compound 3.10 at 2.5 
µM concentration. At 250 nM concentration compounds 3.17, 3.18, 3.20 and 3.23 
were the most potent analogues tested. Compound 3.20 was the most potent 
analogue tested at 50 nM concentration. Compound 3.16 did not show any 
activity at 250 nM concentration. 
Because the use of DCF fluorescence as an endpoint has been shown to 
lack specificity under certain circumstances,100,101 it was shown in the present 
study that the increase in DCF fluorescence induced by DEM was completely 
reversed by superoxide dismutase + catalase, or by the antioxidant N-
acetylcysteine (data not shown).  
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Table 4: Suppression of ROS by pyridinol antioxidants in cultured CEM 
lymphocytes treated with DEM. Experiment performed by Dr. Ruth Goldschmidt. 
 ROS suppression activity (%) 
Compound 0.25 µM 0.5 µM 2.5 µM 
idebenone - - 35 ± 7 
decylubiquinone - - 88 ± 5 
3.1 42 ± 4 58 ± 4 94 ± 3 
3.2 28 ± 8 35 ± 5 75 ± 5 
3.3 22 ± 6 11 ± 6 33 ± 7 
3.4 77 ± 3 90 ± 4 98 ± 3 
3.6 - - 31 ± 4 
3.7 47 ± 5 69 ± 2 100 ± 2 
3.8 85 ± 2 98 ± 2 96 ± 2 
3.9 40 ± 2 63 ± 3 62 ± 2 
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Table 5: Suppression of ROS by pyrimidinol antioxidants in cultured CEM 
lymphocytes treated with DEM. Experiment performed by Dr. Ruth Goldschmidt. 
 ROS suppression activity (%) 
Compound 0.05 µM 0.25 µM 0.5 µM 2.5 µM 
3.10 - - - 74 ± 6.0 
3.15 - - - 90 ± 3 
3.16 - 0 ± 1 - - 
3.17 - 89 ± 3.0 - - 
3.18 - 90 ± 1.0 - - 
3.19 - 54 ± 4.0 - - 
3.20 71 ± 3.0 89 ± 7.0 90 ± 7.0 89 ± 5.0 
3.21 52 ± 4.0 75 ± 4.0 89 ± 7.0 88 ± 8.0 
3.22 31 ± 4.0 40 ± 2.0 63 ± 3.0 90 ± 5.0 
3.23 - 82± 3.0 - 91 ± 5.0 
3.24 - 49 ± 5.0 - 87 ± 6.0 
 
Protection of FRDA lymphocytes presented in Table 6 shows that 
analogue 3.8 was more potent than compound 3.1. Similarly, compound 3.20 was 
more potent that its parent compound 3.10. Compounds 3.8 and 3.20 showed 
almost complete protection at 250 nM concentration. 
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Table 6: Suppression of ROS by pyridinol and pyrimidinol antioxidants in 
cultured FRDA lymphocytes treated with DEM. Experiment performed by Dr. 
Omar M. Khdour. 
 ROS suppression activity (%) 
Compound 0.25 µM 0.5 µM 2.5 µM 
idebenone 21 ± 4.8 38 ± 4.2 75 ± 4.3 
3.1 29 ± 4.4 40 ± 5.0 78 ± 4.3 
3.8 86 ± 5.1 92 ± 3.0 - 
3.10 35 ± 4.4 48 ± 4.2 83 ± 4.0 
3.20 87 ± 3.3 94 ± 0.7 - 
 
 Preservation of mitochondrial membrane potential 
The ability of the pyridinol and pyrimidinol analogues to preserve 
mitochondrial membrane potential under conditions of oxidative stress was 
studied. Mitochondrial membrane potential, Δψm, is an important parameter of 
mitochondrial integrity and is essential for maintaining the physiological function 
of the respiratory chain in ATP synthesis.102 Δψm was estimated using the cationic 
fluorescent probe tetramethylrhodamine methyl ester (TMRM), which 
preferentially accumulates in the mitochondria due to the negative membrane 
potential across the inner mitochondrial membrane, in accordance with the Δψm 
Nernst potential.103 The red fluorescent signal in mitochondria decreases when 
Δψm is impaired, and can be measured using flow cytometry. A representative 
flow cytometric two-dimensional color density dot plot analyses of the 
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mitochondrial membrane potential measurements with and without incubation in 
the presence of selected compounds are shown in Figure 26. 
  
untreated 
control 
Treated 
control FCCP no TMRM 
    
3.1 (0.5 µM) 3.4 (0.5 µM) 3.7 (0.5 µM) Idebenone (0.5 µM) 
    
3.1 (1 µM) 3.4 (1 µM) 3.7 (1 µM) Idebenone (1 µM) 
    
3.1 (2.5 µM) 3.4 (2.5 µM) 3.7 (2.5 µM) Idebenone (2.5 µM) 
    
Figure 26: A representative flow cytometric two-dimensional color density dot 
plot analyses of the mitochondrial membrane potential measurements. Experiment 
performed by Dr. Omar M. Khdour. 
 
The percentage of cells with intact mitochondrial membrane potential 
appears in the top right quadrant of individual treatments. Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP), a commonly used uncoupler of 
oxidative phosphorylation in mitochondria, was employed to dissipate the 
chemiosmotic proton gradient (ΔµH+). The lower levels of TMRM fluorescence 
resulting from FCCP treatment reflect the depolarization of mitochondrial inner 
membrane potential. Figure 27 summarizes the relative geometric mean 
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fluorescence intensity (GMFI) of the flow cytometric profiles of some pyridinol 
analogues. It shows clearly that compound 3.4 had the greatest potency among 
pyridinol analogues, and acted in a dose-dependent manner; compound 3.7 was 
almost as good although not strictly dose-dependent in this experiment.  These 
three compounds were clearly better than idebenone, and better than compounds 
3.1 and 3.2, which had activity in the same range as idebenone. Finally, 
compound 3.3 had the lowest activity and the redox core of compound 3.1 was 
completely inactive.  
 
Figure 27: Mitochondrial membrane potential protection of some pyridinol 
analogues. 98 Experiment performed by Dr. Omar M. Khdour. 
 
For pyrimidinol analogues it was found that compounds with longer 
aliphatic side chains, like compounds 3.20 and 3.22, clearly have better activities 
protecting the mitochondrial membrane potential (Figure 28). Also, it was found 
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that more electron donating groups present in the redox core like in compound 
3.19 provides enhanced protection.  
Interestingly, compound 3.24 showed the lowest protection of the 
mitochondrial membrane potential among the analogues with long aliphatic side 
chains. Suggesting that there is an optimal side chain length to support this 
property. 
 
 
Figure 28: Mitochondrial membrane potential protection of some pyrimidinol 
analogues. Experiment performed by Dr. Omar M. Khdour. 
  
Cytoprotection 
Cytoprotection was measured initially using cultured FRDA lymphocytes 
that were treated with diethyl maleate to induce oxidative stress through depletion 
of glutathione. As shown in Table 7, compounds 3.1, 3.4 and 3.7 were the most 
effective pyridinol analogue having an idebenone side chain at the concentrations 
tested. Compound 3.8 was the most active of the pyridinol analogues. In general 
pyrimidinol analogues had better protective activities than pyridinols and 
idebenone as shown in Table 8. Compounds with long aliphatic side chains, like 
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compounds 3.18, 3.20, 3.22, and 3.23, were the most effective pyrimidinol 
analogues tested at 100 nM concentration.  Compound 3.24 had the lowest 
activity of the pyrimidinol analogues tested. 
 
Table 7: Cytoprotective effects of pyridinol antioxidants on the viability of 
cultured FRDA lymphocytes treated with DEM. Experiment performed by 
Jennifer Jaruvangsanti. 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
idebenone 31 ± 0.6 69 ± 2.8 95 ± 2.0 
decylubiquinone - 83 ± 4.0 90 ± 6.0 
3.1 59 ± 5.3 86 ± 3.8 90 ± 6.6 
3.2 59 ± 2.4 69 ± 8.9 83 ± 5.2 
3.3 17 ± 4.0 16 ± 4.0 19 ± 6.0 
3.4 49 ± 9.0 81 ± 10 92 ± 3.0 
3.6 33 ± 2.0 32 ± 3.0 37 ± 4.0 
3.7 38 ± 7.0 84 ± 4.0 90 ± 3.0 
3.8 80 ± 10 95 ± 5.0 92 ± 3.0 
3.9 19 ± 9.0 34 ± 7.0 70 ± 10 
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Table 8: Cytoprotective effects of pyrimidinol antioxidants on the viability of 
cultured FRDA lymphocytes treated with DEM. Experiment performed by 
Jennifer Jaruvangsanti. 
 Viable cells (%) 
Compound 0.1 µM 0.5 µM 2.5 µM 
3.10 66 ± 7.0 89 ± 8.3 91 ± 8.3 
3.14 68 ± 11 73 ± 9.0 77 ± 8.0 
3.15 62 ± 7.4 89 ± 6.4 87 ± 7.0 
3.16 50 ± 3.6 86 ± 4.4 88 ± 5.6 
3.17 60 ± 4.2 87 ± 3.7 79 ± 5.2 
3.18 68 ± 0.9 88 ± 3.0 93 ± 1.9 
3.19 45 ± 2.4 90 ± 1.8 90 ± 1.2 
3.20 83 ± 4.0 88 ± 8.0 90 ± 5.0 
3.21 52 ± 6.0 68 ± 7.0 92 ± 3.0 
3.22 72 ± 5.0 82 ± 8.0 87 ± 3.0 
3.23 76± 6.0 59 ± 8.0 80 ± 3.0 
3.24 28 ± 6.0 63 ± 13 80 ± 3.0 
 
Mitochondrial electron transport chain function  
The inhibitory effects of the test compounds on bovine heart 
mitochondrial complexes I, III and IV were evaluated using submitochondrial 
particles (SMP), by measuring NADH oxidase activity assay. The results 
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presented in Table 9 show that compounds 3.1, 3.2, 3.3, and 3.4 were all less 
inhibitory to respiratory chain function of complexes I, III and IV than idebenone. 
Compound 3.7 was the most inhibitory and compound 3.8 the least inhibitory of 
the pyridinol analogues.   
 
Table 9: Inhibitory effects of pyridinol analogues on bovine heart mitochondrial 
NADH oxidase activity. Experiment performed by Sriloy Dey. 
 NADH oxidase activity (%) 
Compound 1 µM 5 µM 10 µM 
idebenone 65 ± 2.5 53 ± 3.5 15 ±2.5 
decylubiquinone 93 ± 6.9 82 ± 2.2 62 ± 6.6 
3.1 85 ± 2.5 42 ± 3.5 25 ± 2.5 
3.2 74 ± 2.2 52 ± 3.6 48 ± 2.7 
3.3 71 ± 4.5 49 ± 3.5 43 ± 5.5 
3.4 78 ± 4.0 59 ± 3.8 27 ± 4.0 
3.6 - 65 ± 4.6 50 ± 3.0 
3.7 27 ± 0.8 9 ± 0.3 6 ± 0.2 
3.8 92 ± 11 78 ± 2.0 89 ± 8.0 
 
Table 10 shows that compounds 3.17 and 3.19 were stronger inhibitors of 
NADH oxidase activity than idebenone and compound 3.10, which exhibited 
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inhibition similar to idebenone. Compound 3.15 exhibited less inhibition than 
compound 3.10 but more than compounds 3.16, 3.18, 3.20, 3.22, 3.23 and 3.24.  
 
Table 10: Inhibitory effects of pyrimidinol analogues on bovine heart 
mitochondrial NADH oxidase activity. Experiment performed by Sriloy Dey. 
 NADH oxidase activity (%) 
Compound 1 µM 5 µM 10 µM 
3.10 49 ± 4.3 26 ± 6.7 22 ± 6.4 
3.15 63± 3.0 50 ± 2.1 25 ± 1.2 
3.16 85 ± 7.4 - - 
3.17 40 ± 2.1 18 ± 1.6 4.0 ± 2.1 
3.18 96± 2.6 87 ± 5.0 77 ± 4.4 
3.19 38 ± 2.1 38 ± 3.5 10 ± 2.3 
3.20 84 ± 4.0 78 ± 3.0 75 ± 5.0 
3.22 - 77 ± 1.9 77 ± 4.8 
3.23 - 71 ± 4.3 60 ± 3.3 
3.24 - 73 ± 5.0 73 ± 0.2 
 
For complex I inhibition (Table 11), compounds 3.1, 3.4, 3.5 and 3.7 were 
better inhibitors than idebenone. Compounds 3.1 and 3.7 were the most 
inhibitory. Compound 3.8 was the least inhibitory among of the pyridinol 
analogues.   
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Table 11: Inhibitory effect of pyridinol analogues on bovine heart mitochondrial 
complex I. Experiment performed by Dr. Valérie C. Collin. 
NADH-ubiquinone oxidoreductase activity 
Compound IC50 (µM) Imax (%) 
idebenone 6.3 ± 2.5 84 ± 2.3 
decylubiquinone > 200 ND 
3.1 1.3 ± 0.4 76 ± 3.0 
3.2 7.8 ± 0.1 81 ± 0.6  
3.3 7.8 ± 0.3 84± 2.9 
3.4 2.6 ± 0.1 81 ± 4.4 
3.5 4.0 ± 0.2 84 ± 2.0 
3.7 0.70 ± 0.02 90 ± 0.7 
3.8 > 500 ND 
 
As shown in Table 12 pyrimidinol analogues 3.10, 3.12, 3.14, 3.17, 3.22 
and 2.23 were more inhibitory of complex I than idebenone. Compounds 3.15, 
3.16, 3.19 and 3.20 were less inhibitory than idebenone but more inhibitory than 
compound 3.18. Compound 3.24 was the least inhibitory among the pyrimidinol 
analogues. 
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Table 12: Inhibitory effect of pyrimidinol analogues on bovine heart 
mitochondrial complex I. Experiment performed by Dr. Valérie C. Collin. 
NADH-ubiquinone oxidoreductase activity 
Compound IC50 (µM) Imax (%) 
3.10 1.2 ± 0.1 85 ± 3.0 
3.12 3.0 ± 0.3 82 ± 0.2 
3.13 7.4 ± 0.6 91 ± 1.5  
3.14 1.0 ± 0.2 89 ± 0.3 
3.15 63± 3.0 50 ± 2.1 
3.16 38 ± 3.0 98 ± 1.0 
3.17 1.7 ± 0.8 88 ± 2.0 
3.18 198 ± 12 84 ± 0.6 
3.19 17 ± 5.0 91 ± 1.0 
3.20 19 ± 3.0 86 ± 9.0 
3.22 3 ± 0.3 69 ± 3.0 
3.23 1.3 ± 0.3 71 ± 1.0 
3.24 > 500 ND 
 
ATP production 
The effects of pyridinol and pyrimidinol analogues on cellular ATP levels 
were also studied. All of the cells were adapted to growth on galactose for at least 
one week prior to measuring ATP levels. As shown in Table 13, idebenone 
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strongly diminished ATP levels in Friedreich’s ataxia lymphocytes in a 
concentration dependent fashion. In the presence of 25 µM idebenone, only 
residual ATP concentrations were detected. Compound 3.7 showed a similar 
behavior as idebenone. Compounds 3.4, 3.8 and its acetate form (3.9) were the 
most effective among pyridinol analogues (Table 13). 
 
Table 13: Total ATP concentration in Friedreich’s ataxia lymphocytes, upon 
incubation with the pyridinol compounds for 48 h. Experiment performed by Dr. 
Omar M. Khdour. 
 Total ATP concentration (% of control)  
Compound 1 µM 5 µM 10 µM 25 µM 
idebenone - 73 ± 6.6 46 ± 3.7 2.6 ± 0.8 
decylubiquinone - 93 ± 3.5 76 ± 1.5 63 ± 6.4 
3.4 105 ± 3.0 105 ± 2.5 101 ± 1.3 69 ± 8.8 
3.7 96 ± 3.0 66 ± 4.3 20 ± 1.8 0.6 ± 0.1 
3.8 99 ± 3.3 98 ± 2.5 83 ±2.2 57 ± 2.2 
3.9 98 ± 2.3 100 ± 2.1 94 ± 5.1 94 ± 1.5 
 
Pyrimidinols provided better support for ATP production than idebenone 
and in FRDA lymphocytes at 25 µM concentration (Table 14).  Compounds 3.16, 
3.18, 3.19, 3.20, 3.21, 3.22, 3.23 and 3.24 provided the best support for ATP 
synthesis among the pyrimidinol analogues. Encouragingly, when compounds 
3.20, 3.21, 3.22 and 3.23 were used at 5 µM, there was an increase of about 9% in 
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the ATP production. Compounds 3.22 and 3.23 afforded an increase in the ATP at 
about 12% when used at 1 µM concentration. 
 
Table 14: Total ATP concentration in Friedreich’s ataxia lymphocytes, upon 
incubation with pyrimidinol analogues for 48 h. Experiment performed by Dr. 
Omar M. Khdour. 
 Total ATP concentration (% of control)  
Compound 1 µM 5 µM 10 µM 25 µM 
3.10 - 77 ± 5.1 46 ± 4.2 28 ± 2.3 
3.15 - 80 ± 4.3 66 ± 5.3  46 ± 4.8 
3.16 - 88 ± 4.6 82 ± 2.1 73 ± 2.4 
3.17 - 83 ± 6.8 74 ± 2.6 42 ± 3.5 
3.18 - 95 ± 5.8 90 ± 3.4 75 ± 7.1 
3.19 - 94 ± 6.5 87 ± 1.9 76 ± 4.5 
3.20 - 108 ± 4.8 96 ± 3.6 80 ± 4.3 
3.21 - 109 ± 4.7 101 ± 3.6 92 ± 3.5 
3.22 112 ± 3.2 109 ± 3.6 97 ± 3.7 55 ± 2.8 
3.23 112 ± 2.3 107± 2.6 103 ± 2.6 72 ± 2.9 
3.24 104 ± 2.3 101 ± 2.0 102 ± 2.7 102 ± 2.5 
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3.3 DISCUSSION 
In our efforts to create a potent antioxidant that could be delivered to 
mitochondria, a number of pyridinol and pyrimidinol analogues were synthesized. 
These series of compounds contained idebenone side chains as well as 
hydrocarbon side chains of varying lengths. They also had methyl and methoxyl 
groups at varying positions on the pyridinol and pyrimidinol redox scores. For the 
synthesis of those analogues containing a methyl group ortho to the phenolic OH, 
the alkylation was done by selective lithiation of the methyl group next to the 
pyridine or pyrimidine nitrogen in the fully protected pyridinol or pyrimidinol 
core,88,89 followed by the addition of the corresponding alkyl bromide. When a 
methoxyl group was placed at the ortho position of the phenolic OH, lithiation of 
the methyl group next to the pyridine or pyrimidine nitrogen did not afford the 
desired product; only decomposition was observed. To solve this problem it was 
logical to perform the lithiation on less electron-rich cores, so the alkylation step 
was done before installing the phenolic OH group.  
It was also noticed that for the conversion of the brominated core to the 
corresponding pyridinol or pyrimidinol, the effect of the substituent at the position 
para to the bromide was important. The first strategy involved using a palladium 
catalyst and a phosphorous ligand when the exocyclic amine was protected as the 
dimethyl pyrrole derivative. When the exocyclic amine was protected as a 
dimethylamino group, the conversion of the bromide could not be successfully 
accomplished by this method. Then, a lithium/bromine exchange followed by 
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boronation and subsequent oxidation afforded the corresponding pyridinol and 
pyrimidinol compounds.  
 
Pyridinols  
The antioxidant properties of the new pyridinol analogues were tested and 
analyzed in selected biological and biochemical assays. Cultured Friedreich’s 
ataxia lymphocytes were challenged with diethyl maleate, which depletes cellular 
glutathione.104-106 Diethyl maleate induces greater oxidative stress than is likely to 
be encountered physiologically, permitting the identification of compounds 
anticipated to function robustly under pathophysiological conditions. 
Preliminary results showed the electronic effect of the substituents plays a 
very important role in their activity. It was observed that when the dimethylamino 
group at the para position of phenolic OH was exchanged for a methoxyl group 
(compound 3.5), the activity as antioxidant decreased considerably. The same 
result was observed when a dimethyl pyrrole group (compound 3.3) was used. 
These results are in agreement with the fact that more electron donating groups 
lower the bond dissociation energy of the O-H bond and, therefore, their ability to 
protect against oxidative stress is superior. However, when a methoxyl group 
replaced the methyl group in compound 3.1 to afford compound 3.6, activity 
decreased considerably, possibly due to instability towards air oxidation or 
decomposition of the oxidized form. The greater antioxidant potency of pyridinols 
having a strong donating group at the position para of the phenolic OH group is 
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entirely consistent with the reduction of their redox core at more oxidizing 
potentials than the redox core of idebenone (and coenzyme Q10). 
The results indicated that compound 3.4 performed better than the other 
analogues containing the idebenone side chain. This presumably reflects the steric 
effects of the C-methyl groups of the pyrrolidine moiety in preventing side 
reactions at the unsubstituted position of the pyridine ring of compound 3.4. 
Logically, this prompted us to insert a methyl group at the free position of the 
core of compound 3.1, affording compound 3.7.  
Many compounds have been reported to inhibit mitochondrial complexes 
I107-110 and III111,112 and these invariably strongly diminish cell viability. Since 
idebenone has been found to significantly inhibit complex I,61,62 it seemed logical 
to consider that this property might limit its useful antioxidant properties. 
Accordingly, we evaluated most pyridinol analogues for this property using a 
biochemical assay that measures the activity of NADH oxidase, which 
encompasses mitochondrial complexes I, III, and IV. In fact, most pyridinols were 
found to be superior to idebenone in that they displayed less inhibition of NADH 
oxidase activity (Table 9). While these experiments do not definitively establish 
the biochemical locus of inhibition by these compounds, complex I seems likely 
to be the relevant locus. 
Interestingly, it appears that compound 3.7 had better antioxidant activity 
than 3.1, despite the fact that it was more inhibitory to NADH-ubiquinone 
oxidoreductase (Table 11). This is undoubtedly due to the low stability of 
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compound 3.1 to the redox cycling (Figure 24), which it is thought to be essential 
to its antioxidant function. 
Previously, studies performed in our research group demonstrated that 
quinones having a lipophilic side chain with a polar substituent at the end were 
more inhibitory than those having only hydrocarbons chains, as shown with 
idebenone and decylubiquinone (Tables 9 and 11). So, it was logical to synthesize 
compounds in which the side chain had no hydroxyl group at the end. When the 
side chain of compound 3.7 was changed to a more lipophilic hydrocarbon chain 
(16 carbons) lacking a hydroxyl group at the end, the activity of the antioxidant 
was enhanced several fold. It was observed that compound 3.8 displayed very low 
inhibition of NADH oxidase (Table 9) and NADH-ubiquinone oxidoreductase 
(Table 11), which is presumably the reason that this compound was among the 
most potent antioxidants in the pyridinol series. 
As predicted for this family of pyridinol molecules, the mechanism for the 
scavenging of ROS and lipid radicals is through the formation of a pyridinoxyl 
radical. To test this hypothesis, we studied the ability of compound 3.1 to form a 
radical upon hydrogen abstraction of the hydroxyl group at position 3. As 
described above, the radical derived from compound 3.1 was formed by excitation 
of di-tert-butyl peroxide, and the signal obtained was measured using an ESR 
spectrophotometer (Figure 22A). The signal was characterized by its g factor of 
2.0049 and the small hyperfine coupling of the pyridine ring nitrogen (1.1G).  In 
agreement with the work of Pratt et al.,96 this is attributed to the electron donating 
 91  
character of N(CH3)2  responsible for an increase in contribution to stability 
arising from the higher energy polar structures (Figure 22B). 
It is interesting that the best pyridinol analogues function more effectively 
than idebenone as regards the several parameters studied, and were more potent 
overall as cytoprotective agents. Idebenone has also been reported to form a 
hydroquinone in situ via the action of NAD(P)H-quinone reductases, which 
enables the transfer of electrons to complex III.113 When pyridinol analogues were 
tested for supporting ATP production in FRDA lymphocytes, compounds 3.4, 3.8 
and 3.9 showed the best activity in this assay. These results are in complete 
agreement with their enhanced antioxidant activity and their lesser inhibition of 
the respiratory chain. 
 
Pyrimidinols 
A series of pyrimidinols was subjected to the same biological and 
biochemical assays as were employed for the pyridinol analogues.  The 
antioxidant properties of pyrimidinol analogues were affected similarly as for 
pyridinol analogues. The effect of the electron donating group at the position para 
to the phenoxy OH was very important for their activity. Compounds containing a 
methoxyl group (3.12) or a dimethyl pyrrole group (3.13) at this position had poor 
activity as antioxidants. Contrary to the pyridinols, when a methoxyl group was 
utilized instead of the methyl group ortho to the phenolic OH the antioxidant 
activity was increased significantly. It is well known that introduction of nitrogen 
atoms as part of the six-membered aromatic ring increases the stability of the 
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redox cores.81-83 Also, pyrimidinol analogues do not have free positions on the 
redox core susceptible to nucleophilic attack upon the oxidized forms. Another 
interesting observation was that when the methyl group ortho to the phenolic OH 
was replaced by a methoxyl group the inhibition of the electron transport chain 
decreased. These properties may be the reason why compound 3.15 was the most 
potent pyrimidinol analogue bearing the idebenone side chain.  
Removal of the hydroxyl group at the end of the lipophilic side chain had 
different effects on the activity of the pyrimidinol analogue activities as regards of 
inhibition of the respiratory chain, and consequently in their activity as 
antioxidants. It was observed that when the OH group was removed from 
lipophilic side chain of compound 3.10 to afford compound 3.17, the inhibition of 
NADH oxidase was greater (Table 10), but for NADH-ubiquinone oxidoreductase 
was similar (Table 12). On the other hand, removal of the OH group of the 
lipophilic side chain of compound 3.15 to afford compound 3.19, resulted in 
increased inhibition of NADH oxidase and NADH-ubiquinone oxidoreductase 
activities. After observing this behavior it was decided to create a series of 
analogues containing aliphatic side chains of different lengths. The effectiveness 
of the pyrimidinol analogues is highly dependent on the length of their lipophilic 
side chain. The inhibition of the respiratory chain was decreased when aliphatic 
chains longer and shorter than 10 carbons were used, as observed for pyrimidinol 
analogues 3.16, 3.17 and 3.18. Compound 3.16 did not perform well in other 
biological assays even when it was not a strong inhibitor of the electron transport 
chain. This lack of activity was attributed to its low interaction with lipid 
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membranes. To the contrary compounds 3.17 and 3.18 were potent antioxidant 
pyrimidinol analogues; however 3.17 was a strong inhibitor of the electron 
transport chain.  Exploration of the effects of aliphatic chains longer that 10-
carbons was then pursued. It was observed that when an aliphatic side chain of 18 
carbon atoms was present (compound 3.24), the antioxidant properties were 
diminished as compared to the corresponding analogues with a 16-carbon 
(compound 3.20) or 14-carbon (compound 3.22) aliphatic side chain. From this 
one could assume that the optimal side chain length was 14-16 carbon atoms.       
Interestingly, when a 16-carbon side chain was used, the replacement of 
the methyl groups on the pyrimidinol ring (compound 3.18) for a methoxyl group 
(compound 3.20) produced an increase in the inhibition of the respiratory chain.   
Previously, it was concluded that ubiquinones interact with complex I at 
different sites according to the lipophilicity of their aliphatic side chains.114 The 
wide range of effects observed for the inhibition of the respiratory chain by 
pyrimidinol and pyridinol analogues could suggest different interactions with the 
components of the electron transport chain as well. 
It is interesting to note that when glutathione, present in ~ 1-10 mM 
concentration in cells,115 is completely depleted by diethyl maleate, the best 
pyridinol and pyrimidinol analogues afford protection at the level of nanomolar 
concentrations. These compounds could be recycled in the cell by the action of 
other redox active compounds, just as α-TOH is recycled by vitamin C and 
NADH. The reduction of pyridinol and pyrimidinol analogues at oxidizing 
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potentials suggests that these compounds could be regenerated by superoxide as 
well.116 
   The wide range of activities presented by the analogues here suggested a 
strategy for the synthesis of a large library of compounds. To accomplish this 
goal, a strategy in which a terminal alkene is used as anchoring point, was 
developed and validated by synthesizing compounds 3.22-3.24. 
 
3.4 EXPERIMENTAL 
Reactions were carried out under an atmosphere of argon unless specified 
otherwise.  The glassware was dried in an oven at 110 °C prior to use.  
Tetrahydrofuran was distilled from sodium/benzophenone, dichloromethane was 
distilled from calcium hydride, benzene and toluene were distilled from sodium, 
and triethylamine and diisopropylamine were distilled from potassium hydroxide.  
All other solvents were of analytical grade and were used without further 
purification. Flash column chromatography was carried out using silica gel 
(Silicycle R10030B, 60 Å particle size, 230-400 mesh), applying a low pressure 
stream of nitrogen or air.  Analytical thin layer chromatographic separations were 
carried on glass plates coated with silica gel (60 Å particle size, 250 µm 
thickness, F-254, Silicycle).  The TLC chromatograms were developed using 
iodine vapor, or by immersing the plates either in 2.5% phosphomolybdic acid in 
ethanol, or in 2.0% anisaldehyde in ethanol/sulfuric acid/acetic acid, followed by 
heating (heat gun).  1H NMR chemical shifts were reported relative to residual 
CHCl3 at 7.26 ppm or DMSO at 3.31ppm or methanol-d4 at 3.31 ppm or 
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acetonitrile-d3 at 2.10 ppm and 116.4 ppm; 13C NMR chemical shifts were 
reported relative to the central line of CDCl3 at 77.0 ppm, DMSO-d6 at 39.5 ppm, 
methanol-d4 at 49.0 ppm, or acetonitrile-d3 at 1.89 ppm and 116.4 ppm. High 
resolution mass spectra were obtained in the Arizona State University CLAS High 
Resolution Mass Spectrometry Laboratory. 
 
Br OMOM
 
1-Bromo-9-(methoxymethoxy)nonane (3.25). To a stirred solution containing 
5.00 g (22.4 mmol) of 9-bromo-1-nonanol in 60 mL of anh THF was added 5.10 
mL (5.40g; 67.1 mmol) of MOM-Cl followed by 1.79 g (44.8 mmol) of a 60% 
suspension of NaH in mineral oil. The reaction mixture was stirred at 23 °C for 16 
h. The reaction mixture was carefully quenched with satd aq sodium bicarbonate, 
poured into 200 mL of water and extracted with two 150-mL portions of ether. 
The combined organic solution was washed with 200 mL of brine, dried (MgSO4) 
and then concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 5 cm). Elution with 9:1 hexanes–
ethyl acetate afforded compound 3.10 as colorless oil: yield 4.21 g (70%); silica 
gel TLC Rf 0.45 (9:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.28-1.39 (br, 
10H), 1.56 (quint, 2H, J = 7.2 Hz), 1.82 (quint, 2H, J = 7.2 Hz), 3.33 (s, 3H), 3.37 
(t, 2H, J = 6.8 Hz), 3.48 (t, 2H, J = 6.8 Hz) and 4.59 (s, 2H); 13C NMR (CDCl3) δ 
26.1, 28.1, 28.7, 29.28, 29.33, 29.7, 32.8, 34.0, 55.0, 67.7 and 96.4; mass 
spectrum (APCI), m/z 267.0953 (M+H)+ (C11H24O2Br requires 267.0960). 
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Br
 
6-Amino-3-bromo-2,4-dimethylpyridine (3.26).85 To a stirred solution 
containing 2.00 g (16.3 mmol) of 2-amino-4,6-dimethylpyridine in 25 mL of 
acetonitrile was added 2.90 g (16.3 mmol) of N-bromosuccinimide. The reaction 
mixture was stirred at room temperature for 5 h. The formed precipitate was 
filtered and dried to afford compound 3.26 as a colorless solid: yield 2.76 g 
(84%); mp 143-145 °C; silica gel TLC Rf 0.15 (2:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 2.25 (s, 3H), 2.48 (s, 3H), 4.39 (br s, 2H), and 6.22 (s, 1H); 13C 
NMR (CDCl3) δ 23.3, 25.1, 108.1, 112.3, 148.6, 155.2 and 156.3; mass spectrum 
(APCI), m/z 201.0032 (M+H)+ (C7H10N2Br requires 201.0027). 
N
N
Br
 
3-Bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2,4-dimethylpyridine (3.27). To a 
stirred solution containing 2.76 g (13.8 mmol) of compound 3.26 in 25 mL of 
toluene was added 2.02 mL (1.98 g; 17.2 mmol) of 2,5-hexanedione followed by 
130 mg (0.68 mmol) of p-toluenesulfonic acid. The reaction mixture was stirred at 
reflux for 14 h. The reaction mixture was poured into 150 mL of water and then 
extracted with 200 mL of ethyl acetate. The organic phase was washed with 150 
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mL of brine, dried (MgSO4) and then concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (15 × 6 cm). 
Elution with 6:1 hexanes–ethyl acetate afforded compound 3.27 as an orange oil: 
yield 2.37 g (62%); silica gel TLC Rf 0.70 (6:1 hexanes–ethyl acetate); 1H NMR 
(CDCl3) δ 2.12 (s, 6H), 2.47 (s, 3H), 2.70 (s, 3H), 5.88 (s, 2H), and 6.93 (s, 1H); 
13C NMR (CDCl3) δ 13.1, 23.4, 25.6, 106.9, 121.16, 121.24, 122.5, 128.4, 149.6 
and 157.4; mass spectrum (APCI), m/z 279.0502 (M+H)+ (C13H16N2Br requires 
279.0497). 
N
N
OBn
 
3-(Benzyloxy)-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2,4-dimethylpyridine (3.28). 
To a stirred solution containing 3.13 g (11.2 mmol) of compound 3.27 in 50 mL 
of 1:1 degassed dioxane–water was added 612 mg (0.67 mmol) of Pd2dba3 
followed by 284 mg (0.67 mmol) of 2-di-tert-butylphosphino-2’,4’,6’-
triisopropylbiphenyl (L1) and 1.88 g (33.6 mmol) of KOH. The reaction mixture 
was stirred at 100  °C for 3 h. The reaction mixture was poured into 200 mL of 
water and extracted with two 100-mL portions of ethyl acetate. The aqueous layer 
was acidified with HCl (to pH 2-3) and then extracted with two 100-mL portions 
of ethyl acetate. The combined organic layer was washed with 100 mL of brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was 
dissolved in 50 mL of anh THF and 1.99 mL (2.86 g; 16.8 mmol) of benzyl 
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bromide followed by 807 mg (22.4 mmol) of 60% sodium hydride suspension in 
mineral oil were added. The reaction mixture was stirred at 23 °C for 16 h. The 
reaction mixture was poured into 150 mL of water and extracted with two 100-
mL portions of diethyl ether. The combined organic layer was washed with 100 
mL of brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (15 × 6 cm). 
Elution with hexanes (removal of unreacted benzyl bromide) and then with 4:1 
hexanes–diethyl ether afforded compound 3.28 as a yellowish oil: yield 2.82 g 
(82%); silica gel TLC Rf 0.65 (5:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 
2.17 (s, 6H), 2.37 (s, 3H), 2.58 (s, 3H), 4.94 (s, 2H), 5.91 (s, 2H), 6.98 (s, 1H), 
and 7.40-7.50 (m, 5H); 13C NMR (CDCl3) δ 13.1, 16.2, 19.5, 74.6, 106.4, 121.9, 
127.9, 128.31, 128.34, 128.6, 136.7, 142.0, 146.6, 151.0 and 152.0; mass 
spectrum (APCI), m/z 307.1801 (M+H)+ (C20H23N2O requires 307.1810). 
N
N
OBn
OMOM
 
3-(Benzyloxy)-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-(10-
(methoxymethoxy)decyl)-4-methylpyridine (3.29). To a stirred solution at –78 
°C containing 906 mg (2.95 mmol) of compound 3.28 in 20 mL of anh THF was 
added 789 mg (2.95 mmol) of compound 3.25 followed by 1.99 mL (3.54 mmol) 
of a 1.80 M solution of PhLi in hexane. The reaction mixture was stirred at –78 °C 
for 30 min then the reaction mixture was allowed to warm slowly to 23 °C; the 
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reaction mixture was then stirred at 23 °C for 30 min. The reaction was quenched 
with satd aq ammonium chloride and then poured into 80 mL of water. The 
mixture was then extracted with two 80-mL portions of ethyl acetate. The 
combined organic layer was then washed with 100 mL of brine, dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 5 cm). Elution with 4:1 hexanes–
ethyl acetate afforded compound 3.29 as a light yellow oil: yield 877 mg (60%); 
silica gel TLC Rf 0.30 (9:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.18-1.22 
(br m, 12H), 1.50 (quint, 2H, J = 6.8 Hz), 1.65 (m, 2H), 2.06 (s, 6H), 2.26 (s, 3H), 
2.75 (dd, 2H, J = 7.6 and 7.6 Hz), 3.28 (s, 3H), 3.43 (t, 2H, J = 6.8 Hz), 4.53 (s, 
2H), 4.82 (s, 2H), 5.78 (s, 2H), 6.79, (s, 1H) and 7.29-7.40 (m, 5H); 13C NMR 
(CDCl3) δ 13.3, 16.4, 26.2, 28.9, 29.40, 29.48, 29.50, 29.55, 29.6, 29.7, 32.1, 
55.1, 67.9, 75.2, 96.4, 106.4, 121.7, 127.7, 128.3, 128.6, 128.9, 138.8, 142.0, 
146.8, 150.8 and 155.9; mass spectrum (APCI), m/z 493.3426 (M+H)+ 
(C31H45N2O3 requires 493.3430). 
N
NH2
OBn
OMOM
 
2-Amino-5-(benzyloxy)-6-(10-(methoxymethoxy)decyl)-4-methylpyridine 
(3.30). To a stirred solution containing 240 mg (0.49 mmol) of compound 3.29 in 
10 mL of 9:1 ethanol–water was added 338 mg (4.87 mmol) of hydroxylamine 
hydrochloride followed by 273 mg (4.87 mmol) of KOH. The reaction mixture 
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was stirred at reflux for 6 h, and then a second portion of 338 mg (4.87 mmol) of 
hydroxylamine hydrochloride was added, followed by 273 mg (4.87 mmol) of 
KOH. The reaction mixture was stirred at reflux for 16 h. The cooled reaction 
mixture was poured into 50 mL of water and extracted with two 50-mL portions 
of dichloromethane. The combined organic layer was washed with 60 mL of 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (10 × 3 cm). Elution with 
9:1 dichloromethane–methanol afforded compound 3.30 as a yellowish oil: yield 
113 mg (56%); silica gel TLC Rf 0.45 (9:1 dichloromethane–methanol); 1H NMR 
(CDCl3) δ 1.24-1.31 (br m, 12H), 1.53-1.63 (m, 4H), 2.16 (s, 3H), 2.62 (dd, 2H, J 
= 8.0 and 8.0 Hz), 3.33 (s, 3H), 3.48 (t, 2H, J = 6.8 Hz), 4.24 (br s, 2H), 4.59 (s, 
2H), 4.71 (s, 2H), 6.16 (s, 1H) and 7.31-7.43 (m, 5H); 13C NMR (CDCl3) δ 16.7, 
29.2, 29.40, 29.46, 29.48, 29.6, 29.7, 29.8, 32.2, 53.4, 55.1, 67.9, 75.4, 96.3, 
108.1, 127.7, 128.0, 128.5, 137.4, 142.5, 144.9, 153.5 and 154.1; mass spectrum 
(APCI), m/z 415.2957 (M+H)+ (C25H39N2O3 requires 415.2961). 
N
N
OBn
OMOM
 
3-(Benzyloxy)-6-(N,N-dimethylamino)-2-(10-(methoxymethoxy)decyl)-4-
methylpyridine (3.31). To a stirred solution containing 218 mg (0.53 mmol) of 
compound 3.30 in 3 mL of anh DMF was added 100 µL (228 mg; 1.59 mmol) of 
methyl iodide followed by 64.0 mg (1.59 mmol) of a 60% suspension of NaH in 
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mineral oil. The reaction mixture was stirred at 23 °C for 3 h. The reaction was 
quenched with 0.5 mL of water and concentrated under diminished pressure. The 
residue was dissolved in 50 mL of dichloromethane and washed with 50 mL of 
brine. The organic solution was dried (MgSO4) and then concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (8 × 3 cm). Elution with 3:1 hexanes–ethyl acetate afforded compound 
3.31 as a yellowish oil: yield 27 mg (21%); silica gel TLC Rf  0.30 (3:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 1.22-1.34 (br m, 12H), 1.56 (quint, 2H, J = 6.8  
Hz), 1.71 (quint, 2H, J = 7.6 Hz), 2.21 (s, 3H), 2.68 (dd, 2H, J = 7.6 and 7.6 Hz) , 
3.01 (s, 6H), 3.43 (s, 3H), 3.49 (t, 2H, J = 6.8 Hz), 4.60 (s, 2H), 4.71 (s, 2H), 6.16 
(s, 1H) and 7.32-7.45 (m, 5H); 13C NMR (CDCl3) δ 16.7, 26.2, 28.7, 29.4, 29.5, 
29.6, 29.73, 29.76, 31.6, 32.0, 38.3, 55.0, 67.9, 75.3, 96.4, 104.9, 127.8, 127.9, 
128.5, 137.7, 141.2, 143.4, 152.9 and 155.7; mass spectrum (APCI), m/z 443.3290 
(M+H)+ (C27H43N2O3 requires 443.3274). 
N
N
OH
OH
 
6-(N,N-Dimethylamino)-2-(10-hydroxydecyl)-4-methylpyridin-3-ol (3.1). To a 
stirred solution containing 27.0 mg (0.09 mmol) compound 3.31 in 3 mL of 
methanol was added one drop of concentrated HCl. The reaction mixture was 
stirred at reflux for 16 h. Then, 3 mg of 20% palladium hydroxide-on-carbon 
(Degussa type E101 NE/N) was added to the cooled reaction mixture, which was 
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stirred at 23 °C under a H2 atmosphere for 15 min. The reaction mixture was 
filtered through Celite and the filtrate was concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 
× 1 cm). Elution with 9:1 dichloromethane–methanol afforded compound 3.1 as a 
colorless oil: yield 10 mg (77%); silica gel TLC Rf  0.50 (9:1 dichloromethane–
methanol); 1H NMR (methanol-d4) δ 1.28-1.34 (br m, 12H), 1.49 (m, 2H), 1.63 
(m, 2H), 2.18 (s, 3H), 2.66 (dd, 2H, J = 7.6 and 7.6 Hz), 2.93 (s, 6H), 3.51 (t, 2H, 
J = 6.4 Hz) and 6.31 (s, 1H); 13C NMR (methanol-d4) δ 15.5, 25.5, 28.2, 29.16, 
29.20, 29.22, 29.24, 29.3, 31.2, 32.2, 38.1, 67.9, 106.0, 138.1, 141.0, 147.1 and 
154.2; mass spectrum (APCI), m/z 309.2553 (M+H)+ (C18H33N2O2 requires 
309.2542). 
N
NH2
OH
OH
 
6-Amino-2-(10-hydroxydecyl)-4-methylpyridin-3-ol (3.2).To a stirred solution 
containing 113 mg (0.27 mmol) of compound 3.30 in 10 mL of methanol was 
added two drops of concentrated HCl. The reaction mixture was stirred at reflux 
for 16 h. To the reaction mixture was added 5 mg of 20% palladium hydroxide-
on-carbon (Degussa type E101 NE/N). The reaction mixture was stirred at 23 °C 
under a H2 atmosphere for 15 min. The reaction mixture was filtered through 
Celite and the filtrate was concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (10 × 1 cm). Elution with 
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17:3 dichloromethane–methanol afforded compound 3.2 as a colorless solid: yield 
22 mg (29%); mp 138-139 °C; silica gel TLC Rf 0.20 (17:3 dichloromethane–
methanol); 1H NMR (methanol-d4) δ 1.28-1.35 (m, 12H), 1.48-1.58 (m, 4H), 2.13 
(s, 3H), 2.60 (dd, 2H, J = 7.6 and 7.6 Hz), 3.51 (t, 2H, J = 6.8 Hz) and 6.25 (s, 
1H); 13C NMR (methanol-d4) δ 15.2, 25.5, 28.8, 29.15, 29.20, 29.22, 29.3, 31.5, 
32.2, 61.6, 108.4, 139.2, 141.7, 146.9 and 152.5; mass spectrum (APCI), m/z 
281.2231 (M+H)+ (C16H29N2O2 requires 281.2229). 
N
N
OH
OH
 
6-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-(10-hydroxydecyl)-4-methylpyridin-3-ol 
(3.3). To a stirred solution containing 321 mg (0.65 mmol) of compound 3.29 in 5 
mL of methanol was added two drops of concentrated HCl. The reaction mixture 
was stirred at reflux for 16 h. To the cooled reaction mixture was added 10 mg of 
20% palladium hydroxide-on-carbon (Degussa type E101 NE/E) and the reaction 
mixture was then stirred at 23 °C under a H2 atmosphere for 15 min. The reaction 
mixture was filtered through Celite and the filtrate was concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (13 × 3 cm). Elution with 1:1 hexanes–ethyl acetate afforded compound 
3.3 as a colorless solid: yield 40 mg (17%); mp 98-99 °C; silica gel TLC Rf 0.42 
(1:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.29-1.35 (m, 12H), 1.53 (quint, 
2H, J = 6.8 Hz), 1.68 (quint, 2H, J = 6.8 Hz), 2.03 (s, 6H), 2.24 (s, 3H), 2.77 (dd, 
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2H, J = 7.6 and 7.6 Hz), 3.60 (t, 2H, J = 6.8 Hz), 5.80 (s, 2H) and 6.80 (s, 1H); 
13C NMR (CDCl3) δ 12.9, 15.9, 25.6, 28.2, 29.24, 29.25, 29.30, 29.36, 29.38, 
32.0, 32.6, 63.0, 106.0, 121.8, 128.5, 134.4, 143.5, 147.9 and 148.3; mass 
spectrum (APCI), m/z 359.2697 (M+H)+ (C22H35N2O2 requires 359.2699).  
N
N
OH
OH
 
6-(2,5-Dimethyl-1H-pyrrolidin-1-yl)-2-(10-hydroxydecyl)-4-methylpyridin-3-
ol (3.4). To a stirred solution containing 479 mg (0.65 mmol) of compound 3.29 
in 5 mL of methanol were added two drops of concentrated HCl. The reaction 
mixture was stirred at reflux for 16 h. To the mixture was added 10 mg of 20% 
palladium hydroxide-on-carbon (Degussa type E101 NE/E) and the reaction 
mixture was then stirred at 23 °C under a H2 atmosphere for 16 h. The reaction 
mixture was filtered through Celite and the filtrate was concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (13 × 3 cm). Elution with 1:1 toluene–ethyl acetate afforded compound 
3.4 as a colorless oil: yield 17 mg (5%); silica gel TLC Rf 0.42 (1:1 hexanes–ethyl 
acetate); 1H NMR (CD3CN) δ 1.24-1.34 (m, 18H), 1.46 (m, 2H), 1.68 (m, 4H), 
2.01 (m, 2H), 2.25 (s, 3H), 2.59 (t, 2H, J = 7.2 Hz), 3.47 (t, 2H, J = 6.4 Hz), 3.87 
(m, 2H) and 6.11 (s, 1H); 13C NMR (CD3CN) δ 16.1, 16.8, 19.6, 22.5, 22.6, 26.6, 
29.0, 30.2, 30.24, 30.27, 30.33, 30.9, 32.6, 32.8, 33.6, 56.1, 62.6, 106.5, 136.9, 
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141.3, 143.6 and 152.9; mass spectrum (APCI), m/z 363.3018 (M+H)+ 
(C22H39N2O2 requires 363.3012). 
N
O
OBn
OMOM
 
3-(Benzyloxy)-6-methoxy-2-(10-(methoxymethoxy)decyl)-4-methylpyridine 
(3.32). To a stirred solution at 0 °C containing 65.0 mg (0.16 mmol) of compound 
3.30 in 2 mL of 1:1 water–50% aq H3PO2 was added 17.0 mg (0.24 mmol) of 
sodium nitrite. The reaction mixture was stirred at 0 °C for 30 min and then at 23 
°C for 16 h. The reaction mixture was neutralized (pH ~ 7) with aqueous NaOH 
and stirred for 2 h. The reaction mixture was poured into 50 mL of water and 
extracted with two 40-mL portions of CH2Cl2. The combined organic layer was 
dried (MgSO4) and concentrated under diminished pressure. The residue was 
dissolved into 5 mL of anh CH2Cl2. To the solution were added 100 µL (228 mg; 
1.60 mmol) of methyl iodide followed by 66.0 mg (0.24 mmol) of Ag2CO3. The 
reaction mixture was stirred overnight at 23°C and protected from light. The 
reaction mixture was filtered and the filtrate was concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (8 × 
1 cm). Elution with 3:1 hexanes–ethyl acetate afforded compound 3.32 as 
colorless oil: yield 18 mg (26%); silica gel TLC Rf 0.55 (4:1 hexanes–ethyl 
acetate) 1H NMR (CDCl3) δ 1.24-1.34 (m, 12H), 1.56 (quint, 2H, J = 7.6 Hz), 
1.70 (quint, 2H, J = 7.6 Hz), 2.22 (s, 3H), 2.70 (dd, 2H, J = 7.6, 7.6 Hz), 3.34 (s, 
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3H), 3.49 (t, 2H, J = 6.8 Hz), 3.86 (s, 3H), 4.60 (s, 2H), 4.74 (s, 2H), 6.37 (s, 1H) 
and 7.33-7.44 (m, 5H); 13C NMR (CDCl3) δ 16.4, 26.2, 28.7, 29.4, 29.52, 29.54, 
29.6, 29.65, 29.73, 31.8, 53.3, 55.1, 67.9, 75.3, 96.4, 108.8, 127.8, 128.1, 128.5, 
137.3, 143.3, 146.6, 152.3 and 159.4; mass spectrum (APCI), m/z 430.2965 
(M+H)+ (C26H39NO4 requires 430.2957). 
N
O
OH
OH
 
2-(10-Hydroxydecyl)-6-methoxy-4-methylpyridin-3-ol (3.5). To a stirred 
solution containing 18 mg (0.04 mmol) of compound 3.32 in 3 mL of methanol 
was added two drops of concentrated HCl. The reaction mixture was stirred at 
reflux for 16 h. To the mixture was added 3 mg of 20% palladium hydroxide-on-
carbon (Degussa type E101 NE/N). The reaction mixture was stirred at room 
temperature under a hydrogen atmosphere for 15 min. The reaction mixture was 
filtered through Celite and the filtrate was concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (5 × 
1 cm). Elution with 3:1 hexanes–ethyl acetate afforded compound 3.5 as white 
solid: yield 8 mg (67%); mp 80-81 °C; silica gel TLC Rf 0.50 (3:1 hexanes–ethyl 
acetate); 1H NMR (CD3OD) δ 1.27 (br s, 12H), 1.49 (br s, 2H), 1.64 (br s, 2H), 
2.41 (br s, 3H), 2.81 (br s, 2H), 3.51 (br s, 3H), 4.02 (br s, 1H) and 7.05 (br s, 
1H); 13C NMR (CD3OD) δ 16.6, 25.5, 28.1, 28.6, 28.9, 29.0, 29.09, 29.14, 29.2, 
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32.2, 56.4, 61.6, 107.6, 142.3, 145.3, 148.7 and 155.1; mass spectrum (APCI), m/z 
296.2220 (M+H)+ (C17H30NO3 requires 296.2226). 
O
O
NH2
O
O
 
Dimethyl 2-(1-Aminoethylidene)malonate (3.33).91 To a stirred solution 
containing 4.36 mL (5.04 g; 38.2 mmol) of dimethyl malonate and 2.00 mL (1.57 
g; 38.3 mmol) of acetonitrile in 20 mL of 1,2-dichloroethane was added 8.90 mL 
(19.8 g; 76.0 mmol) of SnCl4. The reaction mixture was stirred at reflux for 2 h. 
The reaction mixture was then concentrated under diminished pressure and the 
residue was dissolved in 100 mL of acetone. Then, 70 mL of satd aq sodium 
carbonate was added and the mixture was stirred for 20 minutes. The mixture was 
poured into 200 mL of satd aq sodium bicarbonate and extracted with two 200-
mL portions of CH2Cl2. The combined organic solution was washed with 200 mL 
of brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was recrystallized from ethyl acetate—hexanes to afforded compound 3.33 as 
colorless crystals: yield 3.96 g (60%); mp 81-82°C; silica gel TLC Rf 0.5 (1:1 
ethyl acetate–hexanes); 1H NMR (CDCl3) δ 2.10 (s, 3H), 3.66 (s, 3H), 3.69 (s, 
3H), 5.29 (br s, 1H) and 8.94 (br s, 1H); 13C NMR (CDCl3) δ 22.0, 51.0, 51.6, 
92.4, 164.0, 168.7 and 168.9; mass spectrum (APCI), m/z 174.0760 (M+H)+ 
(C7H12NO4 requires 174.0766). 
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Methyl 6-(N,N-Dimethylamino)-4-hydroxy-2-methylnicotinate (3.34). A 
solution containing 1.10 g (6.36 mmol) of compound 3.33 and 1.40 mL (1.28 g; 
9.57 mmol) of N,N’-dimethylacetamide dimethyl acetal in 10 mL of anh dioxane 
was stirred at reflux for 3 h then 1.24 g (12.7 mmol) of sodium tert-butoxide was 
added and the reaction mixture was stirred at reflux for 3h. The reaction mixture 
was poured into 100 mL of water and extracted with two 80-mL portions of ethyl 
acetate. The combined organic solution was washed with 80 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 4 cm). Elution with 3:1 hexanes–
ethyl acetate afforded compound 3.34 as a colorless solid: yield 689 mg (51%); 
mp 61-62 °C; silica gel TLC Rf 0.47 (3:1 ethyl acetate–hexnanes); 1H NMR 
(CDCl3) δ 2.58 (s, 3H), 3.06 (s, 6H), 3.87 (s, 3H), 5.97 (s, 1H) and 11.88 (s, 1H); 
13C NMR (CDCl3) δ 27.5, 37.4, 51.6, 88.6, 99.3, 160.3, 161.9, 169.3 and 171.9; 
mass spectrum (APCI), m/z 211.1081 (M+H)+ (C10H15N2O3 requires 211.1083). 
N
O
COOMe
N
 
Methyl 6-(N,N-Dimethylamino)-4-methoxy-2-methylnicotinate (3.35). To a 
stirred solution containing 689 mg (3.27 mmol) of compound 3.34 in 10 mL of 
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anh DMF was added 1.91 g (18.0 mmol) of anh sodium carbonate followed by 
611 mL (1.39 g; 9.81 mmol) of methyl iodide. The reaction mixture was stirred at 
23 °C for 16 h. Then the reaction mixture was poured into 80 mL of water and 
extracted with two 80-mL portions of ethyl acetate. The combined organic 
solution was washed with 80 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 3 cm). Elution with 1:1 hexanes–diethyl ether afforded compound 
3.35 as a colorless solid: yield 340 mg (47%); mp 65-66°C; silica gel TLC Rf  
0.15 (1:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 2.37 (s, 3H), 3.07 (s, 6H), 
3.80 (s, 3H), 3.82 (s, 3H) and 5.72 (s, 1H); 13C NMR (CDCl3) δ 23.5, 37.8, 51.7, 
55.2, 84.5, 107.6, 156.7, 160.3, 165.2 and 168.4; mass spectrum (APCI), m/z 
225.1246 (M+H)+ (C11H17N2O3 requires 225.1239). 
N
O
N
 
2-(N,N-dimethylamino)-4-methoxy-6-methylpyridine (3.36). A solution 
containing 340 mg (1.52 mmol) of compound 3.35 in 5 mL of 6 N aq HCl was 
stirred at reflux for 16 h. The reaction mixture was poured into 50 mL of water 
and the pH was adjusted to 12. The mixture was extracted with two 40-mL 
portions of ethyl acetate. The combined organic solution was washed with 40 mL 
of brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (6 × 2 cm). Elution with 
9:1 dichloromethane–methanol afforded compound 3.36 as a colorless oil: yield 
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87 mg (34%); silica gel TLC Rf  0.25 (9:1 dichloromethane–methanol); 1H NMR 
(CDCl3) δ 2.33 (s, 3H), 3.02 (s, 6H), 3.75 (s, 3H), 5.77 (s, 1H) and 6.03 (s, 1H); 
13C NMR (CDCl3) δ 24.8, 38.0, 54.7, 87.4, 98.5, 157.9, 160.8 and167.5; mass 
spectrum (APCI), m/z 167.1183 (M+H)+ (C9H15N2O requires 167.1184). 
N
O
N
OMOM
 
2-(N,N-dimethylamino)-4-methoxy-6-(10-(methoxymethoxy)decyl)-N,N-
dimethylpyridine (3.37). To a stirred solution containing 156 mg (0.94 mmol) of 
compound 3.36 in 5 mL of anh THF was added 252 mg (0.94 mmol) of 
compound 3.25 followed by 650 µL (1.04 mmol) of 1.6 M n-BuLi in pentane. 
The reaction mixture was stirred at 23°C for 15 min. The reaction was quenched 
with satd aq ammonium chloride and poured into 50 mL of water. The mixture 
was extracted with two 50-mL portions of ethyl acetate. The combined organic 
solution was washed with 50 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 3 cm). Elution with 1:1 hexanes–ethyl acetate afforded compound 
3.37 as yellowish oil: yield 235 mg (70%); silica gel TLC Rf  0.47 (1:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 1.24 (br m, 12H), 1.55 (quint, 2H, J = 6.4 Hz), 
1.68 (quint, 2H, J = 7.6 Hz), 2.55 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.03 (s, 6H), 
3.46 (s, 3H), 3.49 (t, 2H, J = 6.8 Hz), 3.76 (s, 3H), 4.59 (s, 2H), 5.77 (s, 1H) and 
6.01 (s, 1H); 13C NMR (CDCl3) δ 26.2, 29.3, 29.4, 29.48, 29.50, 29.55, 29.60, 
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29.62, 29.7, 38.0, 54.6, 55.0, 67.9, 87.4, 96.4, 97.9, 160.8, 162.1 and 167.4; mass 
spectrum (APCI), m/z (M+H)+ 353.2808 (C20H37N2O3 requires 353.2804). 
N
O
N
Br
OMOM
 
5-Bromo-2-(N,N-dimethylamino)-4-methoxy-6-(10-
(methoxymethoxy)decylpyridine (3.38). To a stirred solution containing 213 mg 
(0.60 mmol) of compound 3.37 in 5 mL of acetonitrile was added 107 mg (0.60 
mmol) of N-bromosuccinimide. The reaction mixture was stirred at 23 °C 
protected from light for 3 h. The reaction mixture was poured into 50 mL of satd 
aq sodium bicarbonate and extracted with two 50-mL portions of ethyl acetate. 
The combined organic layer was washed with 50 mL of brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 3 cm). Elution with 4:1 hexanes–
ethyl acetate afforded compound 3.38 as a yellowish oil: yield 114 mg (44%); 
silica gel TLC Rf  0.45 (4:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.29 (br 
m, 12H), 1.56 (quint, 2H, J = 7.2 Hz), 1.68 (quint, 2H, J = 7.2 Hz), 2.55 (dd, 2H, 
J = 7.6 Hz and 7.6 Hz), 3.03 (s, 6H), 3.33 (s, 3H), 3.48 (t, 2H, J = 6.8 Hz), 3.85 
(s, 3H), 4.59 (s, 2H) and 5.76 (s, 1H); 13C NMR (CDCl3) δ 26.2, 28.1, 29.4, 29.47, 
29.51, 29.57, 29.65, 29.72, 37.3, 38.05, 55.0, 55.7, 67.9, 86.5, 96.4, 97.3, 158.8, 
159.1 and 162.6; mass spectrum (APCI), m/z (M+H)+ 431.1913 (C20H36N2O3Br 
requires 431.1909). 
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6-(N,N-Dimethylamino)-4-methoxy-2-(10-(methoxymethoxy)decyl)pyridin-3-
ol (3.39). To a stirred solution containing 114 mg (0.26 mmol) of compound 3.38 
in 5 mL of anh THF was added 413 µL (0.66 mmol) of 1.6 M n-BuLi in pentane. 
The reaction mixture was stirred at 23 °C for 10 min. Then was added 89.0 µL 
(82.9 mg; 0.79 mmol) of trimethylborate and the reaction mixture was stirred at 
23 °C for 30 min. Then was added 684 µL (12.6 mmol) of 35% aq H2O2 followed 
by 684 µL of 1 N NaOH. The reaction mixture was stirred at 23 °C for 2 h and 
then poured into 20 mL of water. The mixture was extracted with two 20-mL 
portions of ethyl acetate. The combined organic layer was washed with 20 mL of 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
1:1 hexanes–ethyl acetate afforded compound 3.39 as a yellowish oil: yield 20 mg 
(21%); silica gel TLC Rf 0.1 (1:1 hexanes–ethyl acetate); 1H NMR (CD3OD) δ 
1.29 (br s, 12H), 1.56 (br m, 4H), 2.66 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.00 (s, 
6H), 3.29 (s, 3H), 3.48 (t, 2H, J = 6.8 Hz), 3.90 (s, 3H), 4.56 (s, 2H) and 6.11 (s, 
1H); 13C NMR (CD3OD) δ 25.9, 28.1, 29.07, 29.11, 29.19, 29.24, 29.4, 30.1, 
35.2, 38.2, 53.9, 54.9, 67.5, 87.9, 96.0, 132.8, 143.7, 153.9 and 157.4; mass 
spectrum (APCI), m/z (M+H)+ 369.2760 (C20H37N2O4 requires 369.2753) 
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6-(N,N-Dimethylamino)-2-(10-hydroxydecyl)-4-methoxypyridin-3-ol (3.6). To 
a stirred solution containing compound 3.39 in 5 mL of methanol was added a 
drop of conc HCl. The reaction mixture was stirred at reflux for 2 h. A drop of 
conc NH4OH was added and the mixture was concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 
× 1 cm). Elution with 9:1 dichloromethane–methanol afforded compound 3.6 as a 
yellowish oil: yield 7 mg (40%); silica gel TLC Rf 0.2 (9:1 dichloromethane–
methanol); 1H NMR (CD3OD) δ 1.29 (br m, 12H), 1.49 (quint, 2H, J = 6.8 Hz), 
1.62 (quint, 2H, J = 7.2 Hz), 2.66 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.00 (s, 6H), 
3.49 (t, 2H, J = 6.8 Hz), 3.90 (s, 3H) and 6.11 (s, 1H); 13C NMR (CD3OD) δ 25.5, 
28.1, 29.08, 29.13, 29.14, 29.2, 29.3, 30.1, 32.2, 38.2, 54.9, 61.6, 87.9, 132.8, 
143.9, 154.0 and 157.3; mass spectrum (APCI), m/z (M+H)+ 325.2489 
(C18H33N2O3 requires 325.2491). 
N
OH
NH2
 
6-Amino-2,4,5-trimethylpyridin-3-ol (3.40).95 To a stirred solution containing 
10.0 g  (48.6 mmol) of 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol 
hydrochloride in 37 mL of thionyl chloride was added 370 µL (372 mg; 0.51 
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mmol) of  DMF. The reaction mixture was the stirred at reflux for 2 h. The cooled 
reaction mixture was treated with 20 mL of diethyl ether. The resulting 
suspension was stirred for 1 h and the formed precipitate was filtered and washed 
with 20 mL of ether. The solid so obtained was dissolved in 42 mL of glacial 
acetic acid and 9.80 g (150 mmol) of zinc dust was added in three portions. The 
resulting suspension was stirred and heated at reflux for 2 h. The cooled reaction 
mixture was filtered and washed with glacial acetic acid. The filtrate was 
neutralized with 6 M NaOH and the formed precipitate was filtered and washed 
with a small amount of brine. The orange precipitate was dissolved in 10 N HCl 
solution and the HCl adduct was salted out with NaCl. The solid so obtained was 
dissolved in 200 mL of satd aq sodium bicarbonate. Then a diazonium salt, 
freshly prepared by slowly mixing 4.00 mL (4.09 g; 43.9 mmol) of aniline in 40 
mL of 6 N HCl at 0 °C with a solution containing 3.00 g (44.0 mmol) of NaNO2 
in 15 mL of water, was added to the reaction mixture dropwise. After 1 h, a red 
precipitate that had formed was filtered. The diazo intermediate was dissolved in 
80 mL of 1:1 methanol–formic acid and 14.1 g (220 mmol) of zinc dust was 
added in three portions. The reaction mixture was then stirred at reflux for 2 h. 
The cooled reaction mixture was then filtered and the filtrate was washed with hot 
MeOH. The MeOH was concentrated and the resulting white precipitate was 
filtered, washed with ether, dried, and then dissolved in hot water and adjusted to 
pH 8.0 with 6 M NaOH. Upon cooling the solution, a white precipitate formed. 
The precipitate was filtered, dissolved in EtOH and filtered through a silica gel 
pad. The filtrate was concentrated under diminished pressure to afford compound 
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3.40 as a pale orange solid; yield 1.54 g (21%); mp 169-171 °C; silica gel TLC Rf 
0.20 (9:1 dichloromethane–methanol); 1H NMR (DMSO-d6) δ 1.88 (s, 3H), 2.00 
(s, 3H), 2.12 (s, 3H), 4.86 (br s, 2 H), and 7.40 (br s, 1H); 13C NMR (DMSO-d6) δ 
12.9, 13.4, 19.4, 112.7, 135.0, 140.2, 141.4 and 151.3. 
N
N
OH
 
6-(2,5-Dimethyl-1H-pyrrol-1-yl)-2,4,5-trimethylpyridin-3-ol (3.41). To a 
stirred solution containing 1.36 g (8.94 mmol) of compound 3.40 in 50 mL of 
toluene was added 1.32 mL (1.28 g; 11.2 mmol) of 2,5-hexanedione followed by 
86.0 mg (0.45 mmol) of p-toluenesulfonic acid. The reaction mixture was stirred 
and heated at reflux for 14 h using a Dean-Stark apparatus. The reaction mixture 
was poured into 80 mL of water and then extracted with 100 mL of ethyl acetate. 
The organic solution was washed with 80 mL of brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 6 cm). Elution with 2:1 hexanes–
ethyl acetate afforded compound 3.41 as colorless needles: yield 1.54 g (75%); 
mp 218-219 °C; silica gel TLC Rf 0.25 (2:1 hexanes–ethyl acetate); 1H NMR 
(CD3OD) δ 1.75 (s, 3H), 1.86 (s, 6H), 2.24 (s, 3H), 2.38 (s, 3H) and 5.77 (s, 2H); 
13C NMR (CD3OD) δ 12.4, 12.8, 13.6, 18.6, 106.7, 129.1, 131.1, 136.7, 142.7, 
144.0 and 151.2; mass spectrum (APCI), m/z (M+H)+ 231.1492 (C14H19N2O 
requires 231.1497). 
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3-(Benzyloxy)-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2,4,5-trimethylpyridine (3.42). 
To a stirred solution containing 1.54 g (6.69 mmol) of compound 3.41 in 50 mL 
of anh THF was added 1.19 mL (1.71 g; 10.0 mmol) of benzyl bromide followed 
by 803 mg (20.1 mmol) of 60% sodium hydride suspension in mineral oil. The 
reaction mixture was stirred at 23 °C for 16 h. The reaction mixture was poured 
into 150 mL of water and extracted with two 100-mL portions of ether. The 
combined organic layer was washed with 100 mL of brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 6 cm). Elution with hexanes 
(separation of unreacted benzyl bromide) and then with 4:1 hexanes–diethyl ether 
afforded compound 3.42 as yellowish crystals: yield 1.67 g (78%); mp 64-65 °C; 
silica gel TLC Rf  0.60 (2:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.83 (s, 
3H), 1.95 (s, 6H), 2.27 (s, 3H), 2.52 (s, 3H), 4.89 (s, 2H), 5.87 (s, 2H) and 7.40-
7.50 (m, 5H); 13C NMR (CDCl3) δ 12.5, 13.3, 13.8, 19.5, 74.9, 105.8, 128.0, 
128.1, 128.5, 128.8, 129.7, 136.7, 141.2, 145.8 149.5 and 151.6; mass spectrum 
(APCI), m/z (M+H)+ 321.1969 (C21H25N2O requires 321.1967). 
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3-(Benzyloxy)-6-(2,5-dimethyl-1H-pyrrol-1-yl)- 2-[10-
(methoxymethoxy)decyl]-4,5-dimethylpyridine (3.43). To a stirred solution at –
78 °C containing 670 mg (2.09 mmol) of compound 3.42 in 30 mL of anh THF 
was added 314 mL (243 mg; 2.09 mmol) of N,N,N’,N’-
tetramethylethylenediamine (TMEDA) followed by 1.00 mL (2.50 mmol) of a 
2.50 M solution of n-BuLi in hexane. The reaction mixture was stirred for 5 min 
at –78 °C and then 615 mg (2.30 mmol) of compound 3.25 was added. The 
reaction mixture was stirred at –78 °C for 30 min, then the reaction mixture was 
warmed to 23 °C slowly and stirred for 30 min. The reaction was quenched with 
satd aq ammonium chloride and then poured into 50 mL of water. The mixture 
was then extracted with two 80-mL portions of ether. The combined organic layer 
was then washed with 100 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (15 × 3 cm). Elution with 4:1 hexanes–ether afforded compound 3.43 as a 
colorless oil: yield 432 mg (41%); silica gel TLC Rf  0.25 (4:1 hexanes–ether); 1H 
NMR (CDCl3) δ 1.21-1.32 (br m, 12H), 1.55 (m, 2H), 1.68 (m, 2H), 1.81 (s, 3H), 
1.92 (s, 6H), 2.25 (s, 3H), 2.82 (dd, 2H, J = 8.0 Hz and 7.6 Hz), 3.33 (s, 3H), 3.48 
(t, 2H, J = 6.7 Hz), 4.59 (s, 2H), 4.85 (s, 2H), 5.85 (s, 2H) and 7.38-7.50 (m, 5H); 
13C NMR (CDCl3) δ 12.6, 13.4, 13.8, 26.3, 29.45, 29.54, 29.63, 29.65, 29.68, 
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29.7, 29.9, 32.4, 55.2, 68.0, 75.6, 96.5, 105.8, 127.8, 128.1, 128.4, 128.8, 129.4, 
137.0, 141.2, 146.0, 151.3 and 153.4; mass spectrum (APCI), m/z (M+H)+ 
507.3590 (C32H47N2O3 requires 507.3587). 
N
NH2
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2-Amino-5-(benzyloxy)-6-[10-(methoxymethoxy)decyl]-4,5-dimethylpyridine 
(3.44). To a stirred solution containing 849 mg (1.68 mmol) of compound 3.43 in 
10 mL of 9:1 ethanol–water was added 2.34 g (33.6 mmol) of hydroxylamine 
hydrochloride followed by 2.07 g (37.0 mmol) of potassium hydroxide. The 
reaction mixture was stirred and heated at reflux for 16 h. The reaction mixture 
was then poured into 50 mL of water and extracted with two 50-mL portions of 
ethyl acetate. The combined organic layer was washed with 60 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 3 cm). Elution with 9:1 
dichloromethane–methanol afforded compound 3.44 as a colorless oil: yield 96 
mg (13%); silica gel TLC Rf 0.45 (9:1 dichloromethane–methanol); 1H NMR 
(CDCl3) δ 1.21-1.32 (br m, 12H), 1.55 (m, 2H), 1.67 (m, 2H), 2.01 (s, 3H), 2.18 
(s, 3H), 2.64 (dd, 2H, J = 8.0 Hz and 8.0 Hz), 3.34 (s, 3H), 3.50 (t, 2H, J = 6.7 
Hz), 4.45 (br s, 2H), 4.60 (s, 2H), 4.69 (s, 2H) and 7.32-7.45 (m, 5H); 13C NMR 
(CDCl3) δ 12.9, 13.1, 21.9, 26.3, 29.46, 29.53, 29.54, 29.63, 29.66, 29.79, 29.87, 
32.2, 55.1, 67.9, 96.4, 113.6, 127.8, 128.0, 128.6, 137.5, 140.1, 144.9, 150.1 and 
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152.8; mass spectrum (APCI), m/z (M+H)+ 429.3114 (C26H41N2O3 requires 
429.3117). 
N
N
OBn
OMOM
 
3-Benzyloxy-6-(N,N-dimethylamino)-2-[10-(methoxymethoxy)decyl]-4,5-
dimethylpyridine (3.45). To a stirred solution containing 96.0 mg (0.22 mmol) of 
compound 3.44 in 3 mL of 1:1 formalin–acetonitrile was added 83.0 mg (1.32 
mmol) of sodium cyanoborohydride followed by 46.0 µL (48.2 mg; 0.80 mmol) 
of glacial acetic acid. The reaction mixture was stirred at 23 °C for 16 h and then 
poured into 20 mL of satd aq sodium bicarbonate. The mixture was then extracted 
with 20 mL of ether. The organic phase was washed with 20 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 2 cm). Elution with 4:1 hexanes–
ether afforded compound 3.45 as a colorless oil: yield 78 mg (77%); silica gel 
TLC Rf  0.30 (4:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 1.21-1.32 (br m, 
12H), 1.55 (m, 2H), 1.73 (m, 2H), 2.18 (s, 3H), 2.19 (s, 3H), 2.64 (m, 8H), 3.36 
(s, 3H), 3.50 (t, 2H, J = 6.8 Hz), 4.62 (s, 2H), 4.73 (s, 2H) and 7.32-7.45 (m, 5H); 
13C NMR (CDCl3) δ 13.2, 15.0, 26.4, 28.8, 29.6, 29.70, 29.74, 29.8, 29.9, 32.0, 
42.7, 55.2, 68.0, 75.4, 96.5, 121.5, 127.9, 128.1, 128.7, 137.7, 140.3, 147.4, 149.6 
and 158.2; mass spectrum (APCI), m/z (M+H)+ 457.3437 (C28H45N2O3 requires 
457.3430). 
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6-(N,N-dimethylamino)-2-(10-hydroxydecyl)-4,5-dimethylpyridin-3-ol (3.7). 
To a stirred solution containing 76.0 mg (0.17 mmol) of compound 3.45 in 3 mL 
of methanol was added 1 drop of concentrated HCl. The reaction mixture was 
stirred at reflux for 2 h. The cooled reaction mixture was concentrated under 
diminished pressure and the residue was partitioned between 20 mL of satd aq 
NaHCO3 and 20 mL of ethyl acetate. The organic layer was washed with 20 mL 
of brine, dried over MgSO4 and concentrated under diminished pressure. The 
residue was dissolved in 2 mL methanol, then 2 mg of 20% palladium hydroxide-
on-carbon (Degussa type E101 NE/N) was added and the reaction mixture was 
stirred at 23 °C under a H2 atmosphere for 15 min. The reaction mixture was 
filtered through Celite® and the filtrate was concentrated under diminished 
pressure to afford compound 3.7 as a yellowish oil: yield 41 mg (79%); silica gel 
TLC Rf 0.50 (9:1 dichloromethane–methanol); 1H NMR (CD3OD) δ 1.28-1.34 (br 
m, 12H), 1.51 (m, 2H), 1.65 (m, 2H), 2.15 (s, 3H), 2.17 (s, 3H), 2.66 (s, 6H), 2.72 
(dd, 2H, J = 8.0 Hz and 7.2 Hz) and 3.51 (t, 2H, J = 6.8 Hz); 13C NMR (CD3OD) 
δ 12.9, 14.6, 26.9, 29.5, 30.46, 30.56, 30.59, 30.66, 30.69, 30.74, 32.7, 33.7, 43.4, 
63.0, 123.7, 136.9, 145.8, 146.4 and 156.3; mass spectrum (APCI), m/z 323.2694 
(M+H)+ (C19H35N2O2 requires 323.2699). 
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3-(Benzyloxy)-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hexadecyl-4,5-
dimethylpyridine (3.46). To a stirred solution at –78 °C containing 1.00 g (3.12 
mmol) of compound 3.42 in 50 mL of anh THF was added 512 µL (397 mg; 3.41 
mmol) of TMEDA followed by 1.44 mL (3.59 mmol) of a 2.50 M solution of n-
BuLi in hexane. The mixture was stirred for 5 min at –78 °C and then 977 µL 
(981 mg; 3.37 mmol) of 1-bromopentadecane was added. The reaction mixture 
was stirred at –78 °C for 30 min. The reaction mixture was warmed to 23 °C 
slowly, and then stirred for 30 min. The reaction was quenched with satd aq 
ammonium chloride and then poured into 50 mL of water. The mixture was then 
extracted with two 80-mL portions of diethyl ether. The combined organic layer 
was then washed with 100 mL of brine, dried (MgSO4) and then concentrated 
under diminished pressure. The residue was purified by chromatography on a 
silica gel column (15 × 5 cm). Elution with 4:1 hexanes–diethyl ether afforded 
compound 3.46 as a light yellow oil: yield 800 mg (48%); silica gel TLC Rf 0.5 
(4:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 0.89 (t, 3H, J = 6.8 Hz) 1.21-
1.32 (br m, 26H), 1.71 (quint, 2H, J = 7.6 Hz), 1.84 (s, 3H), 1.95 (s, 6H), 2.28 (s, 
3H), 2.82 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 4.89 (s, 2H), 4.88 (s, 2H) and 7.38-
7.50 (m, 5H); 13C NMR (CDCl3) δ 12.6, 13.4, 13.8, 14.3, 22.8, 29.46, 29.49, 
29.66, 29.72, 29.74, 29.77, 29.78, 29.83, 32.1, 32.4, 75.6, 96.4, 105.8, 127.9, 
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128.2, 128.4, 128.8, 129.4, 137.0, 141.3, 146.0, 151.3 and 153.4; mass spectrum 
(APCI), m/z 531.4300 (M+H)+ (C36H55N2O requires 531.4314). 
N
NH2
OBn
 
2-Amino-5-(benzyloxy)-6-hexadecyl-4,5-dimethylpyridine (3.47). To a stirred 
solution containing 800 mg (1.51 mmol) of compound 3.46 in 10 mL of 9:1 
ethanol–water was added 785 mg (11.3 mmol) of hydroxylamine hydrochloride 
followed by 615 mg (11.3 mmol) of potassium hydroxide. The reaction mixture 
was then stirred at reflux 6 h. A second portion of 785 mg (11.3 mmol) of 
hydroxylamine hydrochloride followed by 615 mg (11.3 mmol) of potassium 
hydroxide was added and the mixture was stirred at reflux for 16 h. The reaction 
mixture was then poured into 50 mL of water and extracted with two 50-mL 
portions of ethyl acetate. The combined organic layer was washed with 60 mL of 
brine, dried (MgSO4) and then concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 3 cm). 
Elution with 9:1 dichloromethane–methanol afforded compound 3.47 as a 
colorless solid: yield 416 mg (61%); mp 50-52 °C; silica gel TLC Rf  0.65 (9:1 
dichloromethane–methanol); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 6.8 Hz) 1.18-
1.32 (br m, 26H), 1.64 (quint, 2H, J = 7.6 Hz), 2.01 (s, 3H), 2.18 (s, 3H), 2.63 
(dd, 2H, J = 8.0 Hz and 8.0 Hz), 4.25 (br s, 2H), 4.69 (s, 2H) and 7.33-7.45 (m, 
5H); 13C NMR (CDCl3) δ 12.9, 13.1, 14.1, 22.7, 29.3, 29.5, 29.60, 29.62, 29.64, 
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29.7, 29.99, 29.89, 31.9, 32.2, 75.7, 113.6, 127.7, 128.0, 128.5, 137.4, 140.0, 
145.0, 150.2 and 152.5; mass spectrum (APCI), m/z 453.3843 (M+H)+ 
(C30H49N2O requires 453.3845) 
N
N
OBn
 
3-(Benzyloxy)-6-(N,N-dimethylamino)-2-hexadecyl-4,5-dimethylpyridine 
(3.48). To a stirred solution containing 416 mg (0.92 mmol) of compound 3.47 in 
10 mL of 1:1 formalin–acetonitrile were added 347 mg (5.52 mmol) of sodium 
cyanoborohydride followed by 190 µL (199 mg; 3.32 mmol) of glacial acetic 
acid. The reaction mixture was stirred at 23 °C for 16 h and then poured into 50 
mL of satd aq sodium bicarbonate. The mixture was extracted with 80 mL of 
ether. The organic solution was washed with 80 mL of brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 3 cm). Elution with 4:1 hexanes–
diethyl ether afforded compound 3.48 as colorless oil: yield 310 mg (70%); silica 
gel TLC Rf  0.60 (4:1 hexanes–diethyl ether); 1H NMR  (CDCl3) δ 0.86 (t, 3H, J 
= 6.4 Hz) 1.21-1.32 (br m, 26H), 1.72 (quint, 2H, J = 7.2 Hz), 2.17 (s, 3H), 2.18 
(s, 3H), 2.71-2.75 (m, 8H), 4.72 (s, 2H) and 7.34-7.48 (m, 5H); 13C NMR (CDCl3) 
δ 13.1, 14.1, 14.5, 22.6, 22.7, 28.6, 29.3, 29.62, 29.63, 29.7, 31.6, 31.89, 31.90, 
42.6, 75.3, 121.4, 127.7, 128.0, 128.5, 137.5, 140.2, 147.2, 149.5 and 158.1; mass 
spectrum (APCI), m/z 481.4159 (M+H)+ (C32H53N2O requires 481.4158). 
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N
N
OH
 
6-(N,N-Dimethylamino)-2-(hexadecyl)-4,5-dimethylpyridin-3-ol (3.8).  To a 
stirred solution containing 310 mg (0.64 mmol) of compound 3.48 in 15 mL of 
methanol was 3.0 mg of 20% palladium hydroxide-on-carbon (Degussa type E101 
NE/N) and the reaction mixture was stirred at 23 °C under hydrogen atmosphere 
for 15 min. The reaction mixture was filtered through Celite® and the filtrate was 
concentrated under diminished pressure to afford compound 3.8 as a colorless 
solid: yield 246 mg (98%); mp 86-88 °C; silica gel TLC Rf 0.28 (4:1 hexanes–
diethyl ether); 1H NMR (CD3OD) δ 0.89 (t, 3H, J = 6.4 Hz), 1.28-1.36 (br m, 
26H), 1.67 (quint, 2H, J = 7.2 Hz), 2.27 (s, 6H), 2.82 (dd, 2H, J = 7.6 Hz and 7.6 
Hz) and 2.95 (s, 6H); 13C NMR (CD3OD) δ 12.3, 13.1, 13.3, 22.3, 28.0, 29.1, 
29.2, 29.3, 29.37, 29.40, 29.7, 31.7, 42.0, 72.8, 124.1, 127.8, 128.1 and 146.7; 
mass spectrum (APCI), m/z 391.3690 (M+H)+ (C25H47N2O requires 391.3688). 
N
N
OAc
 
3-(Acetoxy)-6-(N,N-dimethylamino)-2-hexadecyl-4,5-dimethylpyridine (3.9). 
To a stirred solution containing 100 mg (0.26 mmol) of compound 3.8 in 2 mL of 
anh DMF was added 108 mg (0.78 mmol) of potassium carbonate followed by 37 
µL (40 mg; 0.39 mmol) of acetic anhydride. The reaction mixture was stirred at 
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23 °C for 1h. The reaction mixture was poured into 30 mL of diethyl ether and 
washed with 20 mL of satd aq sodium bicarbonate, 20 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 3 cm). Elution with 4:1 hexanes–
diethyl ether afforded compound 3.9 as a colorless oil: yield 92 mg (82%); silica 
gel TLC Rf  0.45 (4:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 
6.8 Hz) 1.26-1.32 (br m, 26H), 1.72 (quint, 2H, J = 7.2 Hz), 2.01 (s, 3H), 2.18 (s, 
3H), 2.33 (s, 3H), 2.55 (dd, 2H, J = 7.6 Hz and 7.6 Hz) and 2.75 (s, 6H); 13C 
NMR (CDCl3) δ 13.4, 14.2, 15.1, 20.7, 22.8, 28.1, 29.5, 29.6, 29.7, 29.75, 29.79, 
29.84, 32.1, 32.2, 42.6, 121.3, 139.3, 139.8, 148.1, 159.8 and 169.5; mass 
spectrum (APCI), m/z 433.3785 (M+H)+ (C27H49N2O requires 433.3794). 
N
N
Br
 
5-Bromo-2-(N,N-dimethylamino)-4,6-dimethylpyridine (3.49).85 To a stirred 
solution containing 1.12 g (5.57 mmol) of compound 3.26 in 20 mL of anhydrous 
THF was added 1.04 mL (2.37 g; 16.71 mmol) of methyl iodide followed by 668 
mg (16.7 mmol) of a 60 % suspension of sodium hydride in mineral oil. The 
reaction mixture was stirred at 23 °C for 18 h. The reaction mixture was poured 
into 100 mL of water and extracted with two 100-mL portions of ether. The 
combined organic solution was dried (MgSO4) and then concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
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column (10 × 3 cm). Elution with 9:1 hexanes–diethyl ether afforded compound 
3.49 as a colorless oil: yield 700 mg (55%); silica gel TLC Rf  0.45 (3:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 2.30 (s, 3H), 2.51 (s, 3H), 3.01 (s, 6H) and 
6.22 (s, 1H); 13C NMR (CDCl3) δ 23.7, 25.6, 37.9, 37.9, 105.1, 110.2, 147.4, 
154.6 and 178.5. 
N
N
OH
 
6-(N,N-Dimethylamino)-2,4-dimethylpyridin-3-ol (3.50).85 To a stirred solution 
containing 1.12 g (5.57 mmol) of compound 3.49 in 10 mL of 1:1 degassed 
dioxane–water was added 56 mg (0.06 mmol) of Pd2dba3 followed by 45 mg 
(0.10 mmol) of 2-di-tert-butylphosphino-2’,4’,6’-triisopropylbyphenyl (L1) and 
512 mg (9.15 mmol) of potassium hydroxide. The reaction mixture was stirred at 
100 °C during 4 h. The reaction mixture was poured into 100 mL of water and 
extracted with 75 mL of ethyl ether. The aqueous layer was neutralized (pH ~7.0) 
with HCl and then extracted with two 75-mL portions of ethyl acetate. The 
combined organic solution was washed with 75 mL of brine, dried (MgSO4) and 
then concentrated under diminished pressure to afford compound 3.50 as a light 
brownish solid: yield 200 mg (35%); mp 130-131 °C; silica gel TLC Rf  0.15 (3:1 
hexanes–ethyl acetate); 1H NMR (CD3OD) δ 2.19 (s, 3H), 2.30 (s, 3H), 2.93 (s, 
6H) and 6.31 (s, 1H); 13C NMR (CD3OD) δ 16.8, 18.9, 39.5, 107.4, 139.0, 142.7, 
144.9 and 155.9.  
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O
N
Br
 
5-Bromo-2-(N,N-dimethylamino)-4-methoxy-6-methylpyridine (3.51). To a 
stirred solution containing 87.0 mg (0.52 mmol) of compound 3.36 in 4 mL of 
acetonitrile was added 93.0 mg (0.52 mmol) of N-bromosuccinimide. The 
reaction mixture was stirred at 23 °C protected from light for 4 h. The mixture 
was poured into 20 mL of ethyl acetate and washed with two 20-mL portions of 
satd aq sodium bicarbonate. The organic layer was dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 1 cm). Elution with 1:2 hexanes–
ethyl acetate afforded compound 3.51 as a colorless solid: yield 121 mg (95%); 
mp 58-59°C; silica gel TLC Rf  0.37 (2:1 hexanes–ethyl acetate); 1H NMR 
(CDCl3) δ 2.47 (s, 3H), 3.03 (s, 6H) 3.85 (s, 3H) and 5.75 (s, 1H); 13C NMR 
(CDCl3) δ 25.1, 38.0, 38.0, 55.7, 86.5, 97.4, 155.7, 158.8 and 165.6; mass 
spectrum (APCI), m/z 254.0287 (M+H)+ (C9H14N2OBr requires 254.0290). 
N
O
N
OH
 
6-(N,N-Dimethylamino)-4-methoxy-2-methylpyridin-5-ol (3.52). To a stirred 
solution at –78 °C containing 121 mg (0.49 mmol) of compound 3.51 in 3 mL of 
anh THF was added 763 µL (1.22 mmol) of 1.6 M solution of n-BuLi in hexanes. 
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The reaction mixture was stirred at –78 °C for 20 min. To the mixture was added 
163 µL (152 mg; 1.44 mmol) of trimethyl borate and the reaction mixture was 
stirred at 23 °C for 1 h. To the reaction mixture was added 1.08 mL of 30% aq 
H2O2. The reaction mixture was stirred for 30 min and poured into 20 mL of 
water. The aq mixture was neutralized with dilute aq HCl and extracted with two 
30-mL portions of ethyl acetate. The combined organic solution was washed with 
40 mL of brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 2 cm). 
Elution with 9:1 dichloromethane–methanol afforded compound 3.52 as a 
colorless oil: yield 10 mg (11%); silica gel TLC Rf  0.10 (9:1 dichloromethane–
methanol); 1H NMR (CD3OD) δ 2.27 (s, 3H), 3.00 (s, 6H), 3.90 (s, 3H) and 6.10 
(s, 1H); 13C NMR (CD3OD) δ 15.6, 38.1, 38.1, 54.9, 87.9, 133.0, 139.67, 154.0 
and 157.3; mass spectrum (APCI), m/z 183.1133 (M+H)+ (C9H15N2O2 requires 
183.1134). 
N
N
OH
 
2-(N,N-Dimethylamino)-5-hydroxy-3,4,6-trimethylpyridine (3.53).95 To a 
stirred solution containing 500 mg (3.29 mmol) of compound 3.40 in 10 mL of 
1:1 formalin–acetonitrile was added 860 mg (13.7 mmol) of sodium 
cyanoborohydride followed by 529 µL (621 mg; 10.3 mmol) of glacial acetic 
acid. The reaction mixture was stirred at 23 °C for 2 h and then poured into 20 
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mL of satd aq sodium bicarbonate. The mixture was then extracted with 100 mL 
of ethyl acetate. The organic phase was washed with 50 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 2 cm). Elution with 2:1 hexanes–
ethyl acetate afforded compound 3.53 as a colorless solid: yield 78 mg (77%); mp 
128-129 ºC; silica gel TLC Rf  0.40 (2:1 hexanes–ethyl acetate); 1H NMR 
(CD3OD) δ 2.14 (s, 3H), 2.18 (s, 3H), 2.37 (s, 3H) and 2.69 (s, 6H); 13C NMR 
(CD3OD) δ 12.5, 14.7, 18.9, 43.0, 122.7, 133.9, 138.6, 144.6 and 156.0. 
N N
NH2
 
2-Amino-4,6-dimethylpyrimidine (3.54).  To a stirred solution containing 4.00 g 
(37.0 mmol) of guanidine sulfate and 8.40 g (79.3 mmol) of sodium carbonate in 
25 mL of water was added 6.00 mL (5.88 g; 58.7 mmol) of 2,4-pentanedione. The 
reaction mixture was stirred at 100 ºC for 16 h. The reaction mixture was poured 
into 150 mL of water and then extracted with two 150-mL portions of 
dichloromethane. The combined organic phase was washed with 150 mL of brine, 
dried (MgSO4) and then concentrated under diminished pressure to afford 
compound 3.54 as a colorless solid: yield 4.31g (95%); mp 152-153 °C; silica gel 
TLC Rf  0.50 (9:1 dichloromethane–methanol); 1H NMR (CDCl3) δ 2.24 (s, 6H), 
5.39 (br s, 2H) and 6.33 (s, 1H); 13C NMR (CDCl3) δ 23.7, 110.5, 162.9 and 
167.7; mass spectrum (APCI), m/z 124.0869 (M+H)+ (C6H10N3 requires 
124.0875). 
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Br
 
2-Amino-5-bromo-4,6-dimethylpyrimidine (3.55).  To a stirred solution 
containing 4.31 g (34.8 mmol) of compound 3.54 in 150 mL of acetonitrile was 
added 6.15 g (52.1 mmol) of N-bromosuccinimide. The reaction mixture was 
stirred at 23 °C for 3 h. The formed precipitate was filtered and dried to afford 
compound 3.55 as a colorless solid: yield 5.93 g (83%); mp 183-185 °C; silica gel 
TLC Rf  0.15 (2:1 ethyl acetate–hexanes); 1H NMR (CDCl3) δ 2.44 (s, 6H) and 
5.19 (br s, 2H); 13C NMR (CDCl3) δ 24.7, 109.6, 160.7 and 166.3; mass spectrum 
(APCI), m/z 201.9982 (M+H)+ (C6H9N3Br requires 201.9980). 
N N
N
Br
 
5-Bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyrimidine (3.56).  To 
a stirred solution containing 2.00 g (9.89 mmol) of compound 3.55 in 16 mL of 
anh toluene was added 1.36 mL (1.32 g; 11.6 mmol) of 2,5-hexanedione followed 
by 96 mg (0.50 mmol) of p-toluenesulfonic acid. The reaction mixture was heated 
and stirred at reflux for 12 h using a Dean-Stark apparatus. The reaction mixture 
was poured into 150 mL of water and then extracted with 200 mL of ethyl acetate. 
The organic solution was washed with 150 mL of brine, dried (MgSO4) and 
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concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 5 cm). Elution with 5:1 hexanes–
ethyl acetate afforded compound 3.56 as light yellow crystals: yield 2.23 g (81%); 
mp 64-65 °C; silica gel TLC Rf  0.65 (6:1 hexanes–ethyl acetate); 1H NMR 
(CDCl3) δ 2.34 (s, 6H), 2.67 (s, 6H) and 5.89 (s, 2H); 13C NMR (CDCl3) δ 14.5, 
24.9, 108.7, 118.6, 129.5, 129.5, 155.3 and 166.9; mass spectrum (APCI), m/z 
280.0458 (M+H)+ (C12H15N3Br requires 280.0449). 
N N
N
OBn
 
5-(Benzyloxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyrimidine 
(3.57). To a stirred solution containing 4.87 g (17.4 mmol) of compound 3.56 in 
50 mL of 1:1 dioxane−degassed water was added 632 mg (0.69 mmol) of Pd2dba3 
followed by 293 mg (0.69 mmol) of 2-di-tert-butylphosphino-2',4',6'-
triisopropylbiphenyl (L1) and 2.92 g (52.1 mmol) of KOH. The reaction mixture 
was stirred at 100 °C for 3 h. The cooled reaction mixture was poured into 200 
mL of water and extracted with 100 mL of ethyl acetate. The aqueous layer was 
acidified with HCl (pH 2-3) and then extracted with two 150-mL portions of ethyl 
acetate. The combined organic layer was washed with 150 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was dissolved 
in 50 mL of anh THF and treated with 3.10 mL (4.46 g; 26.1 mmol) of benzyl 
bromide followed by 1.40 g (34.8 mmol) of a 60% suspension of NaH in mineral 
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oil. The reaction mixture was stirred at 23 °C for 48 h. The reaction mixture was 
quenched with satd aq sodium bicarbonate and poured into 150 mL of water and 
extracted with two 150-mL portions of ether. The combined organic layer was 
washed with 150 mL of brine, dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (20 
× 6 cm). Elution with 9:1 hexanes–ethyl acetate afforded compound 3.57 as a 
light yellow oil: yield 4.09 g (76%); silica gel TLC Rf 0.6 (6:1 hexanes–ethyl 
acetate); 1H NMR (CDCl3) δ 2.29 (s, 6H), 2.47 (s, 6H), 4.92 (s, 2H), 5.86 (s, 2H) 
and 7.42 (m, 5H); 13C NMR (CDCl3) δ 14.1, 14.1, 19.1, 19.1, 75.3, 107.9, 107.9, 
128.3, 128.6, 128.6, 129.0, 129.0, 129.2, 129.2, 136.0, 147.7, 152.3, 152.3 and 
161.6; mass spectrum (APCI), m/z 307.1675 (M)+ (C19H21N3O requires 
307.1685). 
N N
N
OBn
OMOM
 
5-(Benzyloxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-(10-
(methoxymethoxy)decyl)-6-methylpyrimidine (3.58).  To a stirred solution 
containing 486 mg (1.58 mmol) of compound 3.57 and 281 mg (1.05 mmol) of 
compound 3.25 in 10 mL of anh THF at −78 °C was added 987 µL (1.58 mmol) 
of a 1.6 M solution of n-BuLi in pentane. The reaction mixture was stirred under 
argon atmosphere at 23 °C for 30 min. The reaction was quenched with satd aq 
ammonium chloride and then poured into 50 mL of water. The mixture was then 
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extracted with two 50-mL portions of ethyl acetate. The combined organic layer 
was washed with 80 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (15 × 3 cm). Elution with 5:1 hexanes–ethyl acetate afforded compound 
3.58 as a light yellow oil: yield 289 mg (56%); silica gel TLC Rf  0.55 (5:1 
hexanes–ethyl acetate); 1H NMR (CDCl3 ) δ 1.33 (m, 12H), 1.60 (m, 2H), 1.82 (m, 
2H), 2.33 (s, 6H), 2.49 (s, 3H), 2.79 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.36 (s, 3H), 
3.52 (t, 2H, J = 6.4 Hz), 4.62 (s, 2H), 4.90 (s, 2H), 5.87 (s, 2H) and 7.41 (m, 5H); 
13C NMR (CDCl3) δ 14.4, 14.4, 19.3, 26.2, 27.7, 29.4, 29.4, 29.5, 29.5, 29.6, 29.8, 
31.6, 55.1, 67.9, 75.7, 96.4, 108.0, 108.0, 128.0, 128.58, 128.62, 128.7, 129.3, 
136.2, 147.4, 147.4, 152.6, 161.6, 161.6 and 165.1; mass spectrum (APCI), m/z 
494.3395 (M+H)+ (C30H44N3O3 requires 494.3383).  
N N
NH2
OBn
OMOM
 
2-Amino-5-(benzyloxy)-4-(10-(methoxymethoxy)decyl)-6-methylpyrimidine 
(3.59).  To a stirred solution containing 230 mg (0.47 mmol) of compound 3.58 in 
15 mL of 9:1 ethanol−water was added 327 mg (4.70 mmol) of hydroxylamine 
hydrochloride followed by 263 mg (4.70 mmol) of KOH. The reaction mixture 
was then heated and stirred at reflux for 5 h. A second portion of 327 mg (4.70 
mmol) of hydroxylamine hydrochloride followed by 263 mg (4.70 mmol) of KOH 
was added and the reaction mixture was heated and stirred at reflux for 12 h. The 
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reaction mixture was poured into 70 mL of water and then treated with 1N NaOH 
until pH 9-10 was reached. The reaction mixture was extracted with two 70-mL 
portions of ethyl acetate. The combined organic layer was washed with 70 mL of 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (10 × 3 cm). Elution with 
2:1 hexanes–ethyl acetate afforded compound 3.59 as a colorless oil: yield 133 
mg (76%); silica gel TLC Rf 0.76 (9:1 dichloromethane–methanol); 1H NMR 
(CDCl3) δ 1.27 (m, 12H), 1.53-1.63 (m, 4H), 2.26 (s, 3H), 2.54 (dd, 2H, J = 7.6, 
7.6 Hz), 3.31 (s, 3H), 3.46 (t, 2H, J = 6.8 Hz), 4.57 (s, 2H), 4.69 (s, 2H), 5.19 (br 
s, 2H) and 7.35-7.37 (m, 5H); 13C NMR (CDCl3) δ 18.9, 26.2, 28.4, 29.36, 29.40, 
29.5, 29.67, 29.70, 31.9, 55.0, 67.8, 75.9, 96.3, 127.9, 128.3, 128.3, 128.6,128.6, 
136.8, 142.8, 158.9, 161.1, 161.1 and 164.8; mass spectrum (APCI), m/z 416.2908 
(M+H)+ (C24H38N3O3 requires 416.2913). 
N N
N
OBn
OH
 
5-(Benzyloxy)-2-(N,N-dimethylamino)-4-(10-hydroxydecyl)-6-
methylpyrimidine (3.60).  A stirred solution containing 180 mg (0.43 mmol) of 
compound 3.59 in 10 mL of 35% aq 1:1 formaldehyde−formic acid was heated 
and stirred at reflux for 16 h. The reaction mixture was poured into 20 mL of 
water and extracted with two 40-mL portions of ethyl acetate. The combined 
organic layer was washed with 40 mL of satd aq NaHCO3 and then 40 mL of 
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brine. The organic solution was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (8 × 3 cm). Elution with 1:2 acetone–hexanes afforded compound 3.60 as 
a colorless oil: yield 44 mg (44%); silica gel TLC Rf 0.58 (1:2 acetone–hexanes); 
1H NMR (CD3OD) δ 1.27 (m, 12H), 1.53-1.73 (m, 4H), 2.26 (s, 3H), 2.55 (dd, 
2H, J = 7.6 Hz and 7.6 Hz), 3.09 (s, 6H), 3.50 (t, 2H, J = 6.8 Hz), 4.71 (s, 2H) 
and 7.35-7.37 (m, 5H); 13C NMR (CD3OD) δ 14.0, 17.8, 25.5, 27.6, 29.1, 29.2, 
29.3, 31.3, 32.3, 36.3, 36.3, 61.6, 75.5, 127.9, 128.3, 128.3, 128.6, 128.6, 137.1, 
141.0, 158.4, 160.5, 161.5 and 163.7; mass spectrum (APCI), m/z 400.2969 
(M+H)+ (C24H38N3O2 requires 400.2964). 
N N
N
OH
OH
 
2-(N,N-Dimethylamino)-4-(10-hydroxydecyl)-6-methylpyrimidin-5-ol (3.10).  
To a stirred solution containing 44.0 mg (0.11 mmol) of compound 3.60 in 3 mL 
of methanol was added 3 mg of 20% palladium hydroxide-on-carbon (Degussa 
type E101 NE/N). The reaction mixture was stirred at 23 °C for 15 min under a 
hydrogen atmosphere. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure to afford compound 3.10 as 
colorless oil: yield 33 mg (100%). An analytical sample was obtained by 
chromatography on a silica gel column (10 × 1 cm). Elution with 2:1 toluene–
ethyl acetate afforded the purified product as a colorless oil; silica gel TLC Rf 
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0.25 (2:1 toluene–ethyl acetate); 1H NMR (CD3OD) δ 1.29-1.35 (m, 12H), 1.49 
(m, 2H), 1.65 (m, 2H), 2.26 (s, 3H), 2.62 (dd, 2H, J = 7.2 Hz and 7.2 Hz), 3.06 (s, 
6H) and 3.51 (t, 2H, J = 6.4 Hz); 13C NMR (CD3OD) δ 17.8, 25.5, 27.3, 29.13, 
29.15, 29.15, 29.18, 29.3, 31.2, 32.2, 36.5, 36.5, 61.6, 138.0, 155.6, 157.3 and 
159.4; mass spectrum (APCI), m/z 310.2490 (M+H)+ (C17H32N3O2 requires 
310.2495).  
N N
NH2
OH
OH
 
2-Amino-4-(10-hydroxydecyl)-6-methylpyrimidin-5-ol (3.11). To a stirred 
solution containing 133 mg (0.48 mmol) of compound 3.59 in 10 mL of methanol 
was added two drops of concentrated HCl and the reaction mixture was stirred at 
reflux for 16 h. To the cooled mixture was added 10 mg of 20% palladium 
hydroxide-on-carbon (Degussa type E101 NE/N). The reaction mixture was 
stirred at 23 °C for 15 min under a hydrogen atmosphere. The reaction mixture 
was filtered through Celite® and the filtrated was concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (13 
× 3 cm). Elution with 17:3 dichloromethane–methanol afforded compound 3.11 
as colorless solid: yield 68 mg (69%); mp 103-104 °C; silica gel TLC Rf  0.20 
(17:3 dichloromethane–methanol); 1H NMR (CD3OD) δ 1.29-1.35 (m, 12H), 1.50 
(quint, 2H, J = 6.8 Hz), 1.64 (quint, 2H, J = 7.6 Hz), 2.37 (s, 3H), 2.71 (dd, 2H, J 
= 7.6 Hz and 7.6 Hz) and 3.51 (t, 2H, J = 6.4 Hz); 13C NMR (CD3OD) δ 16.4, 
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25.5, 27.1, 29.00, 29.02, 29.08, 29.13, 29.3, 30.7, 32.2, 61.6, 139.0, 153.5, 157.6 
and 160.8; mass spectrum (APCI), m/z 282.2170 (M+H)+ (C15H28N3O2 requires 
282.2182). 
N N
Cl
OBn
OMOM
 
5-(Benzyloxy)-2-chloro-4-(10-(methoxymethoxy)decyl)-6-methylpyrimidine 
(3.61). To a stirred solution containing 240 mg (0.58 mmol) of compound 3.54 in 
10 mL of anh CH2Cl2 was added 1.10 g (5.80 mmol) of 
benzyltrimethylammonium chloride followed by 696 µL (603 mg; 5.85 mmol) of 
t-butyl nitrite. The reaction mixture was stirred at 23 °C for 15 h protected from 
light. The mixture was filtered and the filtrate was concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 
× 3 cm). Elution with 4:1 hexanes–ethyl acetate afforded compound 3.61 as a 
colorless oil: yield 44 mg (16%); silica gel TLC Rf  0.45 (4:1 hexanes–ethyl 
acetate); 1H NMR (CDCl3) δ 1.24 (br s, 12H), 1.55 (quint, 2H, J = 7.2 Hz), 1.65 
(quint, 2H, J = 6.8 Hz), 2.42 (s, 3H), 2.67 (dd, 2H, J = 8.0 Hz and 8.0 Hz), 3.33 
(s, 3H), 3.47 (t, 2H, J = 6.8 Hz), 4.59 (s, 2H), 4.83 (s, 2H) and 7.37 (m, 5H); 13C 
NMR (CDCl3) δ 19.3, 26.2, 28.1, 29.3, 29.4, 29.47, 29.51, 29.7, 31.9, 55.0, 67.9, 
76.0, 96.4, 128.1, 128.7, 128.8, 135.7, 149.0, 154.2, 163.8 and 167.4; mass 
spectrum (APCI), m/z (M+H)+ 435.2411 (C24H36N2O3Cl requires 435.2415)  
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5-(Benzyloxy)-2-methoxy-4-(10-(methoxymethoxy)decyl)-6-methylpyrimidine 
(3.62). To a stirred solution containing 41.0 mg (0.09 mmol) of compound 3.61 in 
5 mL of anhydrous methanol was added 22 mg (0.94 mmol) of sodium. The 
reaction mixture was then stirred at reflux for 16 h. The cooled reaction mixture 
was quenched with water and poured into 50 mL of water. The mixture was 
extracted with two 50-mL portions of ethyl acetate. The combined organic 
solution was washed with 50 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (6 × 2 cm). Elution with 1:1 hexanes–ethyl acetate afforded compound 
3.62 as a colorless oil: yield 30 mg (74%); silica gel TLC Rf  0.65 (1:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 1.24 (br m, 12H), 1.55 (quint, 2H, J = 6.8 Hz), 
1.68 (quint, 2H, J = 7.6 Hz), 2.37 (s, 3H), 2.65 (dd, 2H, J = 7.6, 7.6 Hz), 3.33 (s, 
3H), 3.48 (t, 2H, J = 6.8 Hz), 3.93 (s, 3H), 4.59 (s, 2H), 4.83 (s, 2H) and 7.37 (m, 
5H); 13C NMR (CDCl3) δ 19.2, 26.2, 27.9, 29.4, 29.4, 29.51, 29.53, 29.7, 31.7, 
54.7, 55.0, 67.9, 75.8, 96.4, 127.5, 128.4, 128.6, 136.5, 145.1, 160.6, 162.4 and 
165.9; mass spectrum (APCI), m/z (M+H)+ 431.2910 (C25H39N2O4 requires 
431.2910). 
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OH
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4-(10-Hydroxydecyl)-2-methoxy-6-methylpyrimidin-5-ol (3.12). To a stirred 
solution containing 30.0 mg (0.07 mmol) of compound 3.62 in 3 mL of methanol 
was added a drop of concentrated HCl. The mixture was stirred at reflux for 16 h. 
Then was added 2 mg of 20% palladium hydroxide-on-carbon (Degussa type 
E101 NE/N) and the reaction mixture was stirred at 23°C for 20 min. The mixture 
was filtered through Celite® and concentrated under diminished pressure to 
afford compound 3.12 as a yellowish oil: yield 20 mg (97%); silica gel TLC Rf  
0.45 (4:1 hexanes–ethyl acetate); 1H NMR (methanol) δ 1.30 (br m, 12H), 1.50 
(br m, 2H), 1.74 (br m, 2H), 2.56 (s, 3H), 2.89 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 
3.51 (t, 2H, J = 6.4 Hz) and 4.15 (s, 3H); 13C NMR (methanol) δ 16.2, 25.5, 26.8, 
28.9, 29.0, 29.1, 29.18, 29.22, 30.8, 32.2, 56.1, 61.6, 143.1, 153.0 and 156.6 and 
163.0; mass spectrum (APCI), m/z (M+H)+ 297.2180 (C16H29N2O3 requires 
297.2178). 
 
N N
N
OH
OH
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2-(2,5-Dimethyl-1H-pyrrol-1-yl)-4-(10-hydroxydecyl)-6-methylpyrimidin-5-ol 
(3.13). To a stirred solution containing 240 mg (0.48 mmol) of compound 3.58 in 
10 mL of methanol was added two drops of concentrated HCl and the mixture 
was stirred at reflux overnight. To the mixture was added 10 mg of 20% 
palladium hydroxide-on-carbon (Degussa type E101 NE/E). The reaction mixture 
was stirred at 23 °C for 15 min under a hydrogen atmosphere. The reaction 
mixture was filtered through Celite® and the filtrate was concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (13 × 3 cm). Elution with 2:1 toluene–ethyl acetate compound 3.13 
product as colorless oil: yield 13 mg (8%); silica gel TLC Rf  0.40 (2:1 toluene–
ethyl acetate); 1H NMR (CD3OD) δ 1.29-1.35 (m, 12H), 1.49 (m, 2H), 1.71 (m, 
2H), 2.11 (s, 6H), 2.45 (s, 3H), 2.80 (dd, 2H, J = 7.2 Hz and 7.2 Hz), 3.50 (t, 2H, 
J = 6.4 Hz) and 5.74 (s, 2H); 13C NMR (CD3OD) δ 12.0, 17.5, 25.5, 27.3, 28.9, 
29.05, 29.12, 29.18, 29.22, 31.0, 32.2, 61.6, 106.3, 128.4, 146.2, 148.8, 155.4 and 
158.9; mass spectrum (APCI), m/z 360.2659 (M+H)+ (C21H34N3O2 requires 
360.2651).  
N N
N
OH
OH
 
2-(2,5-Dimethylpyrrolidin-1-yl)-4-(10-hydroxydecyl)-6-methylpyrimidin-5-ol 
(3.14). This compound was obtained as a side product in the reaction for the 
preparation of compound 3.13 as a colorless oil: yield 25 mg (14%); silica gel 
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TLC Rf  0.46 (2:1 toluene–ethyl acetate); 1H NMR (CD3OD) δ 1.31 (m, 16H), 
1.51 (m, 2H), 1.69 (m, 4H), 1.98 (m, 2H), 2.25 (s, 3H), 2.61 (dd, 2H, J = 7.2 Hz 
and 7.2 Hz), 3.51 (t, 2H, J = 6.8 Hz) and 4.11 (m, 2H); 13C NMR (CD3OD) δ 
17.6, 21.0, 25.5, 27.1, 29.08, 29.14, 29.2, 29.3, 31.0, 31.5, 32.2, 54.5, 61.6, 137.8, 
141.0, 155.5 and 159.1; mass spectrum (APCI), m/z 364.2954 (M+H)+ 
(C21H38N3O2 requires 364.2964). 
 
N N
N
O
 
2-(N,N-Dimethylamino)-2-methoxy-6-methylpyrimidine (3.63). To a stirred 
solution containing 1.00 g (7.19 mmol) of 2-amino-4-methoxy-6-
methylpyrimidine in 10 mL of anh DMF was added 1.35 mL (3.08 g; 21.7 mmol) 
of methyl iodide followed by 853 mg (21.6 mmol) of a 60% suspension of sodium 
hydride in mineral oil. The reaction mixture was stirred at 23 °C for 20 min. The 
reaction mixture was quenched with water and concentrated under diminished 
pressure in order to remove as much DMF as possible. The residue was dissolved 
in 70 mL of ethyl acetate and washed with 50 mL of water and 50 mL brine. The 
organic solution was dried (MgSO4) and concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (15 × 5 cm). 
Elution with 4:1 hexanes–ethyl acetate afforded compound 3.63 as a colorless oil: 
yield 755 mg (63%); silica gel TLC Rf  0.30 (4:1 hexanes–ethyl ether); 1H NMR 
(CDCl3) δ 2.22 (s, 3H), 3.12 (s, 6H), 3.83 (s, 3H) and 5.76 (s, 1H); 13C NMR 
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(CDCl3) δ 24.1, 36.8, 52.7, 93.7, 162.2, 167.7 and 170.2; mass spectrum (APCI), 
m/z 168.1135 (M+H)+ (C8H14N3O requires 168.1137). 
N N
N
O OMOM
 
2-(N,N-Dimethylamino)-4-methoxy-6-[10-
(methoxymethoxy)decyl]pyrimidine (3.64). To a stirred solution containing 933 
mg (5.58 mmol) of compound 3.63 and 1.5 g (5.58 mmol) of compound 3.25 in 
20 mL of anh THF was added 5.23 mL (8.37 mmol) of 1.6 M n-BuLi in hexanes. 
The reaction mixture was stirred at 23 °C for 20 min. The reaction mixture was 
quenched with satd aq ammonium chloride and poured into 100 mL of water. The 
compound was extracted with two 80-mL portions of ethyl acetate. The combined 
organic layer was washed with 80 mL of brine, dried (MgSO4) and concentrated 
under diminished pressure. The residue was purified by chromatography on a 
silica gel column (15 × 5 cm). Elution with 9:1 hexanes–ethyl acetate afforded 
compound 3.64 as a colorless oil: yield 1.41 g (71%); silica gel TLC Rf  0.45 (9:1 
hexanes–ethyl acetate); 1H-NMR (CDCl3) δ 1.27 (br m, 10H), 1.82 (m, 4H), 2.48 
(dd, 2H, J = 8.0 Hz and 8.0 Hz), 3.14 (s, 6H), 3.33 (s, 3H), 3.48 (t, 2H, J = 6.8 
Hz), 3.85 (s, 3H), 4.59 (s, 2H) and 5.76 (s, 1H); 13C NMR (CDCl3) δ 26.2, 28.5, 
28.7, 29.3, 29.4, 29.45, 29.54, 29.7, 36.8, 37.8, 52.7, 55.0, 67.9, 93.0, 96.4, 162.4, 
170.3 and 172.0; mass spectrum (APCI), m/z 354.2766 (M+H)+ (C19H36N3O3 
requires 254.2757).  
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5-Bromo-2-(N,N-dimethylamino)-4-methoxy-6-(10-
(methoxymethoxy)decyl)pyrimidine (3.65). To a stirred solution containing 1.41 
g (3.99 mmol) of compound 3.64 in 10 mL of acetonitrile was added 852 mg 
(4.79 mmol) of N-bromosuccinimide. The reaction mixture was stirred at 23 °C 
for 5 h and protected from light. The reaction mixture was concentrated under 
diminished pressure and the residue was dissolved into 100 mL of ethyl acetate. 
The organic solution was washed with 100 mL of brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column. Elution with 9:1 hexanes–ethyl acetate 
afforded compound 3.65 as colorless oil: yield 910 mg (53%); silica gel TLC Rf  
0.65 (9:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.27 (br m, 10H), 1.59 (m, 
4H), 2.67 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.11 (s, 6H), 3.33 (s, 3H), 3.48 (t, 2H, 
J = 6.8 Hz), 3.92 (s, 3H) and 4.59 (s, 2H); 13C NMR (CDCl3) δ 26.2, 27.6, 29.3, 
29.4, 29.5, 29.6, 29.7, 36.7, 36.9, 54.0, 55.0, 67.9, 91.2, 96.4, 160.1, 165.1 and 
169.0; mass spectrum (APCI), m/z 432.1857 (M+H)+ (C19H35N3O3Br requires 
432.1862).     
N N
N
O
OH
OMOM
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2-(N,N-Dimethylamino)-4-methoxy-6-(10-(methoxymethoxy)decyl)pyrimidin-
5-ol (3.66). To a stirred solution at –5 °C containing 120 mg (0.25 mmol) of 
compound 3.65 in 3 mL of anh THF was added 390 µL (0.62 mmol) of 1.6 M 
solution of n-BuLi in hexanes. The reaction mixture was stirred at –5 °C for 20 
min. To the mixture was added 84 µL (78 mg; 0.75 mmol) of trimethyl borate and 
the reaction mixture was stirred for 1 h. To the reaction mixture was added 0.55 
mL of 30% aq H2O2 followed by 0.18 mL of 3 N aq NaOH. The reaction mixture 
was stirred for 30 min and poured into 50 mL of water. The aq mixture was 
neutralized with dilute aq HCl and extracted with two 50-mL portions of ethyl 
acetate. The combined organic solution was washed with 80 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 3 cm). Elution with 2:1 hexanes–
ethyl acetate afforded compound 3.66 as a colorless oil: yield 47 mg (51%); silica 
gel TLC Rf  0.50 (2:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.25 (br m, 
10H), 1.59 (m, 4H), 2.58 (br s, 2H), 3.07 (s, 6H), 3.33 (s, 3H), 3.48 (t, 2H, J = 6.8 
Hz), 3.92 (s, 3H) and 4.59 (s, 2H); 13C NMR (CDCl3) δ 26.1, 27.7, 29.3, 29.37, 
29.42, 29.45, 29.52, 29.7, 31.2, 37.2, 53.2, 55.0, 67.9, 96.3, 126.9, 155.0, 155.9 
and 158.0; mass spectrum (APCI), m/z 370.2700 (M+H)+ (C19H36N3O3 requires 
370.2706). 
N N
N
O OH
OH
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2-(N,N-Dimethylamino)-4-(10-hydroxydecyl)-6-methoxypyrimidin-5-ol 
(3.15). To a stirred solution containing 20 mg (0.054 mmol) of compound 3.66 in 
5 mL of methanol was added 2 drops of concentrated HCl. The reaction mixture 
was stirred at reflux for 16 h. The reaction mixture was concentrated under 
diminished pressure and the residue was purified by chromatography on a silica 
gel column (8 × 1 cm). Elution with 1:2 hexanes–ethyl acetate afforded 
compound 3.15 as colorless solid: yield 7 mg (40%); mp 104-105 °C; silica gel 
TLC Rf  0.15 (1:2 hexanes–ethyl acetate); 1H NMR (CD3OD) δ 1.30 (br m, 10H), 
1.49 (m, 2H), 1.64 (m, 2H), 2.76 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.22 (s, 6H), 
3.51 (t, 2H, J = 6.8 Hz) and 4.07 (s, 3H); 13C NMR (CD3OD) δ 25.6, 27.5, 27.7, 
29.02, 29.03, 29.17, 29.19, 29.3, 32.3, 37.2, 54.5, 61.6, 128.1, 146.4, 151.3 and 
162.7; mass spectrum (APCI), m/z 326.2442 (M+H)+ (C17H32N3O3 requires 
326.2444). 
N N
N
OBn
 
5-(Benzyloxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-6-pentylpyrimidine 
(3.67): To a stirred solution at –78 °C containing 1.00 g (3.25 mmol) of 
compound 3.57 and 233 µL (296 mg; 2.16 mmol) of 1-bromobutane in 30 mL of 
anh THF was added 2.70 mL (4.32 mmol) of a 1.6 M solution of n-BuLi in 
pentane. The reaction mixture was stirred at 23 °C for 30 min. The reaction was 
quenched with satd aq ammonium chloride and then poured into 70 mL of water. 
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The mixture was then extracted with two 70-mL portions of diethyl ether. The 
combined organic layer was then washed with 100 mL of brine, dried (MgSO4) 
and then concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 5 cm). Elution with 4:1 hexanes–
diethyl ether afforded compound 3.67 as a colorless oil: yield 533 mg (69%); 
silica gel TLC Rf  0.50 (4:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 0.90 (t, 
3H, J = 7.2 Hz), 1.34 (m, 4H), 1.77 (m, 2H), 2.33 (s, 6H), 2.49 (s, 3H), 2.79 (dd, 
2H, J = 7.6 Hz and 7.6 Hz), 4.91 (s, 2H), 5.88 (s, 2H) and 7.42 (m, 5H); 13C 
NMR (CDCl3) δ 14.0, 14.3, 19.3, 22.5, 27.4, 31.6, 31.7, 75.7, 107.9, 128.0, 128.2, 
128.7, 129.3, 136.2, 147.4, 152.6, 161.6 and 165.1; mass spectrum (APCI), m/z 
364.2394 (M+H)+ (C23H30N3O requires 364.2389). 
N N
N
OBn
 
5-(Benzyloxy)-4-decyl-2-(2,5-dimethyl-1H-pyrrol-1-yl)-6-methylpyrimidine 
(3.68). To a stirred solution at –78 °C containing 1.00 g (3.25 mmol) of compound 
3.57 and 415 µL (452 mg; 2.16 mmol) of 1-bromononane in 30 mL of anh THF 
was added 2.70 mL (4.32 mmol) of a 1.60 M solution of n-BuLi in pentane. The 
reaction mixture was stirred at 23 °C for 30 min. The reaction was quenched with 
satd aq ammonium chloride and then poured into 70 mL of water. The mixture 
was extracted with two 70-mL portions of ether. The combined organic layer was 
then washed with 100 mL of brine, dried (MgSO4) and concentrated under 
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diminished pressure. The residue was purified by chromatography on a silica gel 
column (15 × 5 cm). Elution with 4:1 hexanes–ether afforded compound 3.68 as a 
colorless oil: yield 502 mg (53%); silica gel TLC Rf  0.60 (4:1 hexanes–ether); 1H 
NMR (CDCl3) δ 0.89 (t, 3H, J = 7.2 Hz), 1.25 (m, 14H), 1.75 (m, 2H), 2.31 (s, 
6H), 2.48 (s, 3H), 2.77 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 4.90 (s, 2H), 5.86 (s, 2H) 
and 7.42 (m, 5H); 13C NMR (CDCl3) δ 14.1, 14.3, 19.3, 22.7 27.7, 29.3, 29.4, 
29.51, 29.57, 31.62, 31.9, 75.7, 107.9, 128.0, 128.6, 128.7, 129.3, 136.2, 147.4, 
152.6, 161.6 and 165.1; mass spectrum (APCI), m/z 434.3172 (M+H)+ 
(C28H40N3O requires 434.3171). 
N N
N
OBn
 
5-(Benzyloxy)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-hexadecyl-6-
methylpyrimidine (3.69). To a stirred solution at –78 °C containing 1.00 g (3.25 
mmol) of compound 3.57 and 630 µL (630 mg; 2.16 mmol) of 1-
bromopentadecane in 20 mL of anh THF was added 2.70 mL (4.32 mmol) of a 
1.60 M solution of n-BuLi in pentane. The reaction mixture was stirred at 23 °C 
for 30 min. The reaction was quenched with satd aq ammonium chloride and then 
poured into 70 mL of water. The mixture was then extracted with two 70-mL 
portions of ether. The combined organic layer was washed with 100 mL of brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (15 × 5 cm). Elution with 4:1 
 148  
hexanes–ether afforded compound 3.69 as a colorless oil: yield 269 mg (24%); 
silica gel TLC Rf 0.5 (4:1 hexanes–ether); 1H NMR (CDCl3) δ 0.89 (t, 3H, J = 7.2 
Hz), 1.25 (br m, 26H), 1.75 (quint, 2H, J = 7.2 Hz), 2.29 (s, 6H), 2.47 (s, 3H), 
2.76 (dd, 2H, J = 8.0 Hz and 8.0 Hz), 4.89 (s, 2H), 5.85 (s, 2H) and 7.35 (m, 5H); 
13C NMR (CDCl3) δ 14.1, 14.30, 14.30, 19.3, 22.7, 27.7, 29.3, 29.4, 29.50, 29.55, 
29.63, 29.67, 31.6, 31.9, 75.7, 107.9, 128.0, 128.5, 128.7, 129.3, 136.2, 147.4, 
152.6, 161.6 and 165.1; mass spectrum (APCI), m/z 518.4113 (M+H)+ 
(C34H52N3O requires 518.4110). 
N N
NH2
OBn
 
2-Amino-5-(benzyloxy)-4-methyl-6-pentylpyrimidine (3.70). To a stirred 
solution containing 533 mg (1.46 mmol) of compound 3.67 in 10 mL of 9:1 
ethanol–water was added 1.00 g (14.6 mmol) of hydroxylamine hydrochloride. 
The reaction mixture was then stirred at reflux during 5 h. A second portion of 1.0 
g (14.6 mmol) of hydroxylamine hydrochloride was added and the reaction 
mixture was stirred at reflux for 16 h. The reaction mixture was then poured into 
70 mL of water and adjusted to pH 9-10 with 1 N aq NaOH. The mixture was 
extracted with two 70-mL portions of ethyl acetate. The combined organic layer 
was washed with 70 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 3 cm). Elution with 2:1 hexanes–ethyl acetate afforded compound 
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3.70 as a colorless oil: yield 334 mg (80 %); silica gel TLC Rf  0.25 (2:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 6.8 Hz), 1.27 (m, 4H), 1.63 
(m, 2H), 2.28 (s, 3H), 2.56 (dd, 2H, J = 8.0 Hz and 8.0 Hz), 4.71 (s, 2H), 5.15 (br 
s, 2H) and 7.36 (m, 5H); 13C NMR (CDCl3) δ 13.9, 18.9, 22.4, 28.0, 31.9, 75.9, 
127.9, 128.3, 128.6, 136.8, 142.8, 158.8, 161.1 and 164.9; mass spectrum (APCI), 
m/z 286.1914 (M+H)+ (C17H23N3O requires 286.1919). 
N N
NH2
OBn
 
2-Amino-5-(benzyloxy)-4-decyl-6-methylpyrimidine (3.71). To a stirred 
solution containing 502 mg (1.15 mmol) of compound 3.68 in 10 mL of 9:1 
ethanol–water was added 800 mg (11.5 mmol) of hydroxylamine hydrochloride. 
The reaction mixture was stirred at reflux for 5 h. A second portion of 800 mg 
(11.5 mmol) of hydroxylamine hydrochloride was added and the reaction mixture 
was stirred at reflux for 16 h. The cooled reaction mixture was then poured into 
70 mL of water and then adjusted to pH 9-10 with 1 N aq NaOH. The mixture 
was extracted with two 70-mL portions of ethyl acetate. The combined organic 
layer was washed with 70 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (10 × 3 cm). Elution with 3:2 hexanes–ethyl acetate afforded compound 
3.71 as a colorless oil: yield 305 mg (75%); silica gel TLC Rf  0.25 (3:2 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 0.85 (t, 3H, J = 6.4 Hz), 1.26 (m, 14H), 1.61 
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(m, 2H), 2.27 (s, 3H), 2.56 (dd, 2H, J = 8.0 Hz and 8.0 Hz), 4.71 (s, 2H), 5.24 (br 
s, 2H) and 7.36 (m, 5H); 13C NMR (CDCl3) δ 13.9, 18.9, 22.6, 28.4, 29.3, 29.4, 
29.5, 29.6, 29.7, 31.87, 31.88, 75.9, 127.9, 128.2, 128.6, 136.8, 142.8, 158.9, 
161.1 and 162.8; mass spectrum (APCI), m/z 356.2704 (M+H)+ (C22H34N3O 
requires 356.2702). 
N N
NH2
OBn
 
2-Amino-5-(benzyloxy)-4-hexadecyl-6-methylpyrimidine (3.72). To a stirred 
solution containing 269 mg (0.52 mmol) of compound 3.69 in 10 mL of ethanol 
was added 723 mg (10.4 mmol) of hydroxylamine hydrochloride. The reaction 
mixture was stirred at reflux for 5 h. A second portion of 723 mg (10.4 mmol) of 
hydroxylamine hydrochloride was added and the reaction mixture was stirred at 
reflux for 16 h. The reaction mixture was then poured into 70 mL of water and 
then adjusted to pH 9-10 with 1 N aq NaOH. The mixture was extracted with two 
70-mL portions of ethyl acetate. The combined organic layer was washed with 70 
mL of brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 3 cm). 
Elution with 3:2 hexanes–ethyl acetate afforded compound 3.72 as a colorless oil: 
yield 231 mg (100 %); silica gel TLC Rf  0.25 (1:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 0.85 (t, 3H, J = 6.8 Hz), 1.26 (m, 26H), 1.61 (quint, 2H, J = 7.2 
Hz), 2.28 (s, 3H), 2.56 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 4.72 (s, 2H), 5.03 (br s, 
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2H) and 7.37 (m, 5H); 13C NMR (CDCl3) δ 14.1, 18.9, 22.7, 28.4, 29.3, 29.4, 
29.5, 29.62, 29.63, 29.67, 29.73, 31.9, 75.9, 127.9, 128.2, 128.6, 136.8, 142.9, 
158.8, 161.1 and 164.9; mass spectrum (APCI), m/z  440.3646 (M+H)+ 
(C28H46N3O requires 440.3641). 
N N
N
OBn
 
5-(Benzyloxy)-2-(N,N-dimethylamino)-4-methyl-6-pentylpyrimidine (3.73). 
To a stirred solution containing 334 mg (1.17 mmol) of compound 3.71 in 4 mL 
of methanol was added 4 mL of 35% aq formaldehyde followed by 588 mg (9.35 
mmol) of NaCNBH3. The reaction mixture was stirred at 23 °C for 3 h. The 
reaction mixture was quenched with acetic acid until bubbling ceased then poured 
into 20 mL of water and extracted with two 40-mL portions of ethyl acetate. The 
combined organic layer was washed with 40 mL of satd aq NaHCO3 and 40 mL 
of brine. The organic solution was dried (MgSO4) and then concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (8 × 3 cm). Elution with 2:1 hexanes–ethyl acetate afforded compound 
3.73 as colorless oil: yield 150 mg (41%); silica gel TLC Rf 0.7 (2:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz), 1.33 (m, 4H), 1.69 
(quint, 2H, J = 7.6 Hz), 2.32 (s, 3H), 2.62 (dd, 2H, J = 8.0 Hz and 8.0 Hz), 3.15 
(s, 6H), 4.70 (s, 2H) and 7.37 (m, 5H); 13C NMR (CDCl3) δ 14.0, 19.3, 22.5, 27.5, 
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31.7, 31.8, 37.2, 75.7, 127.9, 128.1, 128.6, 137.2, 141.3, 158.6, 160.0 and 163.5; 
mass spectrum (APCI), m/z 314.2224 (M+H)+ (C19H28N3O requires 314.2232). 
N N
N
OBn
 
5-(Benzyloxy)-4-decyl-2-(N,N-dimethylamino)-6-methylpyrimidine (3.74). To 
a stirred solution containing 305 mg (0.86 mmol) of compound 3.71 in 3 mL of 
methanol was added 3 mL of 35% aq formaldehyde, followed by 271 mg (4.30 
mmol) of NaCNBH3. The reaction mixture was stirred at 23 °C for 3 h. The 
reaction was quenched with acetic acid until bubbling ceased, then poured into 20 
mL of water and extracted with two 40-mL portions of ethyl acetate. The 
combined organic layer was washed with 40 mL of satd aq NaHCO3 and 40 mL 
of brine. The organic solution was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (8 × 3 cm). Elution with 2:1 hexanes–ethyl acetate afforded compound 
3.74 as a colorless oil: yield 154 mg (46%); silica gel TLC Rf 0.8 (2:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.4 Hz), 1.33 (m, 14H), 1.69 
(quint, 2H, J = 7.2 Hz), 2.32 (s, 3H), 2.61 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.14 
(s, 6H), 4.70 (s, 2H) and 7.37 (m, 5H); 13C NMR (CDCl3) δ 14.1, 19.3, 22.7, 27.9, 
29.3, 29.50, 29.55, 29.59, 29.6, 31.7, 31.9, 37.2, 75.7, 127.9, 128.1, 128.5, 137.2, 
141.3, 158.6, 159.0 and 163.5; mass spectrum (APCI), m/z 384.3003 (M+H)+ 
(C24H38N3O requires 384.3015). 
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5-(Benzyloxy)-2-(N,N-dimethylamino)-4-hexadecyl-6-methylpyrimidine 
(3.75). To a stirred solution containing 230 mg (0.52 mmol) of compound 3.72 in 
4 mL of methanol was added 4 mL of 35% aq formaldehyde, followed by 263 mg 
(4.18 mmol) of NaCNBH3. The reaction mixture was stirred at 23 °C for 3 h. The 
reaction was quenched with acetic acid until bubbling ceased, then poured into 20 
mL of water and extracted with two 40-mL portions of ethyl acetate. The 
combined organic layer was washed with 40 mL of satd aq NaHCO3 and 40 mL 
of brine. The organic solution was dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel 
column (8 × 3 cm). Elution with 4:1 hexanes–ethyl acetate afforded compound 
3.75 as a colorless oil: yield 100 mg (41%); silica gel TLC Rf  0.75 (4:1 hexanes–
ethyl acetate); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 6.8 Hz), 1.25 (br m, 26H), 1.68 
(quint, 2H, J = 6.8 Hz), 2.31 (s, 3H), 2.61 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.14 
(s, 6H), 4.69 (s, 2H) and 7.43 (m, 5H); 13C NMR (CDCl3) δ 14.1, 19.3, 22.6, 27.8, 
29.3, 29.50, 29.55, 29.62, 29.64, 29.66, 31.7, 31.9, 37.2, 75.7, 127.9, 128.2, 128.5, 
137.2, 141.3, 158.6, 159.0 and 163.6; mass spectrum (APCI), m/z 468.3950 
(M+H)+ (C30H50N3O requires 468.3954). 
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2-(N,N-Dimethylamino)-4-methyl-6-pentylpyrimidin-5-ol (3.16). To a stirred 
solution containing 150 mg (0.48 mmol) of compound 3.73 in 5 mL of methanol 
was added 5 mg of 20% palladium hydroxide-on-carbon (Degussa typy E101 
NE/E). The reaction mixture was stirred at 23 °C under hydrogen atmosphere for 
15 min. The reaction mixture was filtered through Celite® and the filtrate was 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (8 × 3 cm). Elution with 2:1 hexane–ethyl 
acetate afforded compound 3.16 as a colorless solid: yield 60 mg (56%); mp 61-
62 °C; silica gel TLC Rf 0.50 (2:1 hexanes–ethyl acetate); 1H NMR (CD3OD) δ 
0.89 (t, 3H, J = 5.6 Hz), 1.33 (m, 4H), 1.66 (quint, 2H, J = 7.2 Hz), 2.26 (s, 3H), 
2.62 (dd, 2H, J = 7.6 Hz and 7.6 Hz) and 3.05 (s, 6H); 13C NMR (CD3OD) δ 12.9, 
17.5, 22.3, 27.0, 31.2, 31.4, 36.5, 138.0, 155.6, 157.3 and 159.4; mass spectrum 
(APCI), m/z 224.1769 (M+H)+ (C12H22N3O requires 224.1763). 
N N
N
OH
 
 
4-Decyl-2-(N,N-dimethylamino)-6-methylpyrimidin-5-ol (3.17). To a stirred 
solution containing 150 mg (0.48 mmol) of compound 3.74 in 5 mL of methanol 
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was added 5 mg of 20% palladium hydroxide-on-carbon (Degussa type E101 
NE/E). The reaction mixture was stirred at 23 °C under a hydrogen atmosphere 
for 15 min. The reaction mixture was filtered through Celite® and the filtrate was 
concentrated under diminished pressure to afford compound 3.17 as a colorless 
solid: yield 140 mg (100%). An analytical sample was obtained by 
chromatography on a silica gel column (8 × 1 cm). Elution with 4:1 hexanes–
ethyl acetate afforded compound 3.17 as a colorless solid; mp 71-72 °C; silica gel 
TLC Rf  0.25 (4:1 hexanes–ethyl acetate); 1H NMR (methanol-d4) δ 0.87 (t, 3H, J 
= 6.8 Hz), 1.26 (m, 14H), 1.65 (quint, 2H, J = 7.2 Hz), 2.26 (s, 3H), 2.62 (dd, 2H, 
J = 7.2 Hz and 7.2 Hz) and 3.05 (s, 6H); 13C NMR (methanol-d4) δ 13.0, 17.6, 
22.3, 27.3, 29.0, 29.15, 29.17, 29.26, 29.29, 31.2, 31.6, 36.52, 36.52, 138.0, 155.6, 
157.3 and 159.4; mass spectrum (APCI), m/z 294.2554 (M+H)+ (C17H32N3O 
requires 294.2545). 
N N
N
OH
 
2-(N,N-Dimethylamino)-4-hexadecyl-6-methylpyrimidin-5-ol (3.18). To a 
stirred solution containing 100 mg (0.21 mmol) of compound 3.75 in 5 mL of 
methanol was added 5 mg of 20% palladium hydroxide-on-carbon (Degussa type 
E101 NE/E). The reaction mixture was stirred at 23 °C under a hydrogen 
atmosphere for 15 min. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under diminished pressure to afford compound 3.18 as a 
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colorless solid: yield 79 mg (100%). An analytical sample was obtained by 
chromatography on a silica gel column (8 × 1 cm). Elution with 4:1 hexanes–
ethyl acetate afforded compound 3.18 as a colorless solid; mp 86-87 °C; silica gel 
TLC Rf  0.45 (4:1 hexanes–ethyl acetate); 1H NMR (methanol-d4) δ 0.89 (t, 3H, J 
= 6.8 Hz), 1.30 (m, 26H), 1.67 (quint, 2H, J = 7.2 Hz), 2.28 (s, 3H), 2.63 (dd, 2H, 
J = 7.6 Hz and 7.6 Hz) and 3.07 (s, 6H); 13C NMR (methanol-d4) δ 13.0, 17.5, 
22.3, 27.2, 29.0, 29.10, 29.12, 29.20, 29.29, 29.30, 31.2, 31.6, 36.50, 138.0, 155.6, 
157.3 and 159.4; mass spectrum (APCI), m/z 378.3491 (M+H)+ (C23H44N3O 
requires 378.3484). 
N N
N
O
 
4-Decyl-2-(N,N-dimethylamino)-6-methoxypyrimidine (3.76). To a stirred 
solution containing 1.06 g (6.34 mmol) of compound 3.63 and 1.22 mL (1.32 g; 
6.34 mmol) of 1-bromononane in 20 mL of anh THF was added 5.15 mL (8.34 
mmol) of 1.6 M n-BuLi in hexanes. The reaction mixture was stirred at 23 °C for 
20 min. The reaction mixture was quenched with satd aq ammonium chloride and 
poured into 100 mL of water. The solution was extracted with two 80-mL 
portions of ethyl acetate. The combined organic layer was washed with 80 mL of 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (15 × 5 cm). Elution with 
9:1 hexanes–ethyl acetate afforded compound 3.76 as a colorless oil: yield 1.22 g 
(66%); silica gel TLC Rf 0.7 (9:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 0.85 
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(t, 3H, J = 6.8 Hz), 1.25 (br m, 14H), 1.82 (quint, 2H,  J = 7.2 Hz), 2.46 (dd, 2H, J 
= 7.6 Hz and 7.6 Hz), 3.14 (s, 6H), 3.85 (s, 3H)  and 5.77 (s, 1H); 13C NMR 
(CDCl3) δ 14.1, 22.7, 28.5, 29.31, 29.32, 29.48, 29.54, 29.6, 31.9, 36.8, 37.8, 
52.8, 93.0, 162.3, 170.3 and 173.9; mass spectrum (APCI), m/z 294.2541 (M+H)+ 
(C17H32N3O requires 245.2545). 
N N
N
O
 
2-(N,N-Dimethylamino)-4-hexadecyl-6-methoxypyrimidine (3.77). To a stirred 
solution containing 1.12 g (6.70 mmol) of compound 3.63 and 2.61 mL (2.62 g; 
6.70 mmol) of 1-pentadecane in 20 mL of anh THF was added 6.28 mL (10.1 
mmol) of 1.6 M n-BuLi in hexanes. The reaction mixture was stirred for 20 min at 
23 °C. The reaction mixture was quenched with satd aq ammonium chloride and 
poured into 100 mL of water. The compound was extracted with two 80-mL 
portions of ethyl acetate. The combined organic layer was washed with 80 mL of 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (15 × 5 cm). Elution with 
9:1 hexanes–ethyl acetate afforded compound 3.77 as a colorless solid: yield 
1.58g (62%); mp 49-50 °C; silica gel TLC Rf 0.5 (9:1 hexanes–ethyl ether); 1H 
NMR (CDCl3) δ 0.86 (t, 3H, J = 6.8 Hz), 1.25 (br m, 26H), 1.63 (quint, 2H, J = 
7.2 Hz), 2.46 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.14 (s, 6H), 3.85 (s, 3H) and 5.77 
(s, 1H); 13C NMR (CDCl3) δ 14.1, 22.7, 28.5, 29.3, 29.5, 29.55, 29.64, 29.7, 31.9, 
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36.8, 37.8, 52.7, 93.0, 162.3, 179.3 and 171.9; mass spectrum (APCI), m/z 
378.3483 (M+H)+ (C23H44N3O requires 378.3484). 
N N
N
O
Br
 
5-Bromo-4-decyl-2-(N,N-dimethylamino)-6-methoxypyrimidine (3.78). To a 
stirred solution containing 1.22 g (4.16 mmol) of compound 3.76 in 20 mL of 
acetonitrile was added 808 mg (4.54 mmol) of N-bromosuccinimide. The reaction 
mixture was stirred at 23 °C and protected from light for 5 h. The reaction 
mixture was concentrated under diminished pressure and the residue was 
dissolved in 100 mL of ethyl acetate. The organic solution was washed with 100 
mL of brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (15 × 5 cm). 
Elution with 9:1 hexanes–ethyl ether afforded compound 3.78 as white solid: 
yield 1.27 g (82%); mp 45-46 °C; silica gel TLC Rf 0.75 (9:1 hexanes–ethyl 
ether); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 6.8 Hz), 1.28 (br m, 14H), 1.65 (quint, 
2H, J = 7.2 Hz), 2.68 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.12 (s, 6H) and 3.92 (s, 
3H); 13C NMR (CDCl3) δ 14.1, 22.7, 27.6, 29.3, 29.4, 29.5, 29.57, 29.60, 31.9, 
36.7, 36.9, 36.9, 54.0, 91.2, 160.1, 165.1 and 169.05; mass spectrum (APCI), m/z 
372.1654 (M+H)+ (C17H31N3OBr requires 372.1650). 
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5-Bromo-2-(N,N-dimethylamino)-4-hexadecyl-6-methoxypyrimidine (3.79). 
To a stirred solution containing 1.56 g (4.13 mmol) of compound 3.77 in 30 mL 
of acetonitrile was added 888 mg (4.99 mmol) of N-bromosuccinimide. The 
reaction mixture was stirred at 23 °C for 5 h and protected from light. The 
reaction mixture was concentrated under diminished pressure and the residue was 
dissolved in 100 mL of ethyl acetate. The organic solution was washed with 100 
mL of brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (15 × 5 cm). 
Elution with 9:1 hexanes–ethyl ether afforded compound 3.79 as colorless solid: 
yield 1.80 g (95%); mp 66-67 °C; silica gel TLC Rf 0.60 (9:1 hexanes–ethyl 
ether); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 6.8 Hz), 1.23 (br m, 26H), 1.65 (quint, 
2H, J = 7.2 Hz), 2.68 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.12 (s, 6H) and 3.93 (s, 
3H); 13C NMR (CDCl3) δ 14.1, 26.7, 27.6, 29.3, 39.4, 29.5, 29.57, 29.63, 29.65, 
29.68, 31.9, 36.7, 37.0, 54.0, 91.2, 160.1, 165.1 and 169.1; mass spectrum 
(APCI), m/z 456.2579 (M+H)+ (C23H43N3OBr requires 456.2589). 
N N
N
O
OH
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4-Decyl-2-(N,N-dimethylamino)-6-methoxypyrimidin-5-ol (3.19). To a stirred 
solution at –5 °C containing 500 mg (1.34 mmol) of compound 3.78 in 10 mL of 
anh THF was added 202 µL (156 mg; 1.34 mmol) of TMEDA followed by 2.09 
mL (3.35 mmol) of a1.6 M solution of n-BuLi in hexanes. The reaction mixture 
was stirred at –5 °C for 20 min. To the mixture was added 440 µL (410 mg; 3.94 
mmol) of trimethyl borate and the reaction mixture was stirred at 23 °C for 1 h. 
To reaction mixture was added 3.46 mL of 30 % aq H2O2. The reaction mixture 
was then stirred for 30 min and poured into 100 mL of water. The mixture was 
neutralized with dilute aq HCl and extracted with two 100-mL portions of ethyl 
acetate. The combined organic solution was washed with 100 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 3 cm). Elution with 4:1 hexanes–
ethyl acetate afforded compound 3.20 as white solid: yield 111 mg (27%); mp 59-
60 °C; silica gel TLC Rf 0.60 (4:1 hexanes–ethyl acetate); 1H NMR (CD3OD) δ 
0.87 (t, 3H, J = 6.4 Hz), 1.27 (br m, 14H), 1.62 (quint, 2H, J = 7.2 Hz), 2.58 (dd, 
2H, J = 7.6 Hz and 7.6 Hz), 3.09 (s, 6H) and 3.91 (s, 3H); 13C NMR (CD3OD) δ 
13.1, 22.3, 27.6, 29.1, 29.15, 29.17, 29.29, 29.31, 30.6, 31.7, 36.3. 52.2, 127.0, 
155.9, 155.9 and 159.5; mass spectrum (APCI), m/z 310.2500 (M+H)+ 
(C17H32N3O2 requires 310.2495). 
N N
N
O
OH
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2-(N,N-Dimethylamino)-4-hexadecyl-6-methoxypyrimidin-5-ol (3.20). To a 
stirred solution at –5 °C containing 500 mg (1.10 mmol) of compound 3.79 in 10 
mL of anh THF was added 166 µL (128 mg; 1.10 mmol) of TMEDA followed by 
1.72 mL (2.75 mmol) of 1.6 M solution of n-BuLi in hexanes. The reaction 
mixture was stirred at –5 °C for 20 min. Then to the mixture was added 369 µL 
(344 mg; 3.31 mmol) of trimethyl borate and the reaction mixture was stirred at 
23 °C for 1 h. Then to reaction mixture was added 2.84 mL of 30 % aq H2O2. The 
reaction mixture was then stirred for 30 min and poured into 100 mL of water. 
The mixture was neutralized with dilute aq HCl and extracted with two 100-mL 
portions of ethyl acetate. The combined organic solution was washed with 100 
mL of brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (10 × 3 cm). 
Elution with 4:1 hexanes–ethyl acetate afforded compound 3.20 as a colorless 
solid: yield 240 mg (55%); mp 78-79 °C; silica gel TLC Rf 0.50 (4:1 hexanes–
ethyl acetate); 1H NMR (DMSO-d6) δ 0.81 (t, 3H, J = 6.0 Hz), 1.21 (br m, 26H), 
1.52 (quint, 2H, J = 6.8 Hz), 2.46 (dd, 2H, J = 7.2 Hz and 7.2 Hz), 2.97 (s, 6H), 
3.82 (s, 3H) and 7.77 (s, 1H); 13C NMR (DMSO-d6) δ 14.4, 22.5. 27.7, 29.1, 
29.27, 29.32, 29.38, 29.43, 29.5, 31.2, 31.7, 37.3, 53.1, 127.1, 155.5, 156.8 and 
159.7; mass spectrum (APCI), m/z 394.3430 (M+H)+ (C23H44N3O2 requires 
394.3434). 
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5-(Acetoxy)-2-(N,N-dimethylamino)-4-methoxy-6-hexadecylpyrimidine 
(3.21): To a stirred solution containing 15.0 mg (0.04 mmol) of compound 3.20 in 
1 mL of anh DMF was added 11.0 mg (0.08 mmol) of potassium carbonate 
followed by 5.00 µL (5.40 mg: 0.05 mmol) of acetic anhydride. The reaction 
mixture was stirred at 23 °C for 1 h. The reaction mixture was poured into 10 mL 
of diethyl ether and washed with 10 mL of satd aq sodium bicarbonate, 10 mL of 
brine, dried (MgSO4) and concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (10 × 1 cm). Elution with 
9:1 hexanes–diethyl ether compound 3.21 product as colorless solid: yield 94.0 
mg (80%); mp 45-46 °C; silica gel TLC Rf  0.60 (9:1 hexanes–diethyl ether); 1H 
NMR (CDCl3) δ 0.87 (t, 3H, J = 6.4 Hz), 1.25 (br m, 26H), 1.65 (quint, 2H, J = 
6.8 Hz), 2.27 (s, 3H), 2.42 (dd, 2H, J = 7.6 Hz and 7.6 Hz), 3.12 (s, 6H) and 3.89 
(s, 3H); 13C NMR (CDCl3) δ 14.1, 20.4, 22.7, 27.6, 29.3, 29.40, 29.42, 29.5, 29.6, 
29.66, 29.67, 31.6, 31.9, 37.0, 53.3, 121.8, 159.0, 161.2, 162.1 and 169.1; mass 
spectrum (APCI), m/z 436.3539 (M+H)+ (C25H46N3O2 requires 436.3531). 
N N
N
O
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2-(N,N-Dimethylamino)-4-(γ-butenyl)-6-methoxypyrimidine (3.80). To a 
stirred solution containing 1.42 g (8.49 mmol) of compound 3.63 in 80 mL of anh 
THF at –78°C was added 1.36 mL (1.05 g; 9.07 mmol) of TMEDA followed by 
5.1 mL (12.7 mmol) of a 2.5 M solution of n-BuLi in hexanes. The reaction 
mixture was stirred at –78°C for 15 min then was added 1.10 mL (1.54 g; 12.7 
mmol) of allyl bromide. The reaction mixture was stirred at –78 °C for 1 h. The 
reaction mixture was quenched with satd aq ammonium chloride and poured into 
100 mL of water. The compound was extracted with two 80-mL portions of 
diethyl ether. The combined organic layer was washed with 80 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (15 × 5 cm). Elution with 4:1 hexanes–
diethyl ether afforded compound 3.80 as colorless oil: yield 878 mg (50%); silica 
gel TLC Rf 0.50 (4:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 2.44 (dt, 2H, J = 
14.0 Hz and 6.9 Hz), 2.59 (dd, 2H, J = 8.8 Hz and 6.6 Hz), 3.15 (s, 6H), 3.86 (s, 
3H), 4.94 (m, 1H), 5.05 (ddd, 1H, J = 17.1 Hz, 3.2 Hz and 1.6 Hz), 4.79 (s, 1H) 
and 5.86 (ddt, 1H, J = 16.8 Hz, 10.2 Hz and 6.5 Hz); 13C NMR (CDCl3) δ 32.5, 
36.9, 37.1, 52.8, 93.4, 114.8, 138.2, 162.4, 170.4 and 170.8; mass spectrum 
(FAB), m/z 208.1449 (M+H)+ (C11H18N3O requires 208.1450). 
N N
N
O
Br
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5-Bromo-2-(N,N-dimethylamino)-4-(γ-butenyl)-6-methoxypyrimidine (3.81). 
To a stirred solution containing 1.15 g (5.54 mmol) of compound 3.80 in 30 mL 
of acetonitrile was added 986 mg (5.54 mmol) of N-bromosuccinimide. The 
reaction mixture was stirred at 23 °C and protected from light for 2 h. The 
reaction mixture was concentrated under diminished pressure and the residue was 
dissolved into 100 mL of ethyl acetate. The organic solution was washed with 100 
mL of brine, dried (MgSO4) and concentrated under diminished pressure. The 
residue was purified by chromatography on a silica gel column (15 × 5 cm). 
Elution with 4:1 hexanes–diethyl ether afforded compound 3.81 as a colorless oil: 
yield 1.45 g (92%); silica gel TLC Rf 0.55 (4:1 hexanes–diethyl ether); 1H NMR 
(CDCl3) δ 2.46 (m, 2H), 2.81 (dd, 2H, J = 8.8 Hz and 6.7 Hz), 3.16 (s, 6H), 3.95 
(s, 3H), 4.97 (dddt, 1H, J = 11.5 Hz, 10.2 Hz, 2.0 Hz and 1.4 Hz), 5.05 (ddd, 1H, 
J = 17.1 Hz, 3.2 Hz and 1.6 Hz) and 5.90 (ddt, 1H, J = 16.8 Hz, 10.2 Hz and 6.5 
Hz); 13C NMR (CDCl3) δ 31.6, 36.1, 37.1, 54.2, 91.4, 114.9, 138.2, 160.2, 165.3 
and 168.0; mass spectrum (EI), m/z 285.0481 (M)+ (C11H16N3OBr requires 
285.0477). 
N N
N
O
OH
 
2-(N,N-dimethylamino)-4-(γ-buteneyl)-6-methoxypyrimidin-5-ol (3.82). To a 
stirred solution at –78 °C containing 1.45 g (5.07 mmol) of compound 3.81 in 50 
mL of anh THF was added 830 µL (643 mg; 5.53 mmol) of TMEDA followed by 
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3.04 mL (7.61 mmol) of a 2.5 M solution of n-BuLi in hexanes. The reaction 
mixture was stirred at –78 °C for 40 min. To the mixture was added 845 µL (787 
mg; 7.57 mmol) of trimethyl borate and the reaction mixture was stirred for 30 
min. The reaction mixture was cooled to –78°C and 740 µL of 30% aq H2O2 was 
added. The reaction mixture was stirred for 30 min at –78 °C and then poured into 
50 mL of water. The mixture was extracted with two 50-mL portions of ethyl 
acetate. The combined organic solution was washed with 80 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 5 cm). Elution with 1:1 hexanes–
diethyl ether afforded compound 3.82 as a colorless solid: yield 790 mg (70%); 
mp 59-61ºC; silica gel TLC Rf 0.50 (1:1 hexanes–diethyl ether); 1H NMR 
(CDCl3) δ 2.46 (dt, 2H, J = 14.0 Hz and 7.0 Hz), 2.81 (t, 2H, J = 7.7 Hz), 3.09 (s, 
6H), 3.93 (s, 3H), 4.60 (br s, 1H), 4.87 (ddd, 1H, J = 10.2 Hz, 3.3 Hz and 1.3 Hz), 
4.98 (ddd, 1H, J = 17.2 Hz, 3.6 Hz and 1.6 Hz) and 5.83 (ddt, 1H, J = 16.8 Hz, 
10.2 Hz and 6.5 Hz); 13C NMR (CDCl3) δ 30.6, 36.7, 37.4, 53.4, 114.6, 127.1, 
138.6, 154.0, 156.1 and 158.3; mass spectrum (APCI), m/z 224.1393 (M+H)+ 
(C11H18N3O2 requires 224.1399). 
N N
N
O
OBn
 
5-Benzyloxy-2-(N,N-dimethylamino)-4-(γ-butenyl)-6-methoxypyrimidine 
(3.83). To a stirred solution containing 790 mg (3.54 mmol) of compound 3.82 in 
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15 mL of anh DMF was added 1.47 g (10.6 mmol) of potassium carbonate 
followed by 631 µL (907 mg; 5.31 mmol) of benzyl bromide. The reaction 
mixture was stirred al room temperature for 3h. The reaction mixture was poured 
into 50 mL of satd aq sodium bicarbonate and extracted with two 50-mL portions 
of ethyl acetate. The combined organic solution was washed with 80 mL of brine, 
dried (MgSO4) and concentrated under diminished pressure. The residue was 
purified by chromatography on a silica gel column (10 × 5 cm). Elution with 9:1 
hexanes–diethyl ether gave compound 8.83 as yellowish oil: yield 1.09 g (98%); 
silica gel TLC Rf 0.50 (9:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 2.37 (dt, 
2H, J = 14.1 Hz and 7.0 Hz), 2.62 (m, 2H), 3.14 (s, 6H), 3.97 (s, 3H), 4.83 (s, 
2H), 4.93 (ddt, 1H, J = 10.2 Hz, 2.2 Hz and 1.2 Hz), 5.01 (ddd, 1H, J = 17.1 Hz, 
3.6 Hz and 1.6 Hz), 5.85 (ddt, 1H,  J = 16.8 Hz, 10.2 Hz and 6.5 Hz) and 7.43-
7.31 (m, 5H); 13C NMR (CDCl3) δ 30.6, 31.9, 37.1, 53.1, 75.1, 114.5, 128.0, 
128.4, 129.1, 137.4, 138.5, 157.6, 161.0, 161.8 and 162.5; mass spectrum (APCI), 
m/z 314.1875 (M+H)+ (C18H24N3O2 requires 314.1869). 
 
O
 
8-Methyladamantyloxyoct-1-ene (3.84). To a stirred solution containing 362 mg 
(2.18 mmol) of 1-adamantane methanol and 438 µL (499 mg; 2.61 mmol) of 8-
bromo-1-octene in 10 mL of anh DMF at 0 °C was added 174 mg (4.36 mmol) of 
sodium hydride as a 60% suspension in mineral oil. The reaction mixture was 
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stirred at room temperature for 16 h. The reaction mixture was poured into 50 mL 
of satd aq sodium bicarbonate and extracted with two 50-mL portions of ethyl 
acetate. The combined organic solution was washed with 80 mL of brine, dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified 
by chromatography on a silica gel column (10 × 3 cm). Elution with 95:5 
hexanes–ethyl acetate gave compound 8.84 as yellowish oil: yield 350 mg (58%); 
silica gel TLC Rf 0.50 (95:5 hexanes–ethyl acetate); 1H NMR (CDCl3) d 1.31 (m, 
6H), 1.56 (m, 8H), 1.65 (dt, 6H, J = 24.6 Hz and 7.9 Hz), 1.95 (s, 3H), 2.05 (dd, 
2H, J = 14.1 Hz and 6.9 Hz), 2.95 (s, 2H), 3.37 (t, 2H, J = 6.6 Hz), 4.98 (ddd, 2H, 
J = 20.4 Hz, 11.0 Hz and 5.9 Hz) and 5.81 (ddt, 1H, J = 17.0 Hz, 10.2 Hz and 6.7 
Hz); 13C NMR (CDCl3) d 26.2, 28.5, 29.0, 29.1, 29.7, 33.9, 37.4, 39.9, 71.8, 82.0, 
114.3 and 139.3; mass spectrum (EI), m/z 276.2450 (M)+ (C19H32O requires 
276.2453) 
 
N N
N
O
OH
 
2-(N,N-Dimethylamino)-4-methoxy-6-tetradecylpyrimidin-5-ol (3.22). To a 
stirred solution containing 100 mg (0.32 mmol) of compound 3.83 and 142 µL 
(108 mg; 0.64 mmol) of 1-dodecene in 2.00 mL of anh CH2Cl2 was added 27 mg 
(16 µmol) of Grubb’s 2nd generation catalyst. The reaction mixture was stirred at 
reflux for 16 h. The reaction mixture was concentrated under diminished pressure 
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and the residue was partially purified on a short silica gel pad. The crude mixture 
was concentrated under diminished pressure and the residue was dissolved in 2 
mL of methanol. Then 3 mg of 20% palladium hydroxide-on-carbon (Degussa 
type E101 NE/N) was added and the reaction mixture was stirred at 23 °C for 15 
min under a hydrogen atmosphere. The reaction mixture was filtered through 
Celite® and the filtrate was concentrated under diminished pressure. The residue 
was purified by chromatography on a silica gel column (10 × 2 cm). Elution with 
4:1 hexanes–diethyl ether gave compound 3.22 as a colorless solid: yield 47 mg 
(40%); mp 70-71 °C; silica gel TLC Rf 0.40 (4:1 hexanes–diethyl ether); 1H NMR 
(CDCl3) δ 0.88 (t, 3H, J = 6.7 Hz), 1.30 (br m, 22H), 1.65 (m, 2H), 2.60 (m, 2H), 
3.10 (s, 6H) and 3.95 (s, 3H); 13C NMR (CDCl3) δ 14.3, 22.9, 27.9, 29.5, 29.68, 
29.70 29.8, 29.9, 31.4, 32.0, 37.4, 53.5, 127.1, 155.0, 156.1 and 158.2; mass 
spectrum (APCI), m/z 366.3111 (M+H)+ (C21H40N3O2 requires 366.3121). 
 
 
N N
N
O
OH
O
 
2-(N,N-Dimethylamino)-4-methoxy-6-(10-
methyladamantyloxydecyl)pyrimidin-5-ol (3.23). To a stirred solution 
containing 50.0 mg (0.16 mmol) of compound 3.83 and 88 mg (0.32 mmol) of 
compound 3.84 in 1.00 mL of anh CH2Cl2 was added 14 mg (16 µmol) of 
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Grubb’s 2nd generation catalyst. The reaction mixture was stirred at reflux for 16 
h. The reaction mixture was concentrated under diminished pressure and the 
residue was partially purified on a short silica gel pad. The crude mixture was 
concentrated under diminished pressure and the residue was dissolved in 1 mL of 
methanol. Then 3 mg of 20% palladium hydroxide-on-carbon (Degussa type E101 
NE/N) was added and the reaction mixture was stirred at 23 °C for 15 min under a 
hydrogen atmosphere. The reaction mixture was filtered through Celite® and the 
filtrated was concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 1 cm). Elution with 4:1 hexanes–
diethyl ether gave compound 3.23 as yellowish oil: yield 8.00 mg (11%); silica 
gel TLC Rf  0.20 (4:1 hexanes–diethyl ether); 1H NMR (CDCl3) δ 1.30 (br m, 
12H), 1.53 (m, 6H), 1.62 (br m, 8H), 1.95 (s, 2H), 2.61 (s, 2H), 2.95 (s, 2H), 3.10 
(s, 6H), 3.36 (t, 2H, J = 6.7 Hz), 3.96 (s, 3H) and 4.31 (s, 1H); 13C NMR (CDCl3) 
δ 14.3, 22.8, 26.3, 27.8, 28.5, 29.6, 29.66, 29.69, 29.74, 31.4, 31.7, 31.8, 34.2, 
37.4, 40.0, 53.5, 71.9, 82.0, 127.1, 155.0, 156.1 and 158.1; mass spectrum 
(APCI), m/z 474.3703 (M+H)+ (C28H48N3O3 requires 474.3690). 
N N
N
O
OH
 
2-(N,N-Dimethylamino)-4-methoxy-6-octadecylpyrimidin-5-ol (3.24). To a 
stirred solution containing 100 mg (0.32 mmol) of compound 3.83 and 142 µL 
(111 mg; 0.50 mmol) of 1-hexadecene in 2.00 mL of anh CH2Cl2 was added 27 
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mg (16 µmol) of Grubb’s 2nd generation catalyst. The reaction mixture was stirred 
at reflux for 16 h. The reaction mixture was concentrated under diminished 
pressure and the residue was partially purified on a short silica gel pad. The crude 
mixture was concentrated under diminished pressure and the residue was 
dissolved in 2 mL of methanol. Then 3 mg of 20% palladium hydroxide-on-
carbon (Degussa type E101 NE/N) was added and the reaction mixture was stirred 
at 23 °C for 15 min under a hydrogen atmosphere. The reaction mixture was 
filtered through Celite® and the filtrated was concentrated under diminished 
pressure. The residue was purified by chromatography on a silica gel column (10 
× 1 cm). Elution with 4:1 hexanes–diethyl ether gave compound 3.24 as a 
colorless solid: yield 49 mg (36%); mp 78-79 °C; silica gel TLC Rf  0.45 (4:1 
hexanes–diethyl ether); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 6.8 Hz), 1.27 (br m, 
30H), 1.66 (br m, 2H), 2.62 (m, 2H), 3.10 (s, 6H) and 3.95 (s, 3H). 13C NMR 
(CDCl3) δ 14.3, 15.4, 22.8, 22.9, 27.9, 29.5, 29.68, 29.71, 29.78, 29.82, 29.9, 
31.4, 31.8, 32.1, 37.4, 53.5, 66.0, 127.1, 155.0, 156.1 and 158.2; mass spectrum 
(APCI), m/z 422.3741 (M+H)+ (C25H48N3O2 requires 422.3747). 
N N
NH2
OBn
 
2-Amino-5-(benzyloxy)-4,6-dimethylpyrimidine (3.85). To a stirred solution 
containing 2.85 g (9.27  mmol) of compound 3.57 in 30 mL of 1:1 ethanol–water 
was added 6.44 g (93 mmol) of hydroxylamine hydrochloride. The reaction 
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mixture was stirred at reflux for 18 h. The solution was then adjusted to pH~10 
and diluted in 20 mL of water. The mixture was extracted with two 30-mL 
portions of dichloromethane. The combined organic solution was dried (MgSO4) 
and then concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 4 cm). Elution with 1:2 acetone–
hexanes gave compound 3.85 as a colorless solid: yield: 2.10 g (98%); mp 123-
125°C; silica gel TLC Rf  0.25 (1:2 acetone–hexanes); 1H NMR (CDCl3) δ 2.29 
(s, 6H), 4.74 (s, 2H), 4.80 (br s 2H) and 7.37 (m, 5H); 13C NMR (CDCl3) δ 18.8, 
75.5, 128.1, 128.4, 128.6, 136.6, 143.2, 158.5 and 161.2; mass spectrum (APCI), 
m/z 230.1299 (M+H)+ (C13H16N3O requires 230.1293). 
N N
N
OBn
 
5-Benzyloxy-2-(N,N-dimethylamino)- 4,6-dimethylpyrimidine (3.86). A stirred 
solution containing 500 mg (2.18 mmol) of compound 3.85 in 20 ml of 1:1 
formalin–formic acid was stirred at reflux for 18 h. The reaction mixture was 
poured into 100 mL of 1 N NaOH and extracted with two 100-mL portions of 
dichloromethane. The combined organic solution was dried (MgSO4) and then 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 3 cm). Elution with 3:1 hexanes–
ethyl acetate gave compound 3.86 as a colorless oil: yield: 130 mg (23%); silica 
gel TLC Rf 0.60 (3:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 2.31 (s, 6H), 
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3.14 (s, 6H), 4.74 (s, 2H) and 7.38 (m, 5H); 13C NMR (CDCl3) δ 19.2, 37.3, 75.3, 
128.1, 128.2, 128.6, 137.0, 141.5, 145.5, 158.5 and 160.0; mass spectrum (APCI), 
m/z 258.1614 (M+H)+ (C15H20N3O requires 258.1614). 
N N
N
OH
 
2-(N,N-Dimethylamino)-4,6-dimethylpyrimidin-5-ol (3.87).84 To a stirred 
solution containing 130 mg (0.50 mmol) of compound 3.86 in 4 ml of methanol 
was added 5 mg Pd/C (10%). The reaction mixture was stirred at 23 °C for 5 h 
under a hydrogen atmosphere. The reaction mixture was filtered through Celite® 
and concentrated under diminished pressure to afford compound 3.87 as a 
colorless solid: yield 82 mg (100%); mp 147-148 °C; silica gel TLC Rf 0.15 (3:1 
hexanes–ethyl acetate); 1H NMR (CDCl3) δ 2.35 (s, 6H) and 3.13 (s, 6H); 13C 
NMR (CDCl3) δ 18.7, 37.9, 138.3, 155.4, 155.4 and 155.6. 
N N
N
O
Br
 
5-Bromo-2-(N,N-dimethylamino)-4-methoxy-6-methylpyrimidine (3.88). To a 
stirred solution containing 600 mg (3.59 mmol) of compound 3.63 in 20 mL of 
acetonitrile was added 703 mg (3.95 mmol) of N-bromosuccinimide. The reaction 
mixture was stirred at 23°C and protected from light for 18 h. The mixture was 
poured into 75 mL of ethyl acetate and washed with two 75-mL portions of satd 
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aq sodium bicarbonate. The organic layer was dried (MgSO4) and concentrated 
under diminished pressure to afford compound 3.88 as a colorless solid: yield 
1.15 g (73%); mp 40-41°C; silica gel TLC Rf 0.55 (4:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 2.39 (s, 3H), 3.12 (s, 6H) and 3.93 (s, 3H); 13C NMR (CDCl3) δ 
24.4, 37.0, 37.0, 53.9, 91.3, 160.0, 165.0 and 165.8; mass spectrum (APCI), m/z 
246.0249 (M+H)+ (C8H13N3OBr requires 246.0242). 
N N
N
O
OH
 
2-(N,N-Dimethylamino)-5-hydroxy-4-methoxy-6-methylpyrimidine (3.89). To 
a stirred solution at –5 °C containing 362 mg (1.47 mmol) of compound 3.88 in 
15 mL of anh THF was added 2.29 mL (3.67 mmol) of 1.6 M solution of n-BuLi 
in hexanes. The reaction mixture was stirred at –5 °C for 20 min. To the mixture 
was added 493 µL (459 mg; 4.42 mmol) of trimethyl borate and the reaction 
mixture was stirred for 1 h. To the reaction mixture was added 3.23 mL of 30% aq 
H2O2 followed by 1.05 mL of 3 N aq NaOH. The reaction mixture was stirred for 
30 min and poured into 50 mL of water. The mixture was neutralized with dilute 
aq HCl and extracted with two 50-mL portions of ethyl acetate. The combined 
organic solution was washed with 80 mL of brine, dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (10 × 3 cm). Elution with 1:1 hexanes–
ethyl acetate afforded compound 3.89 as a colorless oil: yield 22 mg (8%); silica 
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gel TLC Rf  0.15 (4:1 hexanes–ethyl acetate); 1H NMR (CD3OD) δ 2.23 (s, 3H), 
3.07 (s, 6H) and 3.92 (s, 3H); 13C NMR (CD3OD) δ 16.3, 36.3, 52.2, 127.3, 152.1, 
155.9 and 159.9; mass spectrum (APCI), m/z 184.1089 (M+H)+ (C8H14N3O2 
requires 184.1086). 
 
Cyclic voltammetry  
Cyclic voltammetry (CV) studies were carried out using a Model 1030 
multi-potentiostat from CH Instruments.  The platinum working electrode 2 mm 
diameter (model CHI102), platinum wire counter electrode (model CHI115), and 
Ag/AgCl reference electrode (model CHI111) were obtained from CH 
Instruments.  Cyclic voltammetry measurements were performed in a precut 20 
mL vial at room temperature in 2 mL of a 0.1 M tetrabutylammonium perchlorate 
solution in acetonitrile containing the pyridinol and pyrimidinol analyte at a 1 mM 
concentration.  The analytes were dissolved in acetonitrile.  The vial was covered 
with a Teflon cap (CHI223) and sealed using parafilm.  All samples were purged 
with nitrogen for 5 min to remove any oxygen.  The substrate was then added 
with a syringe and stirred for 1 minute.  Stirring was stopped and the stream of 
nitrogen was focused above the sample so that only the headspace was streamed 
with nitrogen.  The cell was allowed to sit for one minute to allow for the 
diffusion layer to set up and come to equilibrium.  The parameters used for the 
starting and vertex potential were –1.5 V and 1.5 V respectively, and the scan rate 
was 100 mV/s.  The cyclic voltammagram of CoQ0 was recorded using an initial 
reductive sweep; those of the pyridinols and pyrimidinols involved initial 
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oxidative sweeps. Between each CV experiment, the electrodes were rinsed with 
dichloromethane.  The platinum working electrode was then rinsed with water and 
polished with 0.05 micron aluminum powder and distilled water on a polishing 
pad (CHI120).  Immediately before each CV was performed, all electrodes were 
rinsed with acetonitrile. This experiment was performed by Manikandadas 
Mathilakathu Madathil, ASU. 
 
Electron spin resonance study (ESR) 
Compound 3.1 was dissolved in deoxygenated benzene solution for 
analysis to a final concentration of 10-20 mM. Then, di-tert-butylperoxide (98%, 
Aldrich) was added to a final concentration of 0.1 M. The sample was inserted in 
the ESR cavity and the mercury lamp was turned on. Illumination was done 
directly in the cavity by inserting an optic fiber that was connected to the lamp. 
The ESR spectra was recorded at regular intervals on a X-band Bruker ELEXSYS 
E580 spectrometer using the following settings: microwave frequency 9.70–
9.77 GHz, power 64 mW, modulation amplitude 0.1G, center field 3462 G, sweep 
time 168 s, and time constant 40 ms. The simulations were done using the Winsim 
software. Control experiments (dark sample, and sample without test compounds) 
were measured and gave no signal. This experiment was performed by Dr. Ruth 
Goldschmidt and Manikandadas M. Madathil, ASU. 
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Cell culture experiments 
Friedreich’s ataxia lymphocytes (Coriell, GM158150) were cultured in 
RPMI (Gibco, Grand Island, NY, USA) with 15% fetal bovine serum (Fisher 
Scientific, TX, USA), 2 mM glutamine (HyClone, South Logan, Utah, USA) and 
1% penicillin–streptomycin mix (Cellgro). Cells were maintained in log phase at a 
concentration between 1 × 105 and 1 × 106 cells/mL. 
 
Lipid peroxidation assay 
A quantitative FACS analysis of lipid peroxidation of FRDA lymphocytes, 
which had been treated with diethyl maleate following incubation in the presence 
and absence of the test compounds, was measured as described previously.117 
Briefly, FRDA lymphocytes (5 × 105 cell/ mL) were treated with the test 
compounds at final concentrations of 2.5 and 5 µM and incubated at 37 °C for 16 
h in a humidified atmosphere containing 5% CO2 in air. Cells were treated with 1 
µM C11 BODIPY581/591 in phenol red-free RPMI-1640 media and incubated at 37 
°C in the dark for 30 min. Oxidative stress was induced with 5 mM DEM in 
phenol red-free RPMI-1640 media for 2 h. Treated cells were collected by 
centrifugation at 300 × g for 3 min and then washed with phosphate buffered 
saline. Cells were resuspended in 250 mL of phosphate buffered saline and 
analyzed by FACS (FACS Calibur flow cytometer, Becton Dickinson) to monitor 
the change in intensity of the C11 BODIPY581/591-green (oxidized) fluorescence 
signal. In each analysis, 10,000 events were recorded. Results obtained were 
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verified by running duplicates and repeating experiments in three independent 
experiments. This experiment was performed by Dr. Omar M. Khdour, ASU. 
 
NADH oxidase activity assay 
Mitochondria were prepared as described.118,119 One beef heart was ground 
and blended in sucrose buffer (0.25 M sucrose, 10 mM Tris-HCl, pH 7.8, 
containing 0.2 mM EDTA) at 4 °C. Cell debris were removed by centrifugation at 
1200 × g for 20 min. The supernatant was filtered through two layers of 
cheesecloth. Mitochondria were harvested by centrifugation at 26000 × g for 15 
min and then homogenized in the same buffer with a Dounce homogenizer. 
Mitochondria were harvested by centrifugation at 12000 × g for 30 min, and 
stored at –80 °C in sucrose buffer. Submitochondrial particles (SMPs) were 
prepared as described by Linnane and Titchener.120 Mitochondria were sonicated 
with a Sonic Dismembrator (Fisher Scientific) in 0.25 M sucrose, 5 mM MgCl2, 1 
mM ATP, 10 mM MnCl2, 1 mM sodium succinate, 10 mM Tris-HCl, pH 7.8, at 4 
°C. Cell debris was pelleted by centrifugation at 20000 × g for 7 min at 4 °C. 
SMPs were harvested at 152000 × g for 30 min at 4 °C and stored at –80 °C in 10 
mM Tris-HCl, pH 7.5, containing 0.25 M sucrose, 5 mM MgCl2, 2 mM ATP, 2 
mM glutathione, and 1 mM sodium succinate. The protein concentration was 
determined by BCA titration (Pierce) and the sample was diluted as described 
below. 
The inhibitory effects of the tested compounds on bovine heart 
mitochondrial complex I, III and IV were evaluated. The compounds were 
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dissolved in dimethylsulfoxide (DMSO), and then used to make serial dilutions. 
Maximal DMSO concentrations never exceeded 2% and had no influence on the 
control enzymatic activity. Bovine heart SMPs were diluted to 0.5 mg/mL. The 
enzymatic activities were assayed at 30 °C and monitored spectrophotometrically 
with a Beckman Coulter DU-530 (340 nm, ε 6.22 mM−1cm−1). NADH oxidase 
activity was determined in a reaction medium (2.5 mL total volume) containing 
50 mM Hepes, pH 7.5, and 5 mM MgCl2. The final mitochondrial protein 
concentration was 30 µg/mL. After the pre-equilibration of SMP with inhibitor for 
5 min, the initial rates were calculated from the linear portion of the traces. This 
experiment was performed by Sriloy Dey and Dr. Omar M. Khdour, ASU. 
 
NADH-ubiquinone oxidoreductase activity assay 
The inhibition of NADH-Ubiquinone oxidoreductase activity was 
determined using the same experimental conditions described previously.121,122 
Twelve µg of SMP’s were incubated at 39 °C for 5 min with the test compound in 
1 mL of 50 mM phosphate buffer, pH 7.4, containing 0.25 M sucrose, 1 mM 
MgCl2, 2 µM antimycin A and 2 mM KCN. The reaction was initiated by the 
addition of 50 µM NADH and 50 µM of coenzyme Q1. Enzymatic activity, 
measured by the loss of NADH absorbance, was monitored at 340 nm. This 
experiment was performed by Dr. Valérie C. Collin, ASU. 
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Cell viability (trypan blue exclusion assay) 
A hemocytometer-based assay was used to determine the number of viable 
cells present in the cell suspensions. Briefly, FRDA cells were seeded at a density 
of 5 × 105 cells/mL and treated with different concentrations of the test 
compounds. Cells were incubated at 37 °C in a humidified atmosphere of 5% CO2 
in air for 17 h. Oxidative stress was then induced by incubation with 5 mM DEM 
for 6 h followed by evaluation of cytoprotection. Cell viability was determined by 
the use of 0.4% trypan blue. Cytoprotection by the test compounds was assessed 
with respect to the untreated controls. Cells not treated with DEM had > 90% cell 
viability whereas DEM treatment reduced cell viability to < 20%. The ability of 
the test compounds to protect the cells against the effects of DEM was 
determined. Cell viability was expressed as the percentage of untreated control. 
Data are expressed as means ± S.E.M. (n = 3). This experiment was performed by 
Jennifer Jaruvangsanti, ASU.  
 
Scavenging of reactive oxygen species (ROS) 
Intracellular ROS production was measured using the oxidant-sensitive 
fluorescent probe 2, 7-dichlorodihydrofluorescein diacetate (DCFH-DA) 
(Molecular Probes, Eugene, OR, USA). One mL of CEM lymphocytes (2.5 × 105 
cell/mL) were plated in a 24-well plate, treated with the test compounds and 
incubated for 16 h at 37 °C, in a humidified atmosphere containing 5% CO2 in air. 
Cells were treated with 5 mM diethyl maleate (DEM) for 1 h, collected by 
centrifugation at 300 × g for 3 min and then washed twice with phosphate 
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buffered saline (PBS) (Invitrogen, NY). Cells were resuspended in PBS 
containing 10 mM glucose and incubated at 37 °C in the dark for 25 min with 10 
µM DCFH-DA. Cells were collected by centrifugation at 300 × g for 3 min and 
then washed twice with PBS. The samples were analyzed immediately by flow 
cytometry using a 488 nm excitation laser and FL1-H channel 538 nm emission 
filter. In each analysis, 10,000 events were recorded after cell debris were 
electronically gated. The generation of ROS, mainly peroxides, was detected as a 
result of the oxidation of DCFH (λex 488 nm; λem 515-540 nm). Results obtained 
were verified by running duplicates and repeating experiments in three 
independent experiments. Hydrogen peroxide was used to produce the positive 
control. This experiment was performed by Dr. Omar M. Khdour and Dr. Ruth 
Goldschmidt, ASU. 
 
Maintenance of mitochondrial membrane potential (Δψm) 
Briefly, cells were pre-treated with or without the test compounds for 16 h. 
The cells were treated with 5 mM DEM for 140 min, collected by centrifugation 
at 300 × g for 3 min and then washed twice with phosphate buffered saline. The 
cells were resuspended in PBS containing 20% glucose and incubated at 37 °C in 
the dark for 15 min with 250 nM TMRM. Cells were collected by centrifugation 
at 300 × g for 3 min and were then washed with phosphate buffered saline. The 
samples were analyzed immediately by flow cytometry using a 488 nm excitation 
laser and the FL2-H channel. The results obtained were verified in three 
independent experiments. FCCP, a mitochondrial uncoupler was used to produce 
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a negative control. In each analysis, 10,000 events were recorded. This 
experiment was performed by Dr. Omar M. Khdour 
 
Cellular ATP concentration 
Briefly, lymphocytes (2 × 105 cell/ mL) were plated (1 mL in 12-well 
plates) and treated with the test compounds at final concentrations of 5, 10 and 25 
µM, and then incubated at 37 °C for 48 h in a humidified atmosphere containing 
5% CO2 in air. Cells were transferred (100 µL) to 96-well microtiter black-walled 
cell culture plates (Costar, Corning, NY). The total intracellular ATP level was 
measured in a luminator (Clarity™ luminescence microplate reader) using an ATP 
Bioluminescence Assay Kit (ViaLight®-Plus ATP monitoring reagent kit, Lonza, 
Walkersville, MD) following the manufacturer’s protocol. The total ATP level 
was expressed as a percentage of untreated control. To compare the ATP content 
between normal and CoQ10 deficient lymphocytes, fixed number of lymphocytes 
(1x106 cell/ mL) were incubated for two hours under the above culture conditions. 
Cells were washed in PBS, harvested and lysed immediately in 0.5% Triton X-
100, 10 mM Tris-HCl, pH 7.5, containing 1 mM EDTA, and incubated for 10 min 
on ice. After removal of cell debris by centrifugation (12,000 × g, 15 min, 4 °C), 
the ATP level in the resulting supernatant was determined by luciferase 
bioluminescent assay, using appropriate ATP standards. ATP content measured in 
total cell lysates was expressed as nmoles/mg cellular protein. The protein content 
was determined by the bicinchoninic acid assay method (micro-BCA kit, Pierce) 
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using bovine serum albumin (BSA) as reference. This experiment was performed 
by Dr. Omar M. Khdour. 
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